Expression and comparison of tropomyosin isoform actin-binding properties and their resolution within the thin-filament proteome by Dudekula, Khadar B.
    
 
  
 
 
Expression and Comparison of Tropomyosin Isoform 
Actin-binding Properties and Their Resolution within the 
Thin-filament Proteome 
 
Khadar B. Dudekula 
 
 
 
 
This is a digitised version of a dissertation submitted to the University of 
Bedfordshire.  
It is available to view only.  
This item is subject to copyright. 
 
 
 
 
 
  
 
 
 
Expression and Comparison of Tropomyosin Isoform 
Actin-binding Properties and Their Resolution within 
the Thin-filament Proteome 
 
Khadar B. Dudekula 
PhD 
2015 
University of Bedfordhire 
  
 
 
 
  
 
 
Expression and Comparison of Tropomyosin Isoform 
Actin-binding Properties and  
Their Resolution within the Thin-filament Proteome 
 
 
 
 
By 
 Khadar B. Dudekula 
 
 
 
A thesis submitted to the University of Bedfordshire in fulfilment of the requirements for 
the degree of Doctor of Philosophy 
January 2015 
University of Bedfordshire
  
 
 
 
  
i 
 
Abstract 
Tropomyosins(Tm) are a group of proteins that regulate the actin filaments in both 
muscle and non-muscle cells. In mammalian cells four Tm species are found: α-Tm (fast) 
encoded by α-Tm /TPM1 gene, β-Tm, encoded by β-Tm/ TPM2 gene, α-Tm (slow) 
encoded by γTm gene/ TPM3 and δ-Tm encoded by δTm / TPM4gene. Mutations in Tm 
are linked to many cardiac and skeletal diseases like hypertrophic cardiac myopathy 
(TPM1 and TPM2), familial cardiac myopathy (TPM1) and skeletal diseases like 
nemaline myopathy (TPM2 and TPM3) along with other sarcomere proteins. The 
hypothesis on which this study is based is, the isoform composition in both muscle and 
non-muscle cells adapts in response to disease and physiological changes. A significant 
part of that adaptation is changes in the thin filament protein isoforms expressed and the 
post translational modifications of these proteins. 
In this study Tpm3.12st isoform of γTm and other striated muscle tropomyosin isoforms 
(Tpm1 and Tpm2) and a non-muscle Tmp4 were characterised using a variety of 
techniques. The aim was to enhance our understanding of the role of tropomyosin 
interactions in regards to its efficiency of actin binding capacity as well as its effect on 
actin polymerisation.  
Human tropomyosin 3 (Tpm3.12st) was expressed in E. coli to produce recombinant 
protein with three N-terminal sequence variants (Met, MM and (M)ASM). The proteins 
were characterised for their binding affinity with actin as this isoform has not been well 
characterised so far. Its properties are compared with other striated muscle tropomyosin 
Tpm1.1st and Tpm2.2st and non-muscle Tpm4.1cy. The proteins were purified through 
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ion exchange chromatography and the purity was checked by using SDS-PAGE and UV 
spectrometry. The molecular weights of the recombinant proteins produced were 
confirmed by mass spectrometry. Cosedimentation assays were performed for their actin 
binding affinity using ultracentrifugation. The variant of Tpm3.12st with AS N-terminal 
extension was found to have similar actin affinity to Tpm1.1st in the range of 0.1-0.8 µM 
(half saturation). However the variants with Met and MM N-termini bound to actin 
weakly with high half saturation concentration of ~ 6 µM and ~8 µM tropomyosin 
respectively. Measurement of actin polymerisation kinetics showed it is affected in 
presence of tropomyosin. From this study it is shown that tropomyosin accelerates the 
initiation step in actin polymerisation with varying differences within the isoforms in 
contrast to several previous studies. There have been very few studies of the effect of 
tropomyosin on actin polymerisation in the last two decades. This work shows that 
tropomyosin isoforms have a large and variable role in controlling actin polymerisation 
and understanding tropomyosin function will need further investigation in this area.  
This study also developed an ELISA screening method using monoclonal antibodies for 
identification and quantification of Tpm3.12st which was tested against all the four 
tropomyosin isoforms. None of the twelve antibodies studied showed reactivity only with 
Tpm3.12st. From the data analysed it is deduced the amino acid residues in the region of 
24-43 shows the prospect of designing a monoclonal antibody specific to Tpm3.12st 
isoform. Accurate quantification of tropomyosin isoforms is key to understanding their 
function and the effects of modulation of isoform composition in health and disease. 
A reverse phase liquid chromatography method was developed which is compatible with 
the analysis of the thin filament proteome using top-down mass spectrometry. Reverse 
  
iii 
 
phase liquid chromatography (RPLC) is one of the most popular methods used in mass 
spectrometry analysis where proteins are separated based on their hydrophobicity. The 
RPLC method developed in this study gives an efficient separation of major thin filament 
proteins along with small soluble proteins that is compatible to use for top down mass 
spectrometry for identification and quantification of proteins, PTMs and isoform 
composition. With a minimum amount of 2 mg of tissue using chicken and mouse heart 
and skeletal muscle samples a buffer system was optimized to extract thin filament 
proteins. With the optimized RPLC method actin, tropomyosin and troponin complex 
subunits (TnC, TnI and TnI) were successfully separated and the proteins were identified 
using SDS-page by comparison with the previous research results. This novel method of 
extraction and the optimised RPLC method will provide a “bird’s eye view” of thin 
filament proteome providing information of PTMs of all the proteins together within one 
single extraction, reducing the time for analysis and the sample size.  This has the 
potential to give insight into tissue, muscle and heart adaptations that could act as a 
prognostic indicator.  
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Chapter 1 
 
1 Introduction 
Striated muscle is highly organized versatile tissue with complex architecture of muscle 
fibers that contribute to a variety of functions in humans. Skeletal muscle is the basic 
example of striated muscle which has been extensively studied. The basic function of the 
muscles depends on individual properties of different muscle fibers and their proportion 
which results in functional diversity of muscles. The heterogeneity in their function 
depends on their differences in structural, molecular, contractile and metabolic properties 
that in turn characterize a muscle’s function.  These structural and functional differences 
in the muscle fibers are due to differential gene expression of the sarcomeric genes which 
results in numerous isoforms of the muscle fiber proteins such as myosin (myosin light 
chains –ELC and RLC, myosin heavy chains -α and β) (Schiaffino and Reggiani, 2011), 
actin (α-actin, β-actin) (Rubenstein, 1990), troponin (TnI, TnT, TnC) (Gomes et al., 
2002) and tropomyosin (Tpm1, Tpm2, Tpm3 and Tpm4) (Gunning et al., 2005a), calcium 
regulatory proteins (Ca2+-ATPase, α-subunit of dihydropyridine receptors) and many 
others.  Muscles are not fixed entities, they are rather dynamic with remarkable adaptive 
capabilities. The adaptive capacity owes due to the presence of various isoforms of the 
proteins and post translational modifications that can adapt to functioning of the tissue. 
This adaptive nature of muscle structures is significant contributor to the survival of the 
organism (Canepari et al., 2010; Pette and Staron, 2000b). 
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The adaptive nature of the muscle fibers results in the physiological changes to the 
muscles in humans. These can change the mass and type of tissue present and their 
properties through post-translational modification of proteins present in them and modify 
the isoforms of the protein expressed (Canepari et al., 2010). These adaptations may lead 
to heart diseases and skeletal muscle diseases or diseases may cause the heart or muscles 
to adapt to new physiological demands (Tardiff, 2011a; Yuan and Solaro, 2008). 
Studying the adaptations in the muscle isoforms gives an insight into the heart 
adaptations and the diseases caused by these transitions in the muscles. The present study 
is to develop a method to analyze the proteins present in the thin filament of the heart and 
skeletal muscles for studying post-translational modification and isoform switching to 
understand the adaptations occurring in both normal and diseased state. This study 
concentrates on tropomyosin and also characterization of tropomyosin 3.12st 
(Tpm3.12st), an actin binding protein in thin filament that helps regulate actin and plays a 
major role in muscle contraction. 
 This chapter gives an introduction to skeletal and cardiac muscle and gives a brief 
description of muscle structure and its physiological functions, muscle proteins and their 
isoforms and information about cardiac diseases and skeletal muscle diseases. 
1.1 Muscle Tissue 
Human body functions necessitates many driven movements both physically (walking, 
running, breathing), and physiologically (movement of contents in digestive tract, 
circulation of blood). Muscle tissue that is specialized in contraction is responsible for 
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these movements in the body. There are basically three types of muscle tissues found in 
the humans i) Skeletal muscles ii) Cardiac muscles and iii) smooth muscles.  
 
Figure 1.1: Skeletal muscle shows striations and is multinucleate. Cardiac muscles 
showing branching and intercalated discs. smooth muscles with no branches and 
striations and a single nucleus for each cell (Martini, 2001).  
 
1.1.1 Skeletal muscle 
 
Skeletal muscles are the large muscles found in the body they are responsible for the 
overall movements in the body and aid in locomotion along with maintaining body 
posture, generation of body heat and storing nutrients (Martini, 2001). Each skeletal 
muscle cell is called muscle fiber, arranged together in a highly organized fashion in 
repeated units in a bundle like manner. Due to their specific arrangement they look like 
long continuous striated structures with numerous nuclei in them (Figure 1.1). Skeletal 
muscles have specific cells called ‘myosatellite cella’, due to which they are capable of 
repairing themselves partially after an injury. Skeletal muscle fibers are bound together 
    Skeletal muscle                            Cardiac muscle                        Smooth Muscle   
Nucleus 
Intercalated discs Striations 
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by collagen and elastic fibers that collect together to form tendon which in turn is 
attached to bone. The tendon pulls the bones of the particular organ when contraction 
occurs in the muscles causing movement.  The contraction process of the skeletal muscles 
is controlled by the nerve signals and they are not capable of functioning involuntarily. 
Hence they are called ‘voluntary striated muscle fibers (Gordon et al., 2000; Martini et 
al., 2008).  
1.1.2 Cardiac Muscle 
 
Cardiac muscle (shown in Figure 1.1) is characteristic to only heart muscles, which is 
also striated but extensively branched tissue.  Contraction of cardiac muscles assists in 
pumping and circulation of blood to the organs, and maintains blood hydrostatic pressure. 
Each cardiac muscle cell is called cardiocyte and is similar to skeletal cells in having 
striations however it has only one nucleus per each cell and is smaller than the skeletal 
muscle cell. Cardiac muscle cells are inter connected and consist of  extensive branching, 
these  connections form intercalated discs which consist of gap junctions where 
movement of ions takes places during contraction, desmosomes and proteoglycans link 
the cells together during contraction. Cardiac muscles have characteristic specialized 
cells called ‘pacemaker cells’ that regulate the muscle contraction in heart, rather than 
working on receiving the nerve signals. Hence cardiac muscles are called ‘involuntary 
striated muscles’. 
1.1.3 Smooth muscles 
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Smooth muscles (Figure 1.1) are present in the visceral organs of the body like digestive 
system, respiratory organs, blood vessels and others. They help in regulating the diameter 
of blood vessels, respiratory tract movement and respiration, food movement in the 
digestive tract etc. Smooth muscles are single cell units with their own nucleus. These 
cells are capable of dividing and thus are able to repair after an injury. The muscle fibers 
are arranged differently in smooth muscles than in the skeletal muscles and are not 
striated. Smooth muscle contraction is not controlled by the nervous system and hence 
they are called ‘non-striated involuntary muscles’. 
Even though there are structural differences in all these different muscle tissues, 
organization of muscle tissue, muscle regulation and contraction process is similar.  
1.2 Organization of skeletal muscle 
 
The cross section of muscle tissue (Figure 1.2) show bundle of muscle tissue is enclosed 
with in a thick tissue with collagen and elastin fibers called epimysium. The muscle 
tissue itself is formed of bundles of muscle fibers called muscle fascicle. 
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Figure 1.2: Cross-section of muscle tissue: Each muscle fiber is surrounded by soft 
connective tissue endomysium. Few muscle fibers form a bundle called muscle fascicle 
and numerous muscle fascicles are separated by perimysium and this whole muscle tissue 
is surrounded by epimysium. The overall muscle tissue is supplied with nerves for 
receiving signals for contraction and blood vessels supply oxygen and nutrition 
(MARTINI et al., 2008).  
 
Perimysium separates muscle fascicle from each other and is also supplied with nerves 
and blood vessels that control muscle contraction and provide energy and nutrition 
respectively. These nerves and blood vessels branch out into endomysium controlling the 
function of the individual muscle fibers at micro level. Epimysium fills up the space 
between the individual muscle fibers, it contains myosatellites cells that are undivided 
stem cells, help in repairing the skeletal muscle when injured. Figure 1.2 is the cross 
section of muscle tissue showing the organization of the muscle fibers in individual 
skeletal muscle tissue.  
 
Epimysium 
Muscle fascicle  
Nerve 
Perimysium 
Blood vessels 
Muscle fibers Endomysium 
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Endomysium and perimysium elongate and join the epimysium to fuse to form tendon 
and join the bones, so whenever a contraction occurs the bone attached to that muscle 
also moves, resulting in the movement of the body.  
 
1.3 Sarcomere 
The muscle fibers contain myofibrils that are arranged in bundles of thin and thick 
filaments called myofilaments (Figure 1.3a). The myofilament is arranged in repeated 
contractile functional units called sarcomere.  
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Figure 1.3: Major sarcomeric proteins: A. shows the arrangement of myofilaments. B. 
Single contractile functional unit-sarcomere showing I band, A band and M line and Z 
line, green -thin filament, brown – thick filament, Myosin binding protein C -yellow 
transverse line on thick filament, blue – titin, black line on the thin filament – 
tropomyosin, yellow structures on tropomyosin – troponin complex (Gregorio and Antin, 
2000; Martini et al., 2008).  
 
The sarcomere consist of thin and thick filament aligned parallel to each other (Figure 
1.3b), and the interaction of both these filaments is assisted by stabilizing proteins of thin 
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and thick filament and the regulatory proteins thick and thin filaments. The differences in 
the arrangement, size and density of thin and thick filaments gives a banded appearance 
of sarcomere. The band A consists of thick filaments called myosin (brown) as in Figure 
1.3b approximately 1.6 μm long at the center of the sarcomere connected by M line and 
runs lengthwise along whole A band. Myosin is The H-line or H- zone is a resting zone 
where only thick filaments are present. Thin filaments mainly consists of actin filaments 
(green) which are approximately 1.0 μm long and are associated with band I sliding over 
the thick filaments anchored by α-actinins (golden-on Z line) to Z-line where actin is 
capped by Cap Z (pink squares). The I band do not contain thick filaments. Thin 
filaments extend from A band of one sarcomere to A band of another sarcomere and the 
region from one Z line to another Z line makes one sarcomeric unit. The region where 
thin and thick filaments overlap is call the zone of overlap were these two proteins 
interact with each other to generate a force for muscle contraction which will be 
explained in muscle regulation section. Titins are the another type of filaments one of the 
largest proteins so far, helps to keep the thin and thick filaments aligned in proper fashion 
and also helps to the muscle to come to its original relaxing state after each contraction 
cycle. Titin (turquoise) is also believed to resist and prevent any disruption caused due to 
extreme stretch during contraction (Gregorio and Antin, 2000; Martini et al., 2008). One 
thick filament is surrounded by six thin filaments in the lattice structure of muscles.  
1.3.1 Thick filament 
 
Thick filament consists of a bipolar motor protein myosin II. It also contains a large 
protein titin and C, H, X and M proteins which are not discussed in detail in this thesis. 
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1.3.1.1 Myosin 
The thick filament mainly consists of myosin that interacts with actin to produce force 
and the sarcomere shortening during contraction. The type of myosin present in muscles 
is myosin II and is one of the largest protein with a total molecular weight of ~500 kDa. 
It is made of six two polypeptide chains consisting of two heavy chains of ~220 kDa each 
and one pair of each essential light chains (ELC) and regulatory light chains (RLC) of 
~20 kDa each (Martini, 2001).  
 
Figure 1.4: Myosin II structure. A. thick filament – myosin aggregates. B. Myosin II 
with two α-helical coiled coils of heavy chains (pink and red) at the C-terminal end and 
along all the length,  globular heads at N-terminal end with two sets of ELC (blue) and 
RLC (pale blue). C. When Trypsin digestion cleaves myosin II heavy chain into light 
meromyosin (pink) and heavy meromyosin (red) and when heavy meromyosin is digested 
with papain, it is separated into two S1 molecules (globular heads) and S2 (Lehninger et 
al., 2008). 
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Myosin is a α-helical coiled coil, form a myosin heavy chain (MHC) coiled along its 
length at its C-terminal with a large globular head region at the N-terminal end which are 
termed as sub-fragment 1 (S1). The light chains ELC and RLC are associated myosin 
heads with each pair of ELC and RLC on S1 (Figure 1.4b). When the two myosin heavy 
chains (MHC) are digested with trypsin the cleavage separates them into light 
meromyosin and heavy meromyosin. Heavy meromyosin digestion with papain separates 
both S1 fragments from S2 fragment (Figure 1.4c) (Lehninger et al., 2008). 
Myosin II forms aggregates in thick filament under physiological conditions (Figure 
1.4a).  The oppositely charged amino acids in the coiled coil tails called the myosin rods 
forms filaments with a regular interval repeats. This causes the S1 heads project outside 
the filament region and are arranged helically facing in the same direction creating a 
head-to-tail configuration giving myosin a biopolar structure. 
The S1 heads are the site of ATP hydrolysis that provides energy to interact with actin 
filaments to generate force during contraction by filaments sliding over each other which 
will be explained in muscle regulation section 1.4  
Myosin binding protein C (MyBP-C, yellow lines on myosin) in Figure 1.3b is a thick 
filament–associated protein found in the crossbridge containing C zones of striated 
muscle sarcomeres. The C-terminus of the MyBP-C interacts with light meromyosin 
section of the myosin rod and titin to maintain the thick filament structure. It also helps in 
regulating the muscle contraction by binding to subfragment-2 of myosin at its N-
terminus by reducing the actomyosin ATPase activity. There are several models designed 
to explain the interaction of MyBP-C with myosin and how it contributes to contraction, 
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however these is no clear illustration model of its precise position and arrangement on the 
thick filament (Flashman, 2004).  Genetic mutations of MyBP-C are one of the most 
common causes of hypertropic cardiacmyopathies. Three isoforms of MyBP-C are 
known to exist in adult muscle - human fast (MYBPC2) and slow skeletal (MYBPC1) 
isoforms and human cardiac MyBP-C (MYBPC3). The fast and slow skeletal isoforms are 
present either together in some muscle types or can even coexist (Pette and Staron, 2000).  
The other proteins of thick filament, protein C bundles myosin rods together during 
development and proteins X and H are thought to have the same properties as C protein 
(Martini, 2001). The M protein in M line provides support to connect the thick filament 
to A band in the sarcomere. The large protein titin is an elastic molecule providing the 
elasticity property to the sarcomere and helps in the alignment of thick and thin filament 
in the sarcomere (Gordon et al., 2000; Gregorio and Antin, 2000).  
1.3.1.2 Myosin isoforms 
MHC in muscle fibers exists in two types, pure fiber with MHC having a single isoform 
and hybrid fibers with MHC having multiple isoforms. Myosin is one of the proteins that 
exhibits fiber specific isoforms and expression levels varies depending on the fiber type 
(Pette and Staron, 2000). Depending on the fibers, MHC exhibits four types of pure fiber 
types: one slow type I and three fast types. Slow type has isoforms MHC1β, and fast type 
has 2A (MHC2a), type 2D (MHC2d) and type 2B (MCH2b). When these fiber coexpress 
in different tissue fibers hybrid type isoforms are developed (Pette and Staron, 2000b; 
Schiaffino and Reggiani, 2011). Table 1.1 gives few examples of myosin heavy chain 
isoforms and their location in the fiber types.  
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Table 1.1: List of myosin heavy chain isoforms present in adult mammalian muscle 
fibers. 
 
Adapted from  Schiaffino and Reggiani (2011). 
There are other several types of myosin proteins in muscle and non-muscle cell. Myosin I 
is one of the most extensively studied proteins that play a role in transporting membrane 
vesicles, movement of plasma membrane along with actin bundles, phagocytosis. Myosin 
I carries a head similar to myosin II but does not have a coiled long tail instead carries a 
single short tail (Cooper, 2000).  
1.3.2 Thin filament proteins 
 
Thin filament is the main site for the Ca2+ regulation of muscle contraction. The muscle 
contraction is turned “on or off” in presence or absence of Ca2+ (Tobacman, 1996). The 
main proteins that are associated in muscle contraction are actin, tropomyosin and 
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troponin complex associated with other actin binding and actin regulatory proteins in the 
thin filament (Figure 1.5). 
 
Figure 1.5: Thin filament: a. Human thin filament model: Actin filament – grey, 
tropomyosin –orange/green, troponin T – yellow, troponin I-blue, troponin C-red 
(Manning et al., 2011).  b. Molecular arrangement of thick and thin filament proteins 
(Seidman and Seidman, 2001). 
1.3.2.1 Actin 
Actin is a 42 kDa filamentous protein. Actin exists in two forms monomer (G) actin and 
filamentious (F) actin which is a polymer. Actin polymer (F-actin) is formed by 
spontaneous polymerisation of G actin and forms the backbone of the thin filament.  
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Figure 1.6: Actin polymerisation and treadmilling (Pak et al., 2008). 
 
Figure 1.6 shows the actin polymerisation dynamics and treadmilling. Actin 
polymerisation happens by hydrolysis of ATP and forms a filament. The actin filament is 
a polar molecule with pointed and barbed end. Monomer are added at both ends, however 
the polymerisation rate is faster at barbed end than the pointed end. The dynamics of 
actin polymerisation is explained in detail in chapter II (section 2.2.2). Actin forms actin-
nucleotide complex in associated with ADP and the exchange of ADP-G actin with an 
ATP forms a ATP-G actin which initiates polymerisation (Pollard and Cooper, 2009).   
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Figure 1.7: F-actin filament stability showing the interaction between two filaments. 
Both a and b show the actin subunits, the central F-actin subunit - cyan and adjacent 
subunits –shades of green. Dotted lines – salt bridges (Ecken et al., 2014).  
 
The G actin is a bilobed structure with large and small domains. The transition of G-actin 
to F-actin takes place by flattening of the subdomains on binding to Mg2+ ions (Figure 
1.8a and b). Myosin binding site located within the small domain (Kabsch et al., 1990) 
which is also the binding site for the metal ion like Mg2+  or Ca2+ (Ecken et al., 2014) 
(Figure 1.8c and d). F-actin is formed by two long-pitch helical strands. F-actin filament 
is stabilized by the interaction between the subunit domains between the two strands by 
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hydrophobic interactions and also by forming salt bridges (Figure 1.7).  The filaments 
undergo interstand and intrastrand ineraction between the two filaments.  Subdomians 
SD2 and SD4 of one actin and SD3 of the same actin of adjacent subunit forms the 
primary intrastrand interaction. D-loop and the SD3 betasheet form the significant 
interstrand contacts by enclosing tyrosine 169 with a lock and key fit with the other 
filament subunit. Introducing charges at the hydrophobic interfaces of this region disturbs 
polymerisation of  F-actin as well as hampers its stability which can lead to different 
forms of skeletal muscle diseases (Ecken et al., 2014). SD1 and SD2 domains remain 
exposed to the solvent which consist of NH2 and COOH termini and forms the binding 
site for myosin heads.  
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Figure 1.8: Transition of G-actin to F-actin. A. shows the conformational change 
occurring by rotation of SD1 and SD2 by flattening the molecule. B. The positon of 
nucleotide ADP and the binding of Mg2+ ion or Ca2+ ion (green). C. Cryo-EM structure 
of F-actin coiled (grey) with tropomyosin (yellow) D. the close up view of the subunit 
that is interacting with tropomyosin shown in green and cyan which is having the myosin 
binding site (red) (Ecken et al., 2014).  
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Actin like other muscle proteins exhibits tissue specific isoforms with in an organism. 
They are divided into two classes - skeletal muscle and smooth muscle isoactins with 
similar function and are labelled depending on their mobility on acrylamide gels. The 
major actin isoforms are α, β and γ, where β and γ non-muscle isoactins are predominant 
in cytoplasm of all eukaryotes and are distributed differentially depending on the cell 
type. Skeletal specific actin isforms are α-skeletal and α-cardiac similar to α-smooth 
muscle predominantly found in vascular tissue and γ-smooth muscle found in visceral 
tissues (Rubenstein, 1990a). The sequence difference of α-skeletal and γ-smooth muscle 
has only 6 amino acids of 375 residues, mainly found at the myosin binding site. The 
mechanical force generated by smooth muscle is higher than in skeletal muscle. Studies 
found that per unit of cross-sectional area of force generated smooth muscle produce 
same amount of force as skeletal muscle with only 20% of myosin as much myosin, 
showing that the number of crossbridges formed in smooth muscle seems greater than in 
skeletal muscle (Murphy et al., 1974), however Harris  and Warshaw (1993) showed that 
there is no difference in the velocity of force generated by smooth muscle and skeletal 
muscle. 
1.3.2.2 Tropomyosin 
Tropomyosins(Tm) are the group of proteins that regulate the actin filaments in both 
muscle and non-muscle cells. Tm is ~42 nm long, present along the actin filament coiling 
around 4-7 actin molecules forming a sort of back bone to the actin filament and power 
the muscle contraction-relaxation process in striated muscle (skeletal and cardiac 
muscles) (Gordon et al., 2000). Tropomyosin is present in all eukaryotic cells ranging 
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from yeast to human beings. The details of structure and stability of tropomyosin 
molecule are discussed in Chapter II. 
In mammalian striated muscle four Tm species are found: α-tropomyosin (fast)/Tpm1 
encoded by α-Tm gene, β-tropomyosin/ TPM2, encoded by β-Tm gene, α-tropomyosin 
(slow)/ Tpm3 encoded by γTm gene and Tpm4 encoded by δTm gene. Figure 3.1 to Figure 
3.4 in Chapter III, shows the representation of Tm proteins encoded by their respective 
genes.  Each striated muscle consists of at least two of the proteins either as homodimers 
Tpm1/Tpm3 (both α but fast and slow respectively) or heterodimers Tpm1/Tpm2 
(Gimona et al., 1995). Tpm1.1st is predominant in cardiac muscle where as Tpm2.2st is 
found in skeletal muscle. Tpm3.12st is found in slow twitch skeletal muscle, but recent 
studies shows that along with predominant Tpm1.1st, Tpm3.12st is also present in 
cardiac muscles and may possibly have a role in cardiomyopathy causing mutations 
(Schevzov et al., 2011a).  Studies from Creed et al., (2011) showed that Tpm3.iso12st 
isoform is involved in regulation of molecular composition of microfilaments and the 
composition of Tm available to actin filaments decides the functional properties of actin 
cytoskeleton. So far Tpm3.12st has not been characterized for its regulatory properties in 
human cardiac muscle and its significance in the human heart remains unclear. 
Over 40 isoforms of Tm have been identified from the four genes. These are derived from 
alternative splicing of mRNA, alternative promoters and different 3’ terminal 
modifications (Lees‐Miller and Helfman, 1991; Leger et al., 1976). Each gene produces 
different protein isoforms and depending on the protein isoform the gene encodes, they 
have been given specific names. The function of different isoforms of Tm varies 
depending on the actin filament properties of the cell and the different isoforms of Tm 
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that are present in the particular cell. The stability of actin in different cells depends on 
the specific cell Tm isoform that regulates the actin filament properties. More details of 
tropomyosin gene and isoforms are discussed in Chapter III.  
1.3.2.3 Troponin 
In striated muscles contraction is regulated by Ca2+  concentration and  association of 
actin with tropomyosin and troponin complex (Gordon et al., 2000). The force is 
generated by the hydrolysis of ATP during actomyosin cross bridge cycle.  The proteins 
that are mainly involved in Ca2+ regulation include troponin (Tn) complex consisting of 
TnT, TnI and TnC. The troponin complex binds to actin co-operatively (Gordon et al., 
2000) with tropomyosin and actin in 7:1:1 ratio, for every actin molecules 1 tropomyosin 
and 1 troponin complex. The troponin position its self on tropomyosin with an interval of 
~ 37 nm along the length of F-actin-tropomyosin association. While TnT and TnI are 
specific to striated muscle proteins and have three pairs of fibre type specific isoforms 
where as TnC belongs to calmodulin gene family.  Figure 1.9a-b shows the troponin 
complex and the binding sites of tropomyosin on TnT. The details of all these three 
proteins are discussed below.  
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Figure 1.9: Troponin complex showing the binding sites of TnT to tropomyosin. A. 
molecular arrangement of troponin complex, tropomyosin and actin. TnT-yellow, TnI-
Green and TnC-red, Tropomyosin dimer - brown shades, actin –Grey (Tobacman L.S, 
1996). B. Structural interpretation of Tn complex showing the N-terminal region of TnT 
having the binding site for tropomyosin and the C-terminal region interacts with TnC and 
TnI as well as another binding site for tropomyosin (Wei and Jin, 2011). 
 
1.3.2.4 Troponin T (TnT) 
Troponin T acts as the glue to hold the troponin complex together binding to TnC and 
TnI along with being the main interacting site of tropomyosin and actin. It is also 
involved in co-operative activation of thin filament and responsible for regulation of thin 
filament during contraction. Figure 1.9a and b shows the sites occupied on the TnT that 
are responsible for the troponin complex binding to tropomyosin-actin . The TnT1 site 
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lies in the region of 1-158 residues and TnT2 site 159-259 residues at the C-terminal end 
of the sequence obtained by chymotrypsin cleavage. The globular TnT2 region at COOH 
terminal interacts the TnI and TnC along with Tm and the extended TnT1 region interacts 
with Tm along with the COOH terminal region including head to tails overlap region that 
is considered to be the highly flexible region of Tm (Schaertl et al., 1995).  
 The TnT is a 30-35 kDa protein varying with tissue type and the species of the organism 
with 223 – 305 amino acids again variable with in the vertebrate species. The large 
variable size of TnT is due to varying length at the N-terminal region with few N-
terminal amino acids in fish or 70 residues long as in mammalian cardic TnT (Leszyk et 
al., 1987).  The cleavage sites with enzymes calpain separates the N terminal region, and 
caspase cleaves the site of mutation that is related to nemaline myoptathy (Wei and Jin, 
2011). Cardiac TnT is longer than skeletal TnT (~200 Å) approximately  20 Å longer 
than skeletal TnT (Flicker et al., 1982).   
The binding of TnT to TnI-TnC-Tm and Actin is regulated both by presence and absence 
of Ca2+ ions. The interaction of Tn-Tm complex inhibits actomyosin ATPase in the 
absence of Ca2+ and in the presence of Ca2+ ions accelerates the same reaction (Farah et 
al., 1994). This interaction is essentially mediated by the COOH terminal TnT2, but the 
cooperative activation requires TnT1(Schaertl et al., 1995). This interaction activates the 
cooperativity of Tn complex along with Tm overlap regions and actin in addition to 
regulation of ATPase in presence or absence of Ca2+ ions (Pearlstone and Smillie, 1982). 
Hence TnT plays an important role in maintain the cooperative regulation of thin filament 
that is crucial to muscle contraction.  
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TnT exhibits various isoforms in humans and other mammals distributed as fast skeletal 
TnT, slow skeletal TnT and cardiac TnT. In humans cardiac TnT is encoded by TNNT2 
gene produces isoforms by multiple variants by alternative splicing. The most common 
isoforms are TnT1, TnT2, TnT3 and TnT4. All the isoforms are expressed at foetus stage 
with TnT1 and TnT3 being predominant isoforms whereas during development TnT1 is 
lost and TnT3 remains predominant until adult stage. TnT4 and TnT2 are present in least 
abundance in myocardium (Gomes et al., 2002).  
1.3.2.5 Troponin I (TnI) 
TnI inhibits the muscle contraction in the absence of Ca2+ where it binds tightly to 
myosin binding region on the actin and thus inhibits muscle contraction. There are three 
TnI isoforms expressed in humans namely slow skeletal TnI (sTnI), fast skeletal TnI 
(fTnI), and cardiac TnI (cTnI) encoded by TNNI, TNNI2 and TNNI3 genes respectively. 
The difference in N-terminal region (Figure 1.9b) of 31 amino acids in the cTnI 
differentiates the isoforms from skeletal isoforms. This region contains the important 
phosphorylation sites, where it is found to be phosphorylated by protein kinase A (PKA) 
with aderenaline stimulation at Ser23 and Ser24 which causes decrease in overall Ca2+ 
sensitivity (Yuan and Solaro, 2008). TnI binds to TnC  and TnI at C-termial region, and 
has two actin binding regions with one containing the inhibitory peptide and the second 
region containing the actin binding region at the C terminus (Solaro and Van Eyk, 1996).  
The binding region of actin is highly conserved containing residues from 96-116 in rabbit 
skeletal muscle which is found to be able to reduce actomyosin ATPase activity on its 
own with a maximum inhibition of 1:1 ratio to actin. However in physiological 
conditions, in presence of tropomyosin the distribution is of TnI is regulated by 
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cooperative ratio of 7: 1:1 to actin and tropomyosin-troponin. This cooperative 
distribution is one of the main characteristic feature of thin filament regulation which 
plays an important role in muscle regulation (Kobayashi and Solaro, 2005).  
1.3.2.6 Troponin C (TnC) 
Troponin C belongs to calcium binding protein family expressed by TNNC1 gene and is 
representative of calmodulin super family. TnC is 18 kDa protein found in both skeletal 
and cardiac tissues. Figure 1.10 shows the Ca2+ binding site in the ribbon structure of 
TnC.  
 
Figure 1.10: Ribbon structure of TnC. A. Turkey TnC with Ca2+ bound at C terminal 
(black solid circles) B. Rabbit skeletal TnC showing four Ca2+ bound at both N terminal 
and C terminal  regions. Letters A –H are represented to show the orientation of the 
molecule. In B when the Ca2+ are bound at N terminal  the orientation at C is more 
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perpendicular to E than in B whenre there is no Ca2+  bound at the position  forming a E-F 
hand structure (Gordon et al., 2000; Houdusse et al., 1997). 
 
TnC acts as a trigger for the initiation of muscle contraction in presence of when Ca2+ 
concentration reaches to a certain level accessible in the sarcomere. TnC is divided by 
two lobes, the C lobe that binds to a divalent metal ion usually Mg2+  in physiological 
conditions keeping the system in open state hence it is referred to as ‘structural lobe’ and 
the N lobe binds  specifically to Ca2+ with higher selectivity than Mg2+ but has lower 
affinity to divalent ions than C lobe. It is referred to as regulatory lobe as it undergoes 
conformational changes when Ca2+ levels increases (Houdusse et al., 1997) forming an 
EF hand structure where the C region in Figure 1.10b is perpendicular to E. This kind of 
conformation change seems to be important for the interaction of TnC with the other Tn 
subunits. TnC isoforms are also distributed into skeletal TnC and cardiac TnC which is 
similar to slow skeletal TnC. cTnC differs from sTnC by having only single Ca2+ binding 
site at the N-terminal region (Gordon et al., 1997). 
1.4 Muscle regulation-Cross bridge cycle 
In striated muscle the binding of myosin heads to actin is mainly regulated by 
tropomyosin-troponin complex with Ca2+ activation of muscle contraction.  Structural 
modelling of actin-tropomyosin interaction in presence/absence of myosin have given 
clear insight in explaining the positioning and conformations occurring in the Ac-Tm 
complex (Geeves et al., 2005).  
When muscle contracts (shortens) the thick and thin filaments forms slide over each other 
to form actin-myosin cross bridges by the result of force generated by the cross bridge 
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linkage. Myosin ATPase activates the ATP molecule carried by myosin heads and when 
this is hydrolysed energy is used to power the muscle. The ATPase is activated by actin 
and inhibited by ADP and Pi (Lymn and Taylor, 1971). Myosin heads maintains two 
angles with the actin filament, 900 and 450 throughout the cycle.  As shown in Figure 
1.11, Starting from a- rigor state ATP binds to the myosin head and dissociate it form the 
actin filament, and the myosin moves away from the filament (b). The binding of ATP is 
followed by hydrolysis to ADP + Pi and the myosin head is weakly bound (c), strongly 
bound (d) and followed by rigor force generated by the movement of myosin and  
producing sliding movement of actin over myosin shortening the muscle filaments 
(contraction). The cycle completes when ADP (f) is released and the continued by 
addition of ATP (a) to continue the cycle of events (Geeves et al., 2005). Recently Desai 
et al., (2014) using single molecule imaging techniques propose that two myosin heads 
are required to activate thin filament which will enable the binding of consecutive 
binding of 11 myosin heads during initial stages of muscle contraction.  
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Figure 1.11: Cross bridge cycle. Starting from a- rigor state ATP binds to the myosin 
head and dissociate it form the actin filament, and the myosin moves away from the 
filament (b). The binding of ATP is followed by hydrolysis to ADP + Pi and the myosin 
head is weakly bound (c), strongly bound (d) and followed by rigor force generated by 
the movement of myosin and  producing sliding movement of actin over myosin 
shortening the muscle filaments (contraction). The cycle completes when ADP (f) is 
released and the continued by addition of ATP (a) to continue the cycle of events (Geeves 
et al., 2005).  
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1.5 Three state model 
The biochemical interactions occurring during muscle regulation are explained by three-
state steric blocking model proposed by McKillop and Geeves (1993). According to this 
model, in the absence of Ca2+ tropomyosin physically blocks myosin from binding to 
actin. As shown in Figure 1.12a, the structural unit of the thin filament with 7 actin 
monomers (open circles) connected by tropomyosin represented as a blue straight line. 
The Ac-Tm-Tm unit always exists in dynamic equilibrium within the three states 
depending on the position of the Tm over the actin.  
The equilibrium constant KB exist between the blocked state (Figure 1.12a), where 
myosin (S1- represented a cone) binding does not occur in the absence of Ca2+ and the 
closed state. K1 is the binding constant with S1 binding partially to the actin but there is 
no force generation at this state, and KT exists between closed and open states, which 
depends on the number of S1 heads bound to actin sites. In presence of Ca2+ Tm moves, 
exposing the acting binding sites to allow S1 to bind to actin forming an A state with a 
rate constant of K1 as seen in Figure 1.12a during open state (S1 binding at 90
0 to the 
actin unit).  
K2 (Figure 1.12a open state) determines the isomerisation of S1 to rigor-like state (R 
state) to form force generating cross-bridges with actin during contraction (S1 binding at 
450). In the absence of Ca2+ the equilibrium returns back to blocked state. This model has 
been supported by others with different ionic strengths of actin and S1 units (Maytum et 
al., 1999, Geeves & Lehrer, 1994) and Moraczewska et al., (1999) showed that the length 
of Tm is important for the cooperative unit size of the actin and maintenance of 
equilibrium between open and closed states in contrast to McKillop and Geeves (1993).  
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Figure 1.12: Three state model for muscle regulation. A. The three state steric blocking 
model adapted from McKillop and Geeves (1993) and Maytum et al., (1999).  KB – equilibrium 
constant between blocked/closed state, KT – equilibrium constant between closed/open states K1 – 
binding constant to the open/A state where myosin (S1) is partially bound to actin and K2 the 
equilibrium between A/R states with S1 forming strongly bound crossbridges with actin to 
generate force. B and C. Cryo EM structure of A/M rigor -state from three state model, D 
and E. possible tropomyosin movement on actin filament during the M state, where in D 
the tropomyosin rolls or slides as in E (Ecken et al., 2014).  
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From the very recent studies it is now clear that tropomyosin does not bind to actin as a 
rigidly but rather but rather lay along actin in the groves in a semi rigid manner (Li et al., 
2011).  They overlap with each other in a head-to tail manner (Holmes and Lehman, 
2008; Murakami et al., 2008). Recently Ecken et al., (2014) produced models of A state 
and M state of three state model using Cryo-electron microscopy. Figure 1.12b and c 
show the movement of tropomyosin in A state and M ( R) state  and suggest that 
tropomyosin may roll over the actin (Figure 1.12d) or slide (Figure 1.12e). Rotation 
would shift tropomyosin with an azimuthal rotation of ~16Å with a ~70Å left handed 
rotation of tropomyosin and sliding would have the azimuthal rotation of ~13Å in 
addition to a shift of half –tropomyosin repeat, only when tropomyosin is linked end to 
end with the N/C terminal overlap.  
1.6 Diseases related to muscle dysfunction  
Regular functioning of heart is essential for survival of organism due to changes in the 
work load or to adjust to the environmental conditions heart undergo adaptation process 
to meet the demands for the changes. In pathological conditions similar adaptations takes 
place continuously trying to maintain normality. This compensation effect for longer 
period of time results in cardiac diseases that may be fatal to the individual. The severity 
of the symptoms depends on whether the adaptation is a short term or a long term 
adaptation (Meerson and Breger, 1977). 
 Cardiomyopathies, group of heart disorders, are caused due to adaptation in the heart 
muscle.  As shown in Figure 1.13 there are two basic types of cardiomyopathy, those that 
cause a thickening of the muscles – hypertrophic cardiomyopathies (HCM), and those 
where muscle is lost – dilated cardiomyopathies (DCM).   
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Figure 1.13: Normal (B), Hypertrophic (A) and Dilated (C) hearts. The hypertrophic 
heart shows thickening of the muscle, most significantly in the left ventricle wall and 
septum (dividing the two ventricles), decreasing the ventricular volume. In dilated 
cardiomyopathies, there is loss of muscle and the ventricular volume is increased  
(Seidman and Seidman, 2001). 
 
1.7 Causes of cardiomyopathies 
Most of the mutations causing cardiomyopathies are due to missense mutations mainly in 
MyBP-C, myosin heavy chain and myosin light chain mutations and mutations in geners 
encoding actin, troponin complex proteins and tropomyosin. A few are caused due to 
insertions or deletions or by alternate splicing. The mutant proteins are incorporated into 
the cardiac myofilament causing the genotypic and phenotypic variations in the heart 
(Seidman and Seidman, 2001). Hypertrophic cardiomyopathy can be caused by a variety 
of factors. HCM is characterized as enlargement of cardiac muscles with increase in size 
of the ventricular wall thickness (from >5mm to 30mm) (Gordon et al., 2000; Tardiff, 
2011) to its original size (Figure 1.13). Simple hypertrophy of the heart may result as a 
response to exercise (athlete’s heart) and this is not clinically significant. However 
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hypertrophy may also result due to the effects of disease. This can be a secondary effect, 
compensating for effects upon the circulatory system, but also as a genetically inherited 
disease (Familial Hypertrophic Cardiomyopathy, FHC) caused by mutations in the 
sarcomeric proteins (thin and thick filament) . Mutations in the genes encoding the 
cardiac contractile proteins are also responsible in dilated cardiomyopathies (Seidman 
and Seidman, 2011).  
Heart adaptation results in physiological changes to the heart. These can change the mass 
and type of tissue present and can change tissue properties through post translational 
modification of proteins and genetic adaptations that change the isoforms of the protein 
expressed. Adaptations may lead to cardiac disease or vice versa. Adaptations occur to 
adjust to the physiological demands on the heart (Tardiff, 2011; Yuan and Solaro, 2008)  
FHC can also describe mutations in sarcomeric proteins that lead to sudden cardiac death 
(SCD). However the degree of hypertrophy is not always linked to the incidence of SCD 
for all mutations, making diagnosis more difficult. Athletes and young children with high 
demands of physiological activity who have undiagnosed asymptomatic HCM are at high 
risk of SCD.  
The diseases associated with the cardiomyopathies are related with mutations in both 
thick and thin filament proteins of the sarcomere.  
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1.8 Thin filament diseases 
Thin filament mainly consists of actin, troponin (TnI, TnC, TnT), tropomyosin.  A variety 
of mutations occurring in thin filament have been reported that causes different types of 
cardiomyopathies. There is a lot of literature available in case of Troponins and 
especially TnI  (Peng et al., 2013; Seidman and Seidman, 2011; Tardiff, 2011).  Alpha 
Tm is found to cause FHC due to altered contractile function with Asp175Asn mutation 
and is reported to lead to severe dilated cardiomyopathy (DCM) (Prabhakar et al., 2001; 
Regitz-Zagrosek et al., 2000; Thierfelder et al., 1994). There are few mutations relating to 
actin alone that cause cardiomyopathies. Mutations in actin are linked to DCM in some 
cases identified by two mutations in actin Glu361Gly and Arg312His and the incident of 
HCM with actin mutation alone is found to be very rare (Seidman and Seidman, 2001; 
Tardiff, 2011).  
Mutations in beta-Tm (βTm) and gamma Tm (γTm) cause nemaline myopathy (NM) 
along with mutations occurring in actin, nebulin and troponin. NM is accompanied with 
electron-dense rods in skeletal muscle. The main cause of the mutation is found in the 
γTm / TPM3 gene present in slow-twitch skeletal muscle (Durling et al., 2002, Clarkson 
et al., 2004). Mutations in TPM3 gene are also been associated with neuromuscular 
transmission defect in congenital myopathy, chronic leukaemia and over expression of 
TPM3 have been linked with heptatocellular carcinoma in humans. Congenital myopathy 
with fibre type disproportion (CFTD) associated with mutations in TPM3 gene along with 
selenoprodin N, skeletal muscle α-actin and skeletal muscle rynanodine receptor (Li et 
al., 2011a; Nance et al., 2012).  
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1.9 Disease causing protein modifications 
The post-translational modifications (PTMs) of sarcomere proteins affect the structure 
and function of proteins resulting in shifts in isoform populations, forming degradation 
products, addition or deletion of protein availability, altered protein expression, 
availability of Ca2+ ions and ATPase activity (Tardiff, 2011b; Zhang and Ge, 2011b). 
Cardiac proteomics presents the next level in understanding cardiac disease and 
adaptation, where the physiological changes and genetic mutations taking place in the 
heart responsible for cardiac adaptations can be explained in terms of the changes 
occurring in sarcomere at the protein level. These changes are being identified using 
advanced techniques of mass spectrometry for protein isoform identification, PTMs  and 
protein interactions (Arab et al., 2006a; Arrell et al., 2001a; Peng et al., 2010; Peng et al., 
2014a; White and Eyk, 2007). Some progress in this area has already been made with Ge 
et al., (2009a) used top-down high resolution mass spectrometry analysis to characterize 
cardiac myosin binding protein-c phosphorylation sites. The phosphorylation sites of rat 
cardiac troponin have been reported by Solis et al., (2008) by top-down MS using 
electron capture dissociation ionisation. 
1.10 Aim of this study  
The general aim of this study is to quantify tropomyosin isoforms with various 
techniques in different scenarios. First attempt is to express Tpm3.12st isoform in E. coli 
and characterise its actin binding properties using co-sedimentation assays. Three 
variants of Tpm3.12st are produced with additional small amino acid residues to mimic 
the N-terminal acetylation of the protein. This will enable to investigate this isoform 
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affinity to actin in comparison with other muscle isoforms (Tpm1.1st, Tpm2.2st and 
Tpm4.1cy).  
Second aim is to use tropomyosin recombinant proteins to study the effect of each 
tropomyosin isoform on actin polymerisation dynamics in order to understand the actin 
polymer association as tropomyosin exhibit different properties in various tissues 
(Gunning et al., 2008a).  
Third objective was an attempt to design a monoclonal antibody specific to human 
Tpm3.12st sequence to use for identification of this isoform in tissues and cells. The 
present antibody used for Tpm3 is CG3 (Lin et al., 1985) which identifies all Tpm3 
isoforms, both high molecular and low molecular weight isoforms.  
And finally, a novel method was developed to extract thin filament proteins from muscle 
tissue (skeletal and cardiac) and other soluble proteins for separation and identification of 
these proteins using reverse phase liquid chromatography (RP-HPLC). This method when 
integrated with mass spectrometry would be potentially used to quantify thin filament 
protein isoforms and their post translational modifications which will provide information 
on the protein composition and ratio of isoform composition.   
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Chapter II 
Expression and Characterisation of Human Tropomyosin 3 
(Tpm3) isoform 12.st in Escherichia coli  
&  
Effect of Tropomyosin Isofroms on Actin Polyerisation 
 
2  Introduction 
Tropomyosin is a significant component of thin filament and has multiple roles in 
regulating actin filaments in tissues and cells. Tropomyosin is α-helical dimer protein, 
polymerizes head-tail to form a continuous filament along the grooves of actin filament 
(Gunning et al., 2008a). The head to tail association along the length of protein is 
important for actin binding (Hitchcock-degregori, 1993). As mentioned in chapter I 
tropomyosin with troponin complex form a Ca2+ sensitive switch that regulates muscle 
contraction. Crick (1952) suggests that helical coils are present in the form of heptad 
repeats with hydrophobic amino acids every first and fourth residues forming the 
hydrophobic core. The hydrophobic interactions of amino acids in proteins play major 
role in the stability and three dimensional structure of proteins. Alteration in the 
positioning of hydrophobic core amino acids affects the stability of the proteins. 
Tropomyosin structure is extensively studied as it is the first α-helical coiled coil protein 
where its amino acid sequence was determined (Kwok and Hodges, 2004; Parry et al., 
2008). 
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Tropomyosin is a two-stranded α-helical coiled coil protein characterised by a heptad 
repeat, the positions denoted as “abcdefg” with  hydrophobic amino acids positioned at a 
and d. These non-polar amino acids initiates the formation of a left handed α-helical 
coiled structure from two right handed helical coils to form a dimer tropomyosin α-
helical coiled coil structure Figure 2.1B. The term ‘coiled coil’ is referred to the 
structures that are wound together into super helical coils as exhibited by tropomyosin 
molecule shown in Figure 2.1A. The positions e and g are occupied by oppositely 
charged acidic and basic amino acids which interact with the other filament of the dimer 
to form salt bridges supporting the α-helix stability. The outer amino acids b, c and f are 
occupied either with ionic or polar amino acids forming the external hydrophilic surface 
(Perry, 2001; Zhu et al., 1993).  In two stranded tropomyosin helical coil, the 
hydrophobic a and d positions of the opposite coil lie perpendicular interacting with each 
other (a-d and aꞌ-dꞌ) as shown is Figure 2.1B. Due to the variation in the distance of the 
carbon bonds between a and d, position a usually have isoleucine, valine and threonine 
and the position d usually have leucine and alanine at its hydrophobic core. The 
interactions of hydrophobic core a and d residues are critical for stability of the coiled 
coil (Zhou et al., 1992).  The relationship between the increase in the hydrophobicity of 
the residues at a and d  is directly proportional to the increase in the stability of the 
hydrophobic core of the coil (Kovacs et al., 2006). However, sometimes destabilizing 
clusters are also present at the hydrophobic core such as alanine, lysine, aspartate, 
cystein, proline, arginine and few others (Kwok and Hodges, 2004). Tropomyosin is 
considered to have both stabilizing and destabilizing regions where few hydrophobic 
positions at a and d are occupied with polar or ionic amino acids. These regions of 
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stability associated with destabilizing position at hydrophobic core gives tropomyosin 
structure its unique stability (Kirwan and Hodges, 2010). 
 
Figure 2.1: Heptad repeat arrangement of tropomyosin αhelical coil: A. α-helical 
coiled coil tropomyosin (RSBC-PDB). B. Cross-section view of alpha helical chain 
showing seven residues (a-g). a and d are hydrophobic which keeps coiled coil stable 
with the help of salt bridges between e and g and also showing the position of charge 
transferred when additional amino acids are added to the N-terminal of a recombinant 
proteins that are used to produce for this study. The figure shows the position of 
additional amino acids added at the N-terminal of the recombinant proteins used in this 
study C. Shows the initial N-terminal amino acids of the protein sequence and their 
position in the alpha-helical model. *shows the position of hydrophobic core residues. 
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2.1 Tropomyosin expressed in E. coli and N-terminal methionine acetylation 
N-terminal acetylation of a protein is the addition of acetyl group to the α-amines of the 
N-terminal amino acid in the sequence or the amines of the lysine side chains. The 
acetylation alters the reactive amine group to unreactive amide carrying no charge at the 
end.  This change in the N-terminal sequence changes the steric arrangement and stability 
of the protein structure and 80% of proteins undergo this modification (Phillips, 1963).  
The process of N-terminal methionine or acetylation is an enzymatic activity catalyzed by 
methionine aminopeptidase (MetAps) and Nα acetlytransferase (NAT) and is found to be 
a co-translational process. The removal of the N-terminal-Met is determined by the 
adjacent amino group to the methionine. The smaller amino residues Alanine (Ala), 
Valine (Val), Serine (Ser), Threonine (Thr), Cysteine (Cys), Glycine (Gly) and Proline 
(Pro) are  targeted by the MetAps for acetylation and if there is any larger groups present 
the N-terminal-Met is retained and not acetylated (Bradshaw et al., 1998) which is due to 
the steric hindrance deduced from crystal structure of MetAps (Lowther and Matthews, 
2000). On the other hand, NAT catalysis is carried out by the NAT complex and is 
classified into 3 groups, Nat A, B and C. NAT show the same principle of N-terminal-
Met with only limited residues of specificity with glycine, alanine, serine and threonine 
(GAST substrates) at the downstream of  the amino acid chain. Although there is a 
requirement of smaller amino residue adjacent to N-terminal-Met, there is difference in 
the tolerance of the different classes of these MetAps and NAT complexes  E. coli lacks 
these Nat complex (Xiao et al., 2010).  
Tropomyosin synthesized in eukaryotes is acetylated at its N-terminal methionine as a 
posttranslational modification to perform its function in binding to actin and regulate 
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muscle contraction along with troponin complex. Tropomyosin amino acids at the N-
terminal and C-terminal ends play crucial role in head-tail association of the protein and 
for binding to actin filament. The first and last 9-11 amino acids at the N-terminal and C-
terminal form an overlap region and disruption of this region lowers the affinity to actin 
filament (Cho et al., 1990; Urbancikova and Hitchcock-DeGregori, 1994). Urbancikova 
and Hitchcock-DeGregori (1994) postulated that in order for co-operative binding of 
tropomyosin to actin, the N-terminal methionine should be modified to an amide or the 
N-terminal amino acid in fusion protein should be in a peptide bond. 
Skeletal tropomyosin expressed in E. coli is found to have 30-fold weaker binding to 
actin than the native protein isolated from striated muscle. The difference is that the 
methionine at the N-terminus of the sequence is not acetylated in the protein produced in 
E. coli (Heald and Hitchcock-DeGregori, 1988; Maytum et al., 2001; Monteiro et al., 
1994; Moraczewska et al., 1999; Palm et al., 2003). It is known so far that the acetylation 
of methionine helps in maintaining the stability of Tm helical strands and its high affinity 
for actin in presence of troponin. However, it is thought to protect the proteins from 
degradation by N-terminal proteases. In contrast, according to Hwang et al., (2010) and 
Kim et al., (2013) N-terminal polyubiquitylates creates degradation signals called N-
degrons that cause degradation of destabilizing N-terminal residue of the protein in 
Saccharomyces cerevisiae. 
Escherichia coli is widely used to produce the recombinant tropomyosin to study the 
properties and characterization of the proteins. E. coli is one of the extensively used 
prokaryotic organisms in research and commercial use for genetic manipulation and 
recombinant protein expression and production. Because of its advantages in inexpensive 
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carbon source, easy scale-up and its rapid collection of biomass, E. coli has become one 
of the most commonly used expression systems. However, proteins produced in 
prokaryotes do not undergo post-translational modifications such as phosphorylation, 
acetylation and methylation (Baneyx and Mujacic, 2004). 
To make functional recombinant proteins in E. coli, addition of small amino acids at the 
N-terminus mimics the N-terminal acetylated function of native tropomyosin. Heald and 
Hitchcock-DeGregori (1987) produced fusion recombinant α-tropomyosin with 
additional 80 amino acids at its N-terminal which did bind to actin but was incapable of 
polymerizing and regulating the actomyosin ATPase. Monteiro et al., (1994) showed that  
by adding two or three aminoacids at the N-terminus of chicken skeletal tropomyosin 
produces native like protein. The recombinant proteins retained function of actin binding 
capacity, polymerises in a cooperative manner and also regulates ATPase activity during 
muscle contraction. Maytum et al., (2000) verified the work of Monteiro’s work in yeast 
tropomyosin produced in E. coli and also demonstrated that small changes in N-terminal 
sequence maintains the actin binding property, however it affects the actomyosin 
regulation by changing the apparent equilibrium constant between open and closed states. 
This in turn affects the conformation of Tm on actin and the availability of actin binding 
sites to myosin during muscle regulation. Coulton et al., (2006) showed that unacetylated 
αTm of smooth muscle does bind to actin, however the recombinant αTm expressed in  
E. coli where Ala Ser peptides were added to mimic the acetylation have ~100 fold 
increase in affinity to actin.  Maytum and Konrad (2006) developed a system with yeast 
NatB acetylation complex co-expressed with α-tropomyosin in E. coli and recently 
Johnson et al., (2010) validated the expression system by successfully co-expressing 
  
43 
 
yeast NatB acetylation complex with mammalian α-tropomyosin E. coli but with varying 
levels of acetylation.  
2.2 Effect of Tropomyosin isoforms on actin polymerization 
Actin is a filamentous protein that provides cells mechanical support and is responsible 
for cell movement. Actin in cellular processes is also involved in sensing surrounding 
environment and cell division and intercellular movements (Pollard and Cooper, 2009). 
Approximately 400 genes encode actin in all the biological organisms and the eukaryotic 
cytoskeleton has been evolved from prokaryotes showing highly conserved amino acids 
between the species even though they have divergent sequences (Erickson, 2007). Actin 
is one of the most abundant proteins on earth as it is found at a high cellular 
concentration in all organisms. Actin was discovered in muscles in 1940s which plays 
major role in muscle contraction along with other motor protein myosin (Richards and 
Cavalier-Smith, 2005). All eukaryotes have genes for actin and genes for the actin 
binding myosin protein which produces force to actin filament generating movement 
through hydrolysis of ATP (Erickson, 2007). 
In vivo and in vitro studies showed that actin forms spontaneous filaments from actin 
monomers by hydrolysis of ATP and many other proteins are involved in the 
polymerisation and regulation of actin as shown in Figure 2.2 (Pollard and Borisy, 2003; 
Pollard and Cooper, 2009). The conserved sites present in all the actin molecules both in 
eukaryotes and homologs in prokaryotes were found to be the amino acids involved in 
binding of ATP and the once involved in filament formation were not conserved 
(Richards and Cavalier-Smith, 2005; van den Ent et al., 2001). 
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Figure 2.2:  Structure of actin, filament formation and regulation processes. A. Ribbon model and space filling model of 
actin molecule. B. Filament formation of actin showning nucleation and elongation process. C. Monomer actin binding 
proteins – Prolifin, cofilin and thymosin-ß4. D. Nucleation and elongation by formin. E. Regulation of actin by Arp2/3 
complex, F. Filament reactions occurring in actin , G. Myosin-V walking on the actin filament (Pollard and Cooper, 2009).
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2.2.1 Actin binding proteins and filament formation  
 
Actin filament formation is one of the essential processes for the contractile structures in 
many organisms. The polymerisation of actin is initiated spontaneously to form a nucleus 
(Figure 2.2 a and b) which is a very slow process, but once the filament is formed the 
elongation process is quite rapid as long as the monomer concentration is constant until it 
reaches a steady state where polymerisation completes at which point no net actin 
polymerises (example polymerisation curve shown in Figure 2.5) (Pollard and Cooper, 
2009). Monomers are added to both sides of the filament, however polymerisation is 
faster on barbed end than the pointed end. The actin polymer is a helical polar structure 
as all the monomers in the filament are pointed in the same direction. The association of 
monomeric actin is associated with hydrolysis of ATP to ADP which is incorporated with 
the filament actin (Straub and Feuer, 1950). Filament actin bound to ADP continue 
polymerisation process but the rate at which the polymerisation occurs is five times 
slower than ATP bound actin (Cooke, 1975).  It is also stated by Cooke (1975) that ATP 
hydrolysis  of actin nucleotide complex is not the only factor that initiates polymerisation 
of actin.  
Many accessory proteins are involved in maintaining the availability of monomers, 
initiation, polymerisation, regulate the length of actin filament and the turnover of actin 
filaments depending on the requirement of the system, for example more than hundred 
accessory proteins are involved in actin regulation process in eukaryotes (Richards and 
Cavalier-Smith, 2005). Examples of the accessory proteins that are involved in actin 
polymerisation are shown in Figure 2.2. Thymosin ß4 which blocks the assembly of actin 
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monomers by binding to ATP, profilin inhibits nucleation and pointed-end elongation of 
filament, but not barbed end elongation (Figure 2.2b). Nucleation promoting factors 
(NPF) such as WASp (Wiskott-Aldrich Syndrome protein) bind to actin monomer along 
with  actin related protein -Arp 2/3 complex and formins (Figure 2.2e) (Pollard, 2007) to 
bind to already existing filament competing with profiling which prevents monomer to 
bind to filament at barbed end. Arp 2/3 complex promotes elongation until capping 
protein stops the growth of the filament. Formins found in the actin bundles of 
cytokinetic contractile structures and filopodia, remains associated with the filament ends 
at the barbed end preventing the capping proteins to stop elongation (Wallar and Alberts, 
2003). Cofilin is another protein that binds to NPF proteins and initiated nucleation. 
Other proteins called capping protein such as tropomodulin binds to tropomyosin bound 
actin and caps the filament at the pointed end to stop filament elongation (Weber and 
Pennise, 1994). Cofilin along with gelsolin break the actin filaments into fragments 
which are formed into crosslinks by crosslinking proteins (Figure 2.2f) (Pollard and 
Cooper, 2009; Richards and Cavalier-Smith, 2005). 
2.2.2 Actin polymerisation kinetics 
 
Actin polymerisation has been studied from many years. The first studies focusing on 
actin polymerisation kinetics were developed by Oosawa and Asakura (1975). Later on 
Wegner and Engel (1975) described the process focusing on the importance of the 
kinetics involved in nucleation and elongation during polymerisation measured using 
light scattering and microscopy. According to the theory, actin polymerisation is initiated 
by the result of nucleation and elongates with continuous binding of actin monomers to 
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the ends of filaments. Nucleation consist of aggregation of few monomer units forming a 
dimer, trimer or a tetramer forming a small filament and elongation occurs by sequential 
addition of monomers on either side of the actin filament. The rate constants of the steps 
involved in association and dissociation of monomers were found to be similar in contrast 
to the nucleation step which was very low, and shows that this step is really slow to start.  
According to Wegner and Engel (1975) the preliminary aggregate of size n-1 forms 
rapidly and is capable of dissociation at the same rate, hence is always in equilibrium 
with the monomer instead of initiating a polymer formation. The filament growth is 
initiated when the aggregate formed is stable enough to add more monomers and form a 
filament when the concentration of monomer reaches a steady state (critical concentration 
of unpolymerised actin). In simple terms the polymerisation reaction can be shown in the 
equation below 
 
Where AcG is G-actin and Acf is F-actin, ka and kd are association and dissociation 
constants. When ka is greater than kd polymerisation occurs, when ka is equal to kd the 
system is stable and when kd is greater than ka depolymerisation occurs.  
In biological systems polymerisation happens at both ends of the filament (Oosawa and 
Asakura, 1975). The equilibrium constant for binding of monomer to a polymer at both 
the ends is similar as it leads to the formation of same polymer (Wegner, 1976). Even 
though the association and dissociation constants at both ends may not be similar, 
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however the ratio of the rate constants for both these reactions should be same as shown 
in equation 2.   
                                                                             
Where ka and kaꞌ are the association constants of barbed end and pointed end respectively 
and kd and kdꞌ are the respective dissociation constants.  
The critical concentration (c) in this case can be calculated using equation 3 (Tobacman 
and Korn, 1983).  
 
Where k+ is the sum of the rate constants of association and k– is the sum of the 
dissociation constants at both ends of the filaments.  
The rate of polymerisation (dAp/dt) can be given by the equation (4). 
 
Where   = k+ / k−,  which is the concentration of monomeric actin at steady state 
(critical concentration) and Am is the concentration of monomeric (G) actin, k+ is the sum 
of rate constants of monomer addition and k− is the sum of dissociation of monomer actin 
at both the ends of the filament, F is the concentration of polymer, F actin (Tobacman and 
Korn, 1983; Wegner, 1976). 
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The rate of nucleation can be expressed as in Equation 5, which is the rate of change in 
number of filaments per unit volume (Wegner, 1976). 
 
Where, Kn-1 is the association constant in relation to the concentration of monomer with 
the aggregate of size n-1.  
Equation 4 and 5 together are inter-related which can be used to predict the rate of actin 
nucleation and polymerisation. Integrating the numerical values in these equations would 
generate polymerisation curves that depend on the size of the nucleus, monomer actin 
concentration and critical concentration of monomeric actin.  
Apart from forming filaments, end-to-end association of actin filaments and spontaneous 
fragmentation also happen in natural physiological conditions creating more nucleation 
sites for polymerisation to proceed which changes the kinetics of the polymerisation 
reaction (Wegner, 1982a).  
2.2.3 Actin nucleation kinetics 
 
Nucleation is the process of formation of aggregate that forms the basis for the filament 
to elongate (Wegner and Engel, 1975). Formation of nucleus is the very first step in actin 
polymerisation which leads to elongation. Nucleus formation is considered unfavorable 
followed by favorable rapid elongation process. There are lots of studies pursued to 
interpret the correct actin polymerisation dynamics. Sept and McCammon (2001) studied 
kinetics of actin filament nucleation using thermodynamic Brownian dynamics (BD) uses 
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advance simulation technique to predict protein association rates. According to them the 
formation of nucleus is entropically unfavorable agreeing with physiological studies 
previously (Frieden, 1983a; Frieden and Goddette, 1983b; Tobacman and Korn, 1983; 
Wegner, 1976; Wegner and Engel, 1975). Cardilli and collaborators (2009) proposed 
composition algebra models to show geometric representation of actin polymerisation 
dynamics. Frieden (1983b)  and Cooper et al., (1983a) showed a scheme of association 
and dissociation constants for each step of polymerisation – nucleation , elongation and 
steady state dynamics as shown in equations i - viii.  Step and McCammon (2001) 
predicted the favorable pathway for polymerisation from initiation of nucleus to the 
elongation process as shown in the Figure 2.3 in agreement with Frieden and Goddette 
(1983a) and Cooper et al., (1983a) that the nucleus undergoes a conformational change in 
order to bind additional monomer to form a filament, like binding to a salt ion like Mg2+. 
From all the above mentioned studies the formation of a trimer is the critical nucleus that 
is favorable to proceed to elongation. However Tobacman and Korn (1983) proposed that 
the critical stable nucleus to proceed to polymer is a tetramer.  
i.  
ii.  
iii.  
iv.  
v.  
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vi.  
vii.  
viii.  
In the above equations, i is the initiation of nucleus forming a dimer and vii is the 
elongation step and viii is the fragmentation step. The rate constants of each step are 
given in the Figure 2.3 adapted from  Tobacman and Korn (1983) and Sept and 
McCammon (2001).  
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Figure 2.3: Actin nucleation – polymerisation pathways. Pathways of polymer 
formation from a monomer actin shows the different conformations possible to from a 
dimer and the predicted possible conformation favored to form a trimer and tetramer and 
continuation to a polymer. The favored pathway is shown in red and reversible reaction 
rate constants are given (Cooper et al., 1983a; Sept and McCammon, 2001; Tobacman 
and Korn, 1983).  
 
 
 
2.2.4 Effect of Tropomyosin on actin polymerisation and kinetics 
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Tropomyosin regulates and stabilizes actin filaments in physiological conditions. In 
striated muscle tropomyosin regulates the availability of myosin binding sites on actin 
during contraction in presence of Ca2+ ions (Gunning et al., 2008a). Spudich and Watt 
(1971) established the fact that tropomyosin along with troponin inhibits ATPase by 
binding to actin and not myosin during muscle contraction. In non-muscle cells 
tropomyosin primary role is believed to regulate actin filament proteins and protect the 
actin filaments from severing proteins (Lin et al., 1988; Pittenger et al., 1994b). Studies 
from Caenorhabditis elegans found that tropomyosin stabilises actin filaments and it has 
an opposite effect when ADF/cofilin are present. ADF/cofilin depolymerizes filament 
actin and in presence of tropomyosin this effect is inhibited (Ono and Ono, 2002). The 
presence of tropomyosin on actin filaments was also found to inhibit the Arp2/3 complex, 
which is bound to actin filament initiation to form a branch on the filament.  
Wegner and collaborators initiated studies on the kinetic analysis of actin in presence of 
tropomyosin. Wegner (1980) studied the difference in interaction of tropomyosin 
homodimer (α/α) and heterodimer (α/β) on actin polymerisation these tropomyosin 
isofroms differ with 39 amino acid residues between α chain and β chain. The 23 of these 
residues are situated at the surface of the tropomyosin chain. When tropomyosin is bound 
to actin filament, 9 residues present at the C-terminal end of the tropomyosin interact to 
form a polar end-to-end contact with the adjacent tropomyosin molecule at the N-
terminal end. Tropomyosin binds to actin in a flexible manner that is loosely attached to 
F-actin as it is shown that specific regions of tropomyosin are not even bound to actin 
filament making it flexible to achieve conformational changes during contraction process 
(Lamkin et al., 1983).  
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Figure 2.4: Tropomyosin binding possibilities on actin filament. 1. Individual isolated 
binding along the actin filament, 2. Single contiguous binding and 3. Double contiguous 
binding (redrawn from Wegner, 1980). 
 
As discussed in section 2.1, the interaction of actin-tropomyosin is of co-operative nature. 
Figure 2.4 shows the different types of tropomyosin binding to actin, position 1 shows the 
binding of isolated tropomyosin molecule (a dimer) bound to actin. Isolated binding of 
tropomyosin occurs when magnesium ion concentration is very low (0.5 mM) and 
position 2  single contiguous binding occurs when tropomyosin molecule is interacting 
with other tropomyosin molecule on one side of the helix and  position 3 double 
contiguous interaction where head-to tail interaction on both sides of the tropomyosin 
molecule occurs. The single and double contiguous binding happens when magnesium 
concentration is  higher (1.0 – 2 mM) (Wegner, 1979). These contiguous end-to-end 
interactions of tropomyosin on actin molecules determine the flexibility of the actin 
filament as well as maintain its own flexible interaction with actin in turn                                    
maintaining the co-operative binding with each other (Lehman et al., 2013).   
 
2.2.5 Hill equation simulation 
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The data obtained from the fluorescent labelled actin polymerisation and the 
polymerisation in presence of tropomyosin were fit to least squares to a sigmoidal curve 
using Hill equation to time course of polymerisation of actin to study the effect of 
tropomyosin on actin polymerisation using Origin 6.0 software.  
The basic Hill model has three parameters, x the independent variable which is the time 
(in seconds) taken to reach the polymerisation saturation in this reaction and y is the 
dependent variable, the fluorescent intensity in arbitrary units.  
The equation below was used by the software for fitting the data. 
                                  
Where, Vmax is maximum saturation, x is time in seconds, k is the dissociation constant 
and n is the Hill coefficient which determines the degree of polymerisation and is the 
measure of sigmoidicity. Figure 2.5 shows the computer generated Hill model 
simulations showing sigmoidal curves. The slope of the curve remains same as long as 
one parameter remains constant either the half time (k) or the Hill coefficient (n). As the 
n changes the sigmoidicity changes but the slope of the curves remains same.  
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Figure 2.5: Hill simulations for actin polymerisation. A is simulated with rate constant 
k = 1000 sec which gives the half saturation value with varied n values to show the 
change in sigmoidicity. B have a value of k = 250 sec with variable n value. Changes in 
both k and n changes the slope which in this case is the rate of elongation. I – initiation, E 
– elongation and S- steady state –completion of polymerisation.  
 
In non-muscle cells at low ionic concentrations of monomeric actin, the curves show 
higher sigmoidicity with a long lag phase which indicates that the elongation is due to 
self-reproduction or filaments forming by spontaneous fragmentation. Studies show that 
at lower ionic concentrations due to the lower available actin monomers, nucleation 
process is slower which causes the longer lag-phase with higher sigmoidicity (Cooper et 
al., 1983b; Lal and Korn, 1986; Wegner, 1976; Wegner and Engel, 1975).  
In the present study, a series of actin polymerisation curves were generated by 
experiments conducted using pyrene labelled G-actin in presence and absence of 
tropomyosin. Pyrene G actin when polymerises shows an increase in fluorescence when 
excited at 365 nm without affecting polymerisation kinetics and any binding sites of 
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actin-tropomyosin interaction (Kouyama and Mihashi, 1981). The first phase of 
experiments actin polymerisation concentration was optimised using 2 µM and 6 µM 
PyG-Ac to see the difference in actin polymerisation kinetics in comparison with 
previous studies. To proceed to actin polymerisation in presence of tropomyosin two 
concentration of Tpm1 as initial tropomyosin (0.5 µM and 5 µM) was chosen to check 
the effect of actin polymerisation at low concentration and to see the difference at low 
concentration and by saturation concentration of tropomyosin. 6 µM tropomyosin was 
chosen to proceed with other assays using various tropomyosin isoforms as this should 
give saturation of actin.  
Actin polymerisation in presence and absence of tropomyosin follow a sigmoidal 
pathway, however the half time of the steady state polymerisation taken from the time 
course curve cannot be used to calculate the nucleus number (Cooper et al., 1983a; 
Frieden and Goddette, 1983a). Hence in this study the time course polymerisation curves 
generated using Hill equation are compared qualitatively to show the polymerisation 
pattern of actin-tropomyosin, and the data is not sufficient to calculate the nucleation-
elongation kinetics.  
2.2.6 Aims and Objectives 
 
The aim of this chapter is to express recombinant human tropomyosin 3 isoform 12.st 
(Tpm3 iso12st) from striated muscle, (will refer in the whole thesis as Tpm3) in E. coli in 
three different versions with variation at the N-terminus. Using co-sedimentation assays 
the protein is characterized for its actin binding affinity compared along with other 
tropomyosin isoform Tpm1.1st, Tpm2.2st and Tpm4.1cy as this isoform is not yet been 
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characterized for its actin binding affinity and little is known about its role in thin 
filament. For this study I produced Tpm3 which is considered to be 285 amino acids (aa) 
length. In this study, three versions of Tpm3 were produced with 284 aa with on singl 
“Met” at the N-terminal end of the sequence,  285 aa with “Met-Met” which is the 
original sequence (Figure 2.6) and 286 aa (Met)-Ala-Ser” at the N-terminal end of the 
sequence. The positions of the positive charge transfer when these aminoacids are added 
to the N-terminal end of the sequence are shown in Figure 2.1B.  
The importance of studying the effect of tropomyosin on actin polymerisation is it gives 
the ability to quantitatively measure the incorporation of monomer to polymer and how 
presence of tropomyosin molecule affects this polymer association. Given to its role in 
mammalian cellular processes it is important to understand tropomyosins effect on actin 
polymerisation as it is known that isoforms of tropomyosins are in different 
concentrations in the cell (Schevzov et al., 2005).  
 
2.3  Materials 
Chemicals used for the experiments were obtained from Sigma-Aldrich, Thermo-Fisher 
and BDH. 30% Protogel (Acrylamide-bisacrylamide) obtained from National diagnostics. 
Enzymes and buffers were obtained from New England Biolabs and Thermo-Fisher. 
DNA plasmid extraction kit is from Eppendorf and homemade kit. Gel purification kit 
used from Eppendorf. Table 6.1 in appendix gives the list of all the chemicals and their 
suppliers used for the experiments. Recipes of all the buffers are found in buffers section 
(Section 6.2) in the appendix.  
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2.4 Experimental Methods 
2.4.1 Construction of different tropomyosin isoform expression vectors  
 
Fully sequenced cDNA clones of human tropomyosin 3 isoform 12st (Tpm3.12st) (NCBI 
sequence accession number NP_689476.2 shown in Figure 2.6 in E. coli culture were 
obtained from Thermo scientific. Tpm4 isoform 1 (284aa) cDNA clones was obtained 
from Thermo Scientific, where the sequence was codon optimised for expression in E. 
coli. The nucleotide sequence alignment comparing the human Tpm4 sequence 
(accession no: NM_001145160.1) and the synthesised codon optimised gene is shown in 
Figure 2.7.  
The oligonucleotide primers were obtained from Sigma- Aldrich. Tpm3 primers were 
designed according to Maytum et al., (2000) with a native sequence of 285 Met 
Met(MM) amino acids(aa), a 284 aa with single Met (M),  and 286 aa Met, Ala, Ser 
(MAS) at the amino terminal to substitute the N-terminal acetylation in E. coli with 5’- 
Nde I and 3’- Xho I restriction sites. Xho I is used for TPM3 it has multiple BamHI 
cleavage sites in the sequence itself. For Tpm4 DNA was synthesized with 5’-Nde I and 
3’-Bam HI restriction sites. Table 2.1 shows the forward 5’ and reverse 3’ primers 
designed with the cleavage sites in bold.  
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Figure 2.6: Tpm3.12st protein  sequence used for designing primers (NCBI sequence accession number NP_689476.2).  
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Table 2.1: Primer sequence designed for human tropomyosins to express in E. coli.  
 
Note: The upper case and lower case amino acids represent the original human TPM3 sequence and the 
additional fusion aa at the N-terminal respectively. TPM1, TPM2 and TPM4 were designed with BamHI 
and NdeI restriction sites and TPM3 with NdeI and XhoI retriction sites. * TPM4 was synthetically 
synthesised. “▼ “ Restriction sites.  
 
The sequence for Tpm3 oligonucleotides were designed with NdeI and XhoI restriction 
sites and for Tpm4 with BamHI and NdeI restriction sites. (BamHI-G▼GATCC, NdeI-
CA▼TATG, XhoI-C▼TCGAG). Clones of Tpm1 and Tpm2 and clones of Tpm1 HCM 
mutation A63V and K70T were given by Dr. Robin Maytum. 
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Figure 2.7: Tpm4- Nucleotide sequence alignment: The top sequence is from the human Tpm4 sequence with accession 
number. The bottom one Tpm4-Seq read, is the codon optimized synthesized gene used for expression of protein in this study. 
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2.4.1.1  Amplification of Tropomyosin cDNA isoforms 
 
The Tpm3 cDNA clones obtained were in glycerol stock with 25 ug/ml of 
chloramphenicol resistance clone. 50 ml LB media with 25 ug/ml chloramphenicol was 
inoculated with cDNA culture (100 ml of LB: 1g bacteriological peptone, 5 g yeast 
extract and 5 g NaCl. pH 7.5) and grown 8 hours at 370C and plasmid DNA was 
extracted using mini plasmid extraction kit from Eppendorf.  Three variant of Tpm3 
iso12st were synthesised with the primer designed as shown in Table 2.1. Tpm4 gene was 
synthetic DNA and hence the DNA was used directly for amplification. 
2.4.1.2  Polymerase chain reaction 
 
PCR was used to amplify the gene of interest and also to insert additional peptides at the 
N-terminus of the sequence to synthesize three fusion variants of Tpm3. The variants in 
this work will be referred as Tpm3-Met, Tpm3-MM and Tpm3-MASM. Tpm4 gene was 
used directly for amplification with additional 3 peptides to mimic the N-terminal 
acetylation of the sequence. 50 μl of PCR mixture was prepared containing 10μl of 10X 
NEB Thermo pol PCR buffer, 200 μM dNTPs, approximately 20 ng template DNA,      
33 nM primers with 2 units of Taq polymerase. A thermal cycler was set as shown in 
Table 2.2 
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 Table 2.2: PCR cycle used for DNA amplification 
 
The PCR reaction products were separated by using 1.5% agarose gel electrophoresis 
with GeneRuler 1 kb DNA ladder. The band matching the size of the insert (853 bp) was 
cut from the gel and purified using eppendorf gel clean up kit following manufacturer’s 
instructions. The DNA extracted was stored at -200C for further use.  
2.4.1.3  Expression of tropomyosin in E. coli with pJC20 plasmid vector 
2.4.1.4  pJC20 Vector 
 
The pJC20 plasmid vector (Figure 2.8) is widely used for efficient and specific over 
expression of cloned genes in E. coli. pJC20 is  a high-copy number expression vector 
with T7 RNA polymerase promoter, and its expression is controlled by lac promoter 
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induced with IPTG. The pJC20 vector has multiple cloning sites with  NdeI, BamHI and 
XhoI restriction sites. It has high copy region of replication, with ampicillin resistant gene 
and T phi terminator. The small size of the vector allows sub cloning of large inserts and 
high plasmid copy numbers obtained results in high yields of the expression genes. It is 
found to be stable in both XL1blue and BL21DE3 strains of E. coli (Clos and Brandau, 
1994). 
 
Figure 2.8: pJC20 vector used for cloning: pJC20 is a 2340 bp circular plasmid 
expression vector with T7 RNA polymerase promoter region and multiple cloning sites 
with NdeI, Bam HI and XhoI restriction sites. It has high copy region of replication with 
ampicillin resistant gene and T phi terminator.  
 
2.4.1.5 Restriction digestion of PCR product 
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Purified DNA from the PCR product and pJC20 vector were double digested using 
Thermo scientific FastDigest NdeI and XhoI for TPM3 variants and for TPM4 NdeI and 
BamHI  restriction enzymes were used. Approximately 300 ng of DNA (40 μl) was 
mixed with 1μl of each buffer with 5 μl of 10X FastDigest Green buffer and made upto 
50 μl with ultrapure water. The mixture was incubated for 30 min at 370C. The pJC20 
vector was also digested with same enzymes at the same time. The digest product was 
separated on 1.5% agarose gels. The band of interest and the vector band were cut from 
the gel and purified by Eppendorf gel clean up kit using manufacturer’s instructions.  
2.4.1.6 Ligation 
 
To insert the Tpm3-DNA into plasmid DNA, T4 ligase was used for ligation. Before 
performing ligation, the ends of the plasmid DNA were dephosphorylated using NEB 
Calf intestinal Alkyl phosphatase (CIP), it catalyses the dephosphorylation of 5’ ends of 
DNA. Dephosphorylation of plasmid DNA prevents re-ligation of the linear plasmid 
reducing the background of ligated colonies. An amout of 2 μl of CIP is added to the 
purified plasmid DNA with 3 μl of NEB buffer 3 and incubated for 1 hour at 25 0C. The 
plasmid is again purified through the same column used for gel clean up kit to remove the 
buffer before ligation.  
For ligating the insert with plasmid DNA, Thermo Scientific T4 DNA ligase is used. T4 
ligase catalyzes the formation of a phosphodiester bond between 5'-phosphate and 3'-
hydroxyl termini in double stranded DNA. Insert DNA was added to pJC20 DNA in 3:1 
ratio, with 1 μl (1 Weiss unit) T4 DNA ligase and 2 μl of 10X T4 ligase buffer and made 
  
67 
 
upto 20 μl of total volume by ultrapure water. The mixture was incubated at 20 0C for 30 
min.  
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2.4.1.7 Preparation of E. coli competent cells 
 
Competent E. coli  cells were prepared according to Nishimura et a.,(1990). LB agar 
place was streaked with bacterial starter culture. A single colony was inoculated into     
50 ml of LB medium supplemented with 10 mM MgSO4 and 0.2% glucose (medium A), 
Mg2+ ions and glucose stimulates transformation efficiency. The culture is grown to mid 
logarithmic phase at 37 0C, reached when the OD600 is between 0.6-1.0. The cells were 
chilled on ice for 30 min and pelleted by spinning at 1500 g for 10 min at 4 0C. The pellet 
was resuspended gently on ice in 0.5 ml medium A and 2.5 ml of storage buffer (sterile 
medium B: LB medium supplemented with 36% glucose, 12% PEG, 12 mM MgSO4,     
pH 7.0)  was added to the cells and mixed well. The competent cells were stored at -80 
0C 
in l00 μl aliquots. 
2.4.1.8 Transformation 
 
Plasmid with Tpm3 gene was transformed into XL blue competent cells to screen for the 
colonies with the insert. Transformation was performed by adding 10 μl of ligation 
mixture containing the Tpm3 plasmids to 100 μl XL blue competent cells defrosted on 
ice. The cells were mixed gently and incubated on ice for 15 min and given a heat shock 
at 42 0C for 2 min and immediately transferred on ice. After 2 min of incubation on ice, 
900 μl of LB was added to a final volume of 1 ml and the mixture was incubated at        
37 0C for 1 hour.  100 μl of culture were plated on LB-agar plate with ampicillin (LB-
Amp plates) which is used as a screening agent for selecting the colonies with plasmid.  
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2.4.1.9 DNA purification and Sequencing 
 
The colonies were screened using PCR and the colonies with positive result were selected 
were inoculated in 1 ml each of LB with 100 μg/ml ampicillin culture media and grown 
over night at 37 0C in a shaker. DNA was purified using FastPlasmid DNA mini-prep kit 
according to manufacturer’s instructions. 4 μl of DNA was used to run on 1.5% agarose 
gel to determine concentration using the Generuler 1 kb DNA ladder.  
The insert was later verified by restriction digest screening. The presence of 852 bp band 
confirms the presence of insert. The DNA coding region of the plasmid is verified by 
using Eurofin MWG operon sequencing read and by sequence alignment with the 
database sequence using BioEdit sequence alignment editor. 
2.4.2 Protein Expression 
 
The purified plasmid DNA was transformed to BL21DE3 that has T7 RNA polymerase. 
Three single colonies were picked for checking expression and were grown in 1 ml 
culture containing 0.1 mM ampicillin at 37 0C. Cells were grown until the OD at 600 nm 
reached around 0.8 considered to be reaching late exponential phase. Isopropyl-β-D-
thiogalactopyranoside (IPTG) is added at a concentration of 0.4 mM and the cells were 
induced for 3 hr for expression.  
To check the expression of protein 150 μl of cells were pelleted at 8K rpm for 1 min and 
the pellet was resuspended in 20 μl dH2O and 20 μl SDS Laemmli buffer was added. The 
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proteins were resolved on 13.5% SDS-PAGE gel to check expression levels. There were 
few colonies expressing protein and one colony was selected used for scaling up the 
protein for growing in 1L LB media with 100 mg/L ampicillin and followed the same 
procedure for expression (Maytum et al., 2000).  
2.4.2.1 Purification of Tropomyosin from E. coli BL-21 strain 
 
Tropomyosin was extracted according to Maytum et al., (2000), where cells from 1 L 
culture were harvested by centrifugation at 8K rpm for 10 min and the pellet was 
resuspended and homogenised in 40 ml of lysis buffer (20 mM Tris pH 7.5, 150 mM 
NaCl, 5 mM EDTA). The homogenate was sonicated for 1 min x 4 cycles keeping on ice 
for 1 min after each cycle. The lysate was boiled for 10 min in boiling water bath, cooled 
on ice and centrifuged at 13K rpm for 15 min to pellet cell debris. The supernatant with 
dissolved proteins was adjusted to pH 4.6 with 1M HCl and 0.1 HCl at the end for 
isoelectric precipitation of tropomyosin as the pI of tropomyosin is at pH 4.6.  The 
precipitate was collected by spinning the supernatant 13K rpm for 10min and the pellet 
was resuspended in 15-20 ml of 5 mM sodium phosphate buffer pH 7.0. The pH is 
adjusted to pH 7.0 after resuspension. Protein was further purified using Q-sepharose 
anion exchange column using a high salt phosphate buffer 5mM sodium phosphate buffer 
pH 7.0 with 1M NaCl and low salt 5 mM sodium phosphate buffer pH 7.0 with 100 mM 
NaCl. Protein was eluted at 40% (0.46 M) salt concentration and was precipitated 
isoelectrically at pH 4.6. The purity of protein is checked at 280/260 nm absorbance and 
concentration was calculated using sequence mass and by its extinction co-efficient E1% 
of 0.6 cm-1 obtained from ExPASY ProtParam. Impurities like DNA and RNA show 
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absorbance at 260 nm by checking the UV spectrum at this wavelength gives the amount 
of impurities present in the protein sample. Figure 2.9 shows the UV spectrum of pure 
protein and the protein with nucleic acid impurities. The purity of protein was visualised 
on SDS-PAGE polyacrylamide gels by collecting fractions at each stage of purification. 
Figure 2.10 shows the flow-chart of the overall procedure of expression and purification 
of tropomyosin isoforms.  
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Figure 2.9: UV spectrum of impure and pure protein. Chart A shows the impurities 
like nucleic acids absorbed at 260nm present in the protein. Chart B shows the final pure 
protein with lower traces of contaminants.  
 
2.4.2.2 Optimization of protein purification  
 
Three different methods were tested for obtaining pure protein. Once the boiled lysate 
was obtained equal amounts of lysates were separated for optimising the method for 
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purification. Isoelectric precipitation (pI), where tropomyosin is precipitated out from the 
solution at the pI of the protein, for tropomyosin its pI is at pH 4.6 (Bailey, 1948).  For 
ethanol precipitation method, 3 times the volume of chilled ethanol was added to the 
lysate and incubated on ice for 30 min and the spin down at 13K rpm for 10 min. 
Ammonium sulphate precipitation, 65% of ammonium sulphate was added and incubated 
on ice for 30 min and centrifuged at 13K rpm for 10 min (Bailey, 1948; Cummins and 
Perry, 1973). The pellet obtained from all the three methods were re-suspended in     5 
mM sodium phosphate buffer pH 7.0 and further purified using Q-sepharose anion 
exchange column. 
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Figure 2.10: Work flow of the methodology of protein expression of TPM3 in E. coli. 
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2.4.2.3 Determination of molecular mass by electrospray mass spectrometry (MS) 
 
The protein molecular weight was determined using electron spray mass spectrometry. 
Prior to analysis with MS, 100 µl of purified tropomyosin was dialysed overnight with    
1 mM Ammonium bicarbonate for desalting as ammonium bicarbonate is volatile in mass 
spectrometer and does not stick to protein preventing any mass shift in the peaks. The 
dialysed sample was spin down at 13K for removing any precipitate and aggregates 
formed. 20 μl of sample was acidified with 0.1% formic acid and 40% methanol was 
added for determining for its mass using Finnigan Mat LCQ ion-trap MS. The mass is 
calculated by multiplying the series of the mass/ charge ratio obtained from the spectra 
with number of charges minus the number of charges. 
2.4.3 Preparation of muscle acetone powder 
 
Acetone powder was prepared essentially according to Spudich and Watt (1971). 
Approximately 1000 g of fresh chicken breast meat was used for extraction actin. The 
meat was rinsed with cold distilled water and chilled on ice for one hour. The meat was 
rinsed with pre-chilled 1 mM EDTA, pH 7.5 and minced in pre-chilled mincer rinsed 
with cold 1 mM EDTA. The extraction process involves subsequent mixing of mince 
muscle in different buffers step wise. The first step of extraction was by stirring the 
mince muscle on ice in two liters of prechilled ice-cold phosphate buffer containing 
(0.15M potassium dihydrogen phosphate (KH2PO4), 0.15M dipotassium phosphate 
(K2HPO4), 0.1M KCl, pH 6.5) for 10 min. This was filtered through sterilized gauze and 
the muscle is transferred to buffer containing 2 liters of ice-cold 0.05 M sodium 
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bicarbonate buffer for 10 min while stirring on ice. After filtering, 2 liters ice-cold 0.1 M 
EDTA, pH 7.5 was added and stirred for 10 minutes on ice and filtered. The mince was 
washed twice with 2 liters of ice-cold distilled water for 5 min and the filtrate was 
discarded at each stage of the process. Later the muscle power was extracted by washing 
the residue with 1 liter of acetone at room temperature repeating washing and filtering 
steps with 1 L of acetone 5 times. During the whole extraction process the temperature of 
all the buffers and the muscle was maintained at 4 0C on ice until acetone wash. The 
powder obtained was dried overnight on paper towels under the hood. The dried powder 
was sieved with a fine metal sieve separating the fine and coarse dried muscle powder. 
The final yield of both fine and coarse muscle powder was transferred into 50 ml falcon 
tubes and weighted for the estimation of total yield. 
2.4.3.1 Extraction of actin from acetone powder  
 
Actin was extracted form chicken skeletal muscle acetone powder as described by 
Cooper et al., (1983b) and Jeffries Criddle et al. (1985b) with few minor modifications.  
1. 5 g of acetone power was added to 150 ml of pre-chilled buffer to 0 0C containing     
10 mM Tris, 0.5 mM ATP, 0.2mM CaCl2 and 1 mM DTT, pH 8.0. The mixture was 
stirred on ice for 1hr slowly and filtered through cheese cloth using a Buchner funnel 
containing filter paper under pressure. The filtrate is first spun at 8K rpm for 10 min to 
remove any solid residues after filtration. G-actin (G-Ac) is polymerised by adding final 
concentrations of 100 mM KCl, 2 mM MgCl2 and stirred at room temperature for 2 hrs. 
The polymerised actin is precipitated by spinning at 55K rpm for 1 hr (Beckman Coulter 
model Optima Max-XP with MLA55 rotor). The pellet is resuspended in 
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depolymerisation buffer (depol buffer) containing 5 mM Tris, 0.2 mM CaCl2, 1 μM ATP, 
0.5 mM DTT, 1 mM NaN3 adjusted to pH 7.5 and dialysed against it overnight changing 
it for couple of times. On day 2, the dialysis residue is spun at 55K rpm for 1 hr to 
remove any left polymerised actin.  The volume of the supernatant is measured and the 
G-actin concentration is determined UV absorption at 280 (scanned between 260-500 nm 
to correct for light scattering) absorbance and concentration was calculated using 
sequence mass and by its extinction co-efficient E1% of 1.108 cm-1 at 280 nm. The purity 
of protein was visualised on SDS-PAGE polyacrylamide gels by collecting fractions at 
each stage of purification. The G-actin is diluted to 1mg/ml concentration using 
depolymerisation buffer. G-actin is polymerised by adding ATP to a final concentration 
of 5 μM, 100 mM KCl and 2 mM MgCl2. Stirred slowly at room temperature for 1 hr and 
spun at 55K rpm for 1 hr. The pellet is resuspended in MOPS buffer containing 100 mM 
KCl, 20 mM MOPS, 5 mM MgCl2 and 1 mM NaN3, pH 7.0 and dialysed against it 
overnight at 4 0C. The concentration of polymerised F-actin (F-Ac) is determined by UV 
scanning and its extinction coefficient of 1.108 cm-1. Required amount of F-Ac was 
distributed for co-sedimentation assays and for pyrene labelling  
2.4.3.2 Pyrene labelled G-actin 
 
The required amount of F-actin needed for actin polymerisaiton assays was used for 
fluorescent labelling with pyrene which was performed according to Cooper et al., 
(1983b). N-(1-pyrenyl) iodoacetamide (Pyrene) was used for labelling, prepared by 
dissolving in dimethylformamide to a concentration of 6 mg/ml (16 μM). It was stored at 
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-20 0C. 7.5 mol of pyrene were added per mole of actin. The amount of pyrene to add for 
specific volume of F-actin was calculated by using the formula:   
Concentration of F-Ac  X  Total volume of F-Ac x 1.5 / Concentration of pyrene 
Pyrene was added slowly to the F-Ac while stirring and the mixture was kept in dark for 
20 hours at room temperature while stirring slowly all the time. After 20 hours the 
mixture was spun at 8000 rpm to remove precipitated pyrene. The labelled F-Ac is 
sediment by spinning at 55 K rpm for 1 hour. The pellet was homogenised in depol buffer 
and dialysed against depol buffer in dark for 24 hours at 4 0C. The pyrene labelled G-Ac 
(Py-G-Ac) was stored on ice in 4 0C refrigerator, this way it was found to store better 
than just storing in 4 0C in refrigerator.  
The concentration of Py-G-Ac was measured using the extinction co-efficient of E1% 
22000 M-1 cm-1 at 344 nm (Kouyama and Mihashi, 1981).  
2.4.4 Co-sedimentation assays 
 
Actin in polymerised form (F-actin) can be precipitated by centrifugation at greater than 
30K rpm. Therefore any protein (like tropomyosin, Tn and myosin) bound to actin will 
also be pelleted when added to it and the unbound protein would be left in the 
supernatant. The same principle is used to determine the affinities of various tropomyosin 
isoforms with actin.  
For co-sedimentation assays varying concentrations of tropomyosin (eg. 0.0 to 10 μM) 
were added to 10 μM actin in standard MOPS assay buffer  containing 20 mM MOPS, 
200 mM NaCl, 5 mM MgCl2, making to a total volume of 100 μl. The reaction mixture 
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was incubated at room temperature for 15 min and spun for 30 min at 55K rpm (Beckman 
Coulter model Optima Max-XP with MLA130 rotor). Supernatant was transferred to 
fresh Eppendorf centrifugation tubes and the pellet is resuspended 70 μl MOPS buffer 
and 30 μl 4X Laemmli buffer making the total volume to 100 μl, and to 30 μl of 
supernatant 30 μl of 4X SDS buffer was added. 15 μl of the sample was loaded on  13.5 
% SDS-PAGE ((Laemmli, 1970) to separate the protein bands. Gels were stained with 
Coomassie Brilliant Blue G250 and destained with 20% methanol containing 5% acetic 
acid. 
2.4.4.1 Densitometry 
 
Densitometry analysis of the co-sedimentation assay SDS-gels was used to calculate the 
binding constants of tropomyosin and actin. Proteins bands from the cosedimentation 
assay gels were quantified by scanning them with Biorad GS800 calibrated densitometer 
along with a Stouffer 21 step density tablet used for calibration.  The densities of the 
protein bands were obtained after calibration of the image with ImageJ software. 
Quantification analysis was performed using Image J software  (Schneider et al., 2012) 
A standard curve was generated by plotting the total tropomyosin (density of Tm in pellet 
and supernatant) against known concentrations which was used to calculate the free Tm 
concentration in the supernatant as shown in Figure 2.21. The dissociation constant (k) at 
half saturation and the Hill coefficient were determined by plotting the staining ratio 
(ratio of Tm and actin densities from the pellet) as a function of free Tm concentrations. 
The data was fitted to Hill equation using Origin 6.0 software.  
  
80 
 
Hill equation used by the software  
Y = Vmax [x
n] ̸ [kn] + [xn] 
Where, Vmax is maximum saturation, x is concentration of the ligand (Tm) , k is the 
dissociation constant and n is the Hill coefficient which determines the degree of the 
interaction between the binding sites which is used as the measure of degree of 
cooperativity.   
2.4.5 Fluorescence Spectrometer  
 
Actin polymerisation with presence and absence of tropomyosin was monitored by 
fluorimetry.  Fluorescence intensity was measured using Amico-Bowman Seires 2- 
Luminescent spectrometer with wavelengths 365 nm and 389 nm for excitation and 
emission respectively  according to Lal and Korn (1986). The emission measured was set 
manually to 10% and all assays were measured with detector voltage of 690 volts set 
manually. The band width was set to 0.5 nm for excitation and 8 nm for emission to 
reduce photo bleaching. Measurements were made at room temperature in a 0.5 cm glass 
cuvette with 300 μl assay total assay volume.  
2.4.5.1 Actin polymerisation assays conditions 
 
Recombinant tropomyosin isoforms prepared as described in section 2.4.22.4.1.3, were 
used for Ac-Tm polymerisation assays according to Lal and Korn (1986). Total assay 
volume was maintained at 300 μl with 6 μM Py-G-Ac alone and 5 uM tropomyosin and 
made up to the volume with depol buffer. Py-G-Ac was incubated with 1 mM EGTA 
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before polymerisation was initiated by adding 100 μM KCl, 2 mM MgCl2 and 0.1 mM 
ATP. Binding measurements were made by sedimentation of fully polymerised actin at 
20 0C.  The samples were spun down at 55 K rpm in Beckman Coulter Optima Max-XP 
with MLA130 rotor of the assays for 1 hour.  The pellet and supernatant were analysed 
using 13.5 % SDS-PAGE gels.  
2.5 Results 
2.5.1 Sequence Confirmation 
 
The sequence of all the clones constructed were confirmed by aligning the sequences 
obtained from Eurofin MWG operon sequencing read and by sequence alignment with 
the database sequence using BioEdit sequence alignment editor. The nucleotide sequence 
was translated to amino acid sequence using BioEdit and the sequence of Tpm3-Met, 
MM and MASM and Tpm4 and the Protparam sequence parameters are given in 
Appendix section 6.3.  
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2.5.2 Expression and Purification of γTm (Tpm3) 
 
A  
Tpm3-Met       MEAIKKKMQMLKLDKENAL 
Tpm3-MM      MMEAIKKKMQMLKLDKENAL 
Tpm3-MASM  (M)ASMEAIKKKMQMLKLDKENAL 
Human Tpm3      MMEAIKKKMQMLKLDKENAL 
 
B  
TPM4-MASM  (M)ASMDAIPKKMQMLKLDKENAL 
Human TPM4      MEAIKKKMQMLKLDKENAL 
  
Figure 2.11:  N-terminal constructs of TPM3 and TPM4: Amino acid sequence 
alignment results of the clones used for expression are shown above. Panel A, For Tpm3-
Met the single Methionine at the N terminal of all the constructs was expected to remove 
by post-translational process and is shown in brackets. All the clones had sequences 
synthesized similar to the human TPM3. Panel B shows the clone sequence read of 
TPM4 and the sequence used for expression (human TPM4) and has higher similarity to 
rat and human skeletal TPM1. 
 
Tropomyosin was expressed at high levels in E. coli, and is soluble in lysis buffer.  
Figure 2.11 shows the expressed constructs with N-terminal sequence. The first 
Methionine is brackets indicating the removal of Methionine by posttranslational process 
which was confirmed by Mass spectrometry analysis of intact protein (Figure 2.17). 
Table 2.3 shows the masses of all the protein isoforms synthesised and the difference in 
calculated mass and the predicted mass. Methionine for TPM3-Met is not removed in the 
recombinant protein which is confirmed with a mass of 32823.6 Da with an acceptable 
error of ~4.9 Da and Tpm3-MM 32950.8 with an error of ~0.9 Da also have an intact 
methionine at the N-terminal. However for Tpm3-MASM with a mass of 32980.46 Da 
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and mass difference of ~127.64 it seems N-terminal methionine is removed by post 
translational process. There was difficulty calculating the m/z value as the spectrum had 
lot of background.  
 
Figure 2.12 : Commassie Blue –stained SDS gels showing protein expression of 
Tpm3 and Tpm4 in E. coli.  Gels a, b, c and d show the protein expression of Tpm3-
MET, Tpm3-MM, Tpm3-MASM and Tpm4-MASM respectively. Uninduced (first lane 
from marker) and induced culture with IPTG (shown with an arrow). 120 μl of culture is 
spun down at 9K rpm and the pelette is resuspended in 20 μl dH2O and 10 μl 4X SDS 
sample buffer. The sample is boiled at 95 0C and 15 μl is loaded on the gel. Arrows 
shows the expressed protein band.  
Figure 2.12 shows the Coomassie Blue-stained SDS-PAGE gels of three variants of 
Tpm3 – Met, MM and MASM.  Total bacterial extracts of uninduced and induced (by 
IPTG) extracts (lane a and b respectively) are shown. The uninduced culture did express 
any protein and the induced extracts shows high level of expression with successful total 
yields of approximately 60 mg per one litre of culture. 
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2.5.3 Purification 
 
Recombinant protein tropomyosin was purified by eluting it with increasing the salt 
concentration using anion exchange Q Sepharose column (GE Helath care HiPrep Q XL 
16/10) Tropomyosin was eluted at 40% salt (0.46 M NaCl). The purification profile is 
shown in Figure 2.13.  Figure 2.14 shows the Coomassie Blue-stained SDS-PAGE gel at 
various stages of protein purification and also different approach for purification. The 
Lane 1 from the marker is bacterial extract induced by IPTG followed by soluble total 
protein in lysis buffer after boiling and removal of solid residue lane 2; lane 3 shows the 
protein precipitated by isoelectric precipitation by adjusting the pH between 4.5-4.6. Lane 
4 shows the next stage of purification where protein is purified by ion-exchange 
chromatography and the eluent collected at 40% salt (Figure 2.13) is adjusted to pH 4.6 
to precipitate out tropomyosin. Two different approaches were tried to purify 
tropomyosin to optimise the amount of extraction and the purity of the sample. After ion-
exchange chromatography, first method was performed as explain before by isoelectric 
precipitation, and the second method (Lane 5) by precipitation the total protein from the 
40% eluent by adding 6times volume of ethanol.  
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Figure 2.13: FPLC elution profile for purification of tropomyosin. Tropomyosin was 
bound to column by 5 mM phosphate buffer with 100 mM NaCl (buffer A) and protein 
was eluted by increasing the salt concentration from 5 mM phosphate buffer with 1 M 
NaCl (buffer B). Tropomyosin is collected at 40% elution and was purified further by 
isoelectric precipitation.  
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Figure 2.14: Stages of purification of Tropomyosin (MASM): Lanes: 1. TPM3 
expressed in culture induced by IPTG, 2, protein extract in lysis buffer after boiling, 3. 
Protein by iso-electronic precipitation at pH 4.5-4.6, 4. pH precipitated protein purified 
by anion exchange chromatography(IEC), 5. Ethanol precipitation, 6. EtOH precipitated 
protein purified by IEC, 7. Ammonium sulphate precipitate, 8. Ammonium sulphate 
precipitate protein purified by IEC. 
 
The pellet was collected by spinning the sample at 8K rpm and was resuspended in 5mM 
phosphate buffer, and further purified by isoelectric precipitation (lane 6). The third 
method was by salting out by adding 60% ammonium sulphate (lane 7). The precipitate 
was further purified by followed isoelectric precipitation after resuspending it in 5mM 
phosphate buffer (Lane 8). Figure 2.15 shows the UV spectrum of the protein purified by 
three methods. The ethanol precipitation method yield was higher compared to other two 
methods for the same volume of soluble protein taken. However the protein purified by 
isoelectric precipitate of 40% eluent was found to be more pure and free from other 
nucleic acids as shown from the spectrum. Protein purified using ammonium sulphate 
precipitation method did give pure protein and also the yield was very low. Figure 2.16 
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shows all the tropomyosin isoforms synthesised for this research work along with two 
HCM mutations A63V and K70T and at the same time reflects the difference in the 
molecular weight of all the protein isoforms.  
 
Figure 2.15: Absorption spectra of different methods for protein purification: 
Ethanol (EtOH) precipitation (red) has given more yields but the purity of the protein is 
less than the isoelectric precipitation (blue) while ammonium sulphate precipitation 
(black) has less yield as well as purity than the other two methods. Hence isoelectric 
precipitation is chosen for future purification processes.  
 
Figure 2.16 shows all the tropomyosin isoforms synthesised for this research work along 
with two HCM mutations A63V and K70T and at the same time reflects the difference in 
the molecular weight of all the protein isoforms. It is observed that the tropomyosin 
isoforms run differently on the SDS gels even though the molecular weight of the 
tropomyosin isoforms does not vary much. This may be due to the fact that tropomyosin 
is usually a heat resistant protein and after it is denatured at higher temperature by boiling 
it refolds to its natural state, hence the protein may still be in its native state on the gel.  
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Figure 2.16: Gel showing all the isoforms of recombinant tropomyosins. Lane1 - 
Tropomyosin extracted from mouse heart (left ventricle), lane 2 – γTpm-Met, lane 3 – 
γTpm-MM, lane 4 - γTpm-MASM, lane 5- αTpm-MASM, lane 6 – βTpm-truncated, lane 
7 – αTPM1- A63V (HCM mutation), lane 8 – αTPM1 – K70T (HCM mutation).   
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Figure 2.17:  Total yield of recombinant proteins per litre of culture. pH- protein 
purified by isoelectric precipitation, Amm.Sulp – Ammonium sulphate, EtOH – Ethanol. 
For Tpm3- MASM the yield is shown form all the three methods employed for 
optimizing the purification method.  
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2.5.4 Mass spectrum of intact pure protein 
 
 
Figure 2.18: MS spectra of the electrospray ionization: The mass is calculated by 
mass/charge ratio (m/z) obtained from the spectra and determining the number of charge 
states of the peaks obtained. Approximately 10μg of protein is injected with 40% 
methanol and 0.1% formic acid for confirming the protein mass. 
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Table 2.3: Mass of the tropomyosins calculated from the m/z ratio of mass 
spectrum: The difference in the sequence mass and the calculated mass of all the 
recombinant tropomyosin isoforms expressed in E. coli. Mass calculated from the m/z 
ratio of the mass spectrometry analysis. 
Protein 
Sequence MW 
(Da) Calculated-MW Difference (Da) 
Tpm1 32856.15 - - 
Tpm2 32850.7 32854.74 4.04 
Tpm3-Met 32818.7 32823.6 4.9 
Tpm3-MM 32949.9 32950.8 0.9 
Tpm3-MASM 33108.1 32980.46 127.64 
Tpm3-Met-K249Q 32818.7 32824.1 5.4 
Tpm4 32722.6 32773.98 51.37 
 
The above table 3 shows the mass calculated from form the mass/charge peaks obtained 
from mass spectrometry analysis. Tpm2, Tpm3-Met, MM and another version of Tpm3 
was accidently produced with a mutation at 249 residue with a lysine to glutamine 
substitution (Tpm3-Met-K249Q), all were found to have intact methionine at the N-
terminal end of the sequence.Tpm3-MASM with a mass difference of 127.64 shows that 
the initial methionine is cleaved during post-translational modification with an error of 4 
Da. On the other hand Tpm4 had a calculated mass difference of 51.37 Da which may be 
due to loss of isoleucine at the C-terminal end or the protein may have not expressed 
correctly, which needs to be confirmed and needs characterising separately. Hence the 
results of Tpm4 are not taken into consideration further in the whole thesis. 
  
2.5.5 Actin Preparation 
Actin was prepared form chicken breast meat. For 1000 grams of mincemeat a total of 
74.04 g of fine acetone powder and 37.35 g of coarse powder were obtained. Figure 1.14 
shows the stages of actin extraction from muscle powder. 
 
Figure 2.19: Actin purification stages. 1. G actin extracted form muscle powder after 
filtration, 2. Polymerised F-actin. 3. Supernatant left after pelleting out F-actin. 4. F actin 
pellet resuspended in depolymerisation buffer. 5- F-actin used for labelling, 6. Pyrene 
labelled F actin, 7. Depolymerized pyrene labelled G-actin.  
 
2.5.6 Pyrene G-actin quantification 
 
Purified Py-G actin as described in methodology was pure as seen in the SDS-Gel in 
Figure 2.19. The purity was also confirmed by the UV absorption spectrum at 280 nm 
and the labelling ratio obtained was 1.09 from this method (Figure 2.20). 
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Figure 2.20: UV spectrum of purified pyrene labelled G-Actin. The peak at 280 nm 
shows the pure G actin and pyrene has an absorption spectrum at 344 nm. Using the 
excitation coefficient of 22000 M-1 pyrene concentration was calculated.  
 
2.5.7 Affinity of Tropomyosin with actin filaments 
 
The affinity of tropomyosin isoforms with actin filament was determined by co-
sedimentation assays and the standard curve generated is shown in Figure 2.21. The 
results of the binding affinity of tropomyosin to actin for all the isoforms produced in this 
study are shown in figures from Figure 2.22 to Figure2.29. The curves are fitted to Hill 
equation and the values obtained for both K50%  (the concentration of free Tm at which 
half actin is saturated) is referred to as binding constant and ‘n’the Hill coefficient that 
determines the sigmoidicity of the curve measures the degree of co-operativity. The 
maximum saturation (Vmax) of actin by tropomyosin which was set constant at 4.0 
staining ratio calculated from the tropomyosin/actin (Tm/Ac) in the pellet. The value 4.0 
is used because the actin and tropomyosin stain differently on a gel. The staining ratio 
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cannot be taken as equivalent for both the proteins as they differ in their molecular 
weight.  
 
 
Figure 2.21: A standard curve used to calculate free tropomyosin concentration in 
the supernatant. Standard curve is generated by plotting band intensity against the 
concentration of Tm used for the assay.  
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Figure 2.22: Actin binding co-sedimentation assay result of Tpm1. The experimental 
details are described in the methodology section. The sequence of bands from left to right  
are 10 μM actin mixed with 0.1, 0.2, 0.5, 1.0, 3.0 and 5.0 μM Tm. Left picture shows the 
gel and the right panel shows the fitted binding curve of Tpm1. The curves are fitted to a 
version of Hill equation and the values obtained for both K50%  (the concentration of free 
Tm at which half actin is saturated) and ‘n’the Hill coefficient that determines the 
sigmoidicity of the curve measures the degree of co-operativity. The results show Tpm1 
shows higher affinity with actin with K50% at 0.6μM of free Tm. The values of K50%  and 
n are given in table 2.4. Circles, squares are the data sets obtained from 2 replicates of the 
experiment. 
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Figure 2.23: Actin binding cosedimentation assay results of Tpm2.  The experimental 
details are described in the methodology section. Left picture shows the gel and the right 
panel shows the fitted binding curve. The curves are fitted to a version of Hill equation 
and the values obtained for both K50%  (the concentration of free Tm at which half actin is 
saturated) and ‘n’the Hill coefficient that determines the sigmoidicity of the curve 
measures the degree of co-operativity. The values of K50%  and n are given in The 
experimental details are described in the methodology section 2.4.4.  
Table 2.4. Top gel on the left side has concentrations of 0, 0.1, 0.2, 0.5, 1.0, 5.0 and 10.0 
μM and the bottom gel has 2.0, 3.0, 7.0, 15.0μM Tm. Higher concentrations are used to 
show the saturation of actin with Tm.  Tpm2 shows lower affinity to actin agreeing with 
previous research results. Circles, squares are the data sets obtained from 2 replicates of 
the experiment.  
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Figure 2.24: Actin binding cosedimentation assay results of Tpm3-Met. The 
experimental details are described in the methodology section. Left picture shows the gel 
and the right panel shows the fitted binding curve. The curves are fitted to a version of 
Hill equation and the values obtained for both K50%  (the concentration of free Tm at 
which half actin is saturated) and ‘n’the Hill coefficient that determines the sigmoidicity 
of the curve measures the degree of co-operativity. The values of K50%  and n are given in 
The experimental details are described in the methodology section 2.4.4.  
Table 2.4. Top gel on the left side has concentrations of 0, 0.1, 0.2, 0.5, 1.0, 5.0 and 10.0 
μM. Circles, squares and triangles are the data obtained from 3 replicates of the 
experiment. For third replicate (triangles) assays was performed up to 10 μM and the 
previous once (circles and squares) upto a maximum of 5 μM Tm.  
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Figure 2.25: Actin binding cosedimentation assay results of Tpm3-MM. The 
experimental details are described in the methodology section. Left picture shows the gel 
and the right panel shows the fitted binding curve. The curves are fitted to a version of 
Hill equation and the values obtained for both K50%  (the concentration of free Tm at 
which half actin is saturated) and ‘n’the Hill coefficient that determines the sigmoidicity 
of the curve measures the degree of co-operativity. The values of K50%  and n are given in 
The experimental details are described in the methodology section 2.4.4.  
Table 2.4. The concentration of Tm, top gel on the left are 0, 0.1, 0.2, 0.5, 1.0, 5.0 from 
left to tight and 10.0 μM and the bottom gel has 2.0, 3.0, 7.0, 15.0 μM Tm.  
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Figure 2.26: Actin binding cosedimentation assay results of Tpm3-MASM.  The 
experimental details are described in the methodology section. Left picture shows the gel 
and the right panel shows the fitted binding curve. The curves are fitted to a version of 
Hill equation and the values obtained for both K50%  (the concentration of free Tm at 
which half actin is saturated) and ‘n’the Hill coefficient that determines the sigmoidicity 
of the curve measures the degree of co-operativity. The values of K50%  and n are given in 
The experimental details are described in the methodology section 2.4.4.  
Table 2.4. The sequence of bands from left to right  are10μM actin mixed with 0.1, 0.2, 
0.5, 1.0, 3.0 and 5.0 μM Tm. Circles, squares are the data sets obtained from 2 replicates 
of the experiment.Tpm3-ASM shows higher affinity with actin with K50% 0.2μM free 
Tm.  
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Figure 2.27: Actin binding cosedimentation assay results of Tpm4-ASM. The 
experimental details are described in the methodology section. Left picture shows the gel 
and the right panel shows the fitted binding curve. The curves are fitted to a version of 
Hill equation and the values obtained for both K50%  (the concentration of free Tm at 
which half actin is saturated) and ‘n’the Hill coefficient that determines the sigmoidicity 
of the curve measures the degree of co-operativity. The values of K50%  and n are given in 
The experimental details are described in the methodology section 2.4.4.  
Table 2.4. Top gel on the left side has concentrations of 0, 0.1, 0.2, 0.5, 1.0, 5.0 from left 
to tight and 10.0 μM and the bottom gel has 2.0, 3.0, 7.0, 15.0 μM Tm. 
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Figure 2.28: Actin binding cosedimentation assay results of Tpm1-A63V (HCM 
mutation).  The experimental details are described in the methodology section. Left 
picture shows the gel and the right panel shows the fitted binding curve. The curves are 
fitted to a version of Hill equation and the values obtained for both K50%  (the 
concentration of free Tm at which half actin is saturated) and ‘n’the Hill coefficient that 
determines the sigmoidicity of the curve measures the degree of co-operativity. The 
values of K50%  and n are given in The experimental details are described in the 
methodology section 2.4.4.  
Table 2.4. The sequence of bands from left to right  are10μM actin mixed with 0.1, 0.2, 
0.5, 1.0, 3.0 and 5.0 μM Tm. Circles, squares are the data sets obtained from 2 replicates 
of the experiment. 
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Figure2.29: Actin binding cosedimentation assay results of Tpm1-K70V (HCM 
mutation).  The experimental details are described in the methodology section. Left 
picture shows the gel and the right panel shows the fitted binding curve. The curves are 
fitted to a version of Hill equation and the values obtained for both K50%  (the 
concentration of free Tm at which half actin is saturated) and ‘n’the Hill coefficient that 
determines the sigmoidicity of the curve measures the degree of co-operativity. The 
values of K50%  and n are given in The experimental details are described in the 
methodology section 2.4.4.  
Table 2.4. Top gel on the left side has concentrations of 0, 0.1, 0.2, 0.5, 1.0, 5.0 and 10.0 
μM. Circles, squares and triangles are the data sets obtained from 4 replicates of the 
experiment. For third and fourth replicate (triangles) assays was performed upto 15 μM 
and the previous once (circles and squares) upto a maximum of 5 μM Tm.  
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Figure 2.30: Co-sedimentation curve of control proteins: The experimental details are 
described in the methodology section 2.4.4.  
Table 2.4: Table showing parameter for curve fits for actin binding co-
sedimentation assays. Vmax is the complete saturation of tropomyosin with actin, K50% 
is concentration of free tropomyosin at which half of actin is saturated and n is the Hill 
coefficient that determines the sigmoidicity of the curve measures.  
Tm isoform Vmax K50% N 
TPM1 (ASM) 0.4 0.62 ± 0.07 0.97 ± 0.10 
TPM2 (truncated) 0.4 6.33 ± 0.18 4. 22 ± 0.51 
TPM3-Met 0.4 5.78 ± 0.11 15.81 ± 3.53 
TPM3-MM 0.4 8.44 ±0.21 6.39 ± 0.99 
TPM3-ASM 0.4 0.28 ± 0.13 0.78 ± 0.26 
TPM4 (ASM) 0.4 6.36 ±0.72 5.55 ± 2.85 
TPM1-A63V 0.4 0.19 ± 0.03 1.17 ± 0.22 
TPM1-K70T 0.4 0.43 ±0.15 1.04 ± 0.30 
 
It can be seen that Tpm1-ASM, Tpm3-ASM,  Tpm1-A63V and Tpm1-K70T affinities 
shown fall in the range of 0.1 to 0.6 μM free tropomyosin agreeing with previous results 
of tropomyosin binding to actin (Heald and Hitchcock-DeGregori, 1988; Maytum et al., 
2001; Monteiro et al., 1994). All these protein isoforms have cleaved N-terminal Met by 
post translational process and the additional ASM remains at N-terminal of the sequence 
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where it replaces the acetlyation of the protein. The HCM mutation A63V found to bind 
very tightly and the other Tpm3 isoform variants with Met and MM does not seem to 
have same affinity as the 3 amino acid fusion (MASM) as their K50% values show greater 
saturation values of ~ 6 μM for Met and ~8 μM for MM supported from the mass 
spectrometry data given in Table 2.3.  Isoform Tpm2 was a truncated WT version where 
the N-terminal sequence was not modified and is seen that the affinity to actin is very low 
and does not bind co-operatively (curve loses its sigmoidicity) that corresponds to the 
previous results On the other hand Tpm4 even thought has been modified at the N-
terminus did not show strong affinity to actin.  
2.5.8 Actin-tropomyosin polymerisation assays. 
 
It was not possible to calculate the curves data to fit to a single kinetic model, however 
the curves fitted with Hill equation were in good agreement with previous time course 
polymerisation curves. Particularly at low total ionic concentrations the measured curves 
were having significantly longer initiation and elongation times showing more 
sigmoidicity in contrast to higher ionic concentration of G actin. For this reason the 
results of actin polymerisation studies with tropomyosin presented are not analysed 
quantitatively as it needs to establish a kinetic model for this kind of reaction. There are 
other simulated kinetic models available for actin-tropomyosin described previously, 
however it needs more data on nucleation and elongation measurements to fit to the right 
model. This set of experiments were analysed qualitatively in comparison with the results 
obtained from previous research results which were primarily done by using Tpm1 
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(Frieden, 1983a; Hitchcock-DeGregori and Heald, 1987; Lal and Korn, 1986; Wegner, 
1980; Wegner and Ruhnau, 1988; Weigt et al., 1991).  
The fluorescent intensity of Pyrene labelled actin increased to 7 fold (Figure 2.31) from 
monomer to filamentous polymerised actin similar to previous studies (Cooper et al., 
1983b; Kouyama and Mihashi, 1981). The critical concentration of actin in physiological 
conditions was measured to be 0.1 μM which remains constant independent of 
concentration of F-Ac. Critical concentration is the total amount of monomer actin left 
unpolymerised. Critical concentration was not measured in this study.   
Figure 2.31 shows the time course polymerisation curves of actin in two different 
concentrations of 2 µM and 6 µM of Pyrene G-actin. Figure 2.31A shows the time course 
polymerisation of 2 µM actin. The polymerisation is initiated by adding 2 mM MgSO4, 
0.1 M KCl, 0.1 mM ATP to pre-incubated Py-Ac with 0.1 mM EGTA. The dots shows 
the data points and the line shows the simulated curved using the data. Figure 2.31B 
shows polymerisation curve of 6 µM actin assays under same condition as mentioned for 
2 µM. The red line is the freshly prepared Py-Ac and black line is actin which was 10 
days old for 6 µM and 12 days old for 2 µM, which I used to show the difference in the 
polymerisation time course. The polymerisation of 6 µM actin is faster than 2 µM actin 
and the final steady state is reached faster with 6 µM  with a half time taken for 
polymerisation taken is 230 seconds which is less than for 2 µM  (721 seconds) to reach 
half polymerisation rate. The half times (k) is given in Table 2.5. It is observed that for 2 
µM there is not much difference between fresh and 12 days old actin, but the amount of 
polymer formed seems higher and the rate of polymerisation seems to be slow with k 
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value increasing to double to 1490 sec which was not the same for 6 µM. Due to these 
minor differences all the data is compared with both of these curves.  
Figure 2.31C shows the difference between the curves of 2 µM and 6 µM actin. 2 µM 
actin show longer initiation phase and the elongation time is longer due to slow formation 
of nucleus which in turn is due to lower concentration of actin (Wegner and Engel, 1975). 
Due to the slower elongation rate it took longer time to reach steady state for 2 µM 
(polymerisation still continues after 120 min ) than 6 µM  actin (reached steady state in 
35 min).  
 The data obtained from all the assays were compared with actin polymerisation with 6 
µM actin both fresh and old polymerisation curves in order to eliminate any difference 
occurring due to storage. All the assays were performed after spinning the sample at 55 k 
rpm to remove any precipitated G actin.  
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Figure 2.31: 2 μM and 6 μM Actin polymerisation. The data is fit to sigmoidal Hill 
equation, the data points are not shown as there are too many data points to interpret with 
the fitted curve. Red line is freshly made Pyrene G Actin and black line is 10 days old for 
6 μM and 12 days old for 2 μM Py-G actin used for polymerisation. A. 2 μM actin only, 
B. 6 μM actin only, C. comparative curves of A and B, D. Comparitive curves of A and B 
showing the lower time scale for clear emphasis of the initiation stage.  
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Figure 2.32: Actin polymerisation with different concentrations of Tpm1. A. 6 μM 
PyG-actin polymerised with 0.5 μM Tpm1, B. A integrated with 6 μM actin curves 
showing the polymerisation rate difference in presence and absence of Tpm1 with both 
fresh actin (red line) and 10 day old actin (black line) C. 2 μM Py-G-actin with 5 μM 
Tpm1 and D integrated with 2 μM actin alone, E and F are with 6 μM actin with 5 μM 
Tpm1.  The inset in the graphs on the left hand side (A, C and E) shows the coomassie 
stained SDS-gels of the assays on the righ hand side ( B, D and F) the inset shows the 
same curves with a different time scale to show the nucleation phase clearly. After 
completion of the polymerisation, the samples were spun down and the supernatant and 
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pellet were separated. The pellet was resuspended in equal amount of buffer along with 
SDS sample buffer and run on 13.5 % SDS gels. S- supernatant, P-Pellet.  The dots on 
the graphs are the data used for generating the curves.  
 
2 µM and 6 µM actin were polymerised with different concentrations of Tpm1. Curve A 
and B from Figure 2.32 shows in presence of 6 µM actin in presence of 0.5 µM Tpm1 
show higher polymerisation rate than actin alone and has very slight higher rate of 
initiation (Table 2.5) but the end fluorescence intensity was higher than the actin alone 
indicating there is more polymerisation at very low Tpm1 concentration. This curve is 
compared with the fresh actin as both polymerisaiton assays were perfomed on the same 
day.  The curves from 6 µM in presence of 5 µM Tpm1 (Figure 2.32E and F) show a 
different scenario as it is seen that presence of Tpm1 in this case has higher initiation rate 
than actin alone but the elongation rate (half time 337 sec) the final polymerisaiton 
product has lowered. With 2 µM actin in presence of 5 µM Tpm1 (Figure 2.32C and D) 
the increase in fluorescence is slower than 6 µM actin however the initiaiton is slightly 
higher than actin alone and the elongation rate is lowered with half maximal 
polymerisation time of 1757 sec, however the final fluorescence intensity was same as in 
the absence of Tpm1 (Vmax of 8 for actin alone and 7.9 in presence of Tpm1). The 
initiation  and elongation of  polymerisaiton seems to affect differently with different 
concentrations of  actin and tropomyosin. With the observations and time restriction,       
6 µM actin and 5 µM tropomyosin concentration were chosen to continue with other 
assays for comparison of other isoforms of tropomyosins.   
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Figure 2.33: Time course polymerisation curves of actin with Tpm2. A. 6 µM actin in 
presence of 5 µM Tpm2. The inset shows the sedimented pellet and supernatent run on 
SDS page gel to check the binding efficiency. B. Curve A integrated into 6 µM actin 
actin curves for comparison. Blue line represent the Tpm2 curve. The inset shows the 
same curves with different time scale to show the initiation more closer. Fluorescence 
intensity is in arbitrary units.  
 
Polymerisation curves of 6 µM in presence of Tpm2 (Figure 2.33 A and B) show an 
overall increase in polymerisation rate with higher initiation and elongation fluorescence 
intensity (k =170 sec) with final polymerisation fluorescence intensity being slightly 
higher than actin alone with a maximal polymerisation intensity of 6.9 (actin alone 6.7). 
Assay performed on day 3 of actin preparation (Refer to Table 2.5).  
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Figure 2.34: Time course polymerisation curves of actin with Tpm3. The expeimental 
conditions are as desciebed in methodology. A. 6 µM actin in presence of 5 µM Tpm3 
Met. The inset shows the sedimented pellet and supernatent run on SDS page gel to check 
the binding efficiency. B. Curve A integrated into 6 µM actin curves for comparison. 
Blue line represent the Tpm3 curve. The inset shows the same curves with different time 
scale to show the initiation more closer. Curves C and D are 6 µM actin in presence of 
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Tpm3-MM and Curves E and F are in presence of Tpm3-MASM.  Fluorescence intensity 
is in arbitrary units. 
 
Figure 2.35: Comparison of time course polymerisation curves of Tpm3-Met, MM 
and MASM. Crosses – Met, squares – MM and dots- MASM. Red line-fresh actin, black 
line – 10day old actin.  
 
The time course polymerisation curves of Tpm3 variants are shown in Figure 2.34 and 
Figure 2.35.  Tpm3-Met (Figure 2.34 A and B) seems to have an increase in 
polymerisation rate similar to Tpm2 with an half maximal polymerisation value of 183 
sec and the maximum fluorescent intensity with 7.6 (Tpm1 6.7). In presence of Tpm3-
MM (Figure 2.34 C and D) the initiation was much faster with k = 138 sec as well as 
elongation rate but the maximum intensity upon completion was 6.38 units which was 
lower than actin alone, which shows the number of actin filaments formed are lower in 
presence of Tpm3-MM. In case of Tpm3-MASM (Figure 2.34 E and F) the initiation rate 
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is higher but the elongation rate is lower than actin alone with k value of 266 sec, 
however the maximum intensity (7.9 units) after the completion of polymerisation was 
higher in presence of Tpm3-MASM. Figure 2.35 shows the difference in effect of 
polymerisation on actin with three different N-terminal variants of Tpm3. There is lot of 
variation how they affect the initiation and elongation even though the experiments were 
performed on the same day with all these variants on day four of actin preparation.  
 
Figure 2.36: Time course polymerisation curve of actin with Tpm4. A. 6 µM actin in 
presence of 5 µM Tpm4. The inset shows the sedimented pellet and supernatent run on 
SDS page gel to check the binding efficiency. B. Curve A integrated into 6 µM actin 
actin curves for comparison. Blue line represent the Tpm4 curve. The inset shows the 
same curves with different time scale to show the initiation more closer. Fluorescence 
intensity is in arbitrary units.  Assay was performed on day 5 of actin preparation.  
 
The actin polymerisation assay performed were on day 5 of actin preparation. Tpm4 is 
more closer to 10 day old actin with slight decrease in elongation rate and the final 
fluorescence intensity (Figure 2.36 A and B).  
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Figure 2.37: Time course polymerisation curve of actin with Tpm1-K70T. A. 6 µM 
actin in presence of 5 µM Tpm1-K70T. The inset shows the sedimented pellet and 
supernatent run on SDS page gel to check the binding efficiency. B. Curve A integrated 
into 6 µM actin actin curves for comparison. Blue line represent the Tpm1-K70T curve. 
The inset shows the same curves with different time scale to show the initiation more 
closer. Fluorescence intensity is in arbitrary units.  Assay was performed on day 5 of 
actin preparation.  
 
Tpm1-K70T is a N-domain α-straited muscle tropomyosin mutation associated with 
familial hypertrophic cardiamyopathy. The effect of actin polymerisation in presence of 
this mutated α-tropomyosin is similar to Tpm1, how ever the rate of initiation is higher 
and elongation is inhibited (k = 261 sec) with the final fluorescence intensity ( 6.9 units) 
lower than Tpm1.  
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Figure 2.38: Time course polymerisation curve of actin with smooth muscle 
fibroblast Tm5A and Tm5B. A. 6 µM actin in presence of 5 µM Tm5A B. Tm5B. The 
inset shows the sedimented pellet and supernatent run on SDS page gel to check the 
binding efficiency. C and D are Curve A and B integrated into 6 µM actin actin curves 
for comparison. Blue line represent the Tm5A and Tm5B in respective graphs. E. 
comparison of Tm5A – blue,  Tm5B- green and Tpm1 – pink. The inset shows the same 
curves with different time scale to show the initiation more closer. Fluorescence intensity 
is in arbitrary units. Assay was performed on day 6 of actin preparation.  
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Figure 2.39: Time course polymerisation curve of actin with ultra short non-muscle 
tropomyosin Tm n3D23. A. 6 µM actin in presence of 5 µM Tm n3D23. The inset 
shows the sedimented pellet and supernatent run on SDS page gel to check the binding 
efficiency. B. Curve A integrated into 6 µM actin actin curves for comparison. Blue line 
represent the Tm n3D23. The inset shows the same curves with different time scale to 
show the initiation more closer. Fluorescence intensity is in arbitrary units. Assay was 
performed on day 6 of actin preparation. 
 
Tm5A and Tm5B are non-muscle tropomyosin from fibroblasts and Tm-n3D23 is a ultra-
short non-muscle tropomyosin. Tm5A and Tm5B have similar regulatory properties of 
actin and myosin but were found to have a lot of variation with their affinity to actin 
(Maytum et al., 2000). As shown in the Figure 2.38A in presence of Tm5A, in 
comparison with 10day old actin, the initiation is higher than actin alone and elongation 
seems to be slower (k = 302.99 sec) but the final filament fluorescent intensity was much 
higher than actin on its own (Vmax = 8.7 units) and although Tm5B (Figure 2.38B) show 
higher initiation similar to all other tropomyosins its elongation is much slower than 
Tm5A ( k = 441.4 sec). Similar to other tropomyosin isoforms ultrashort non-muscle 
tropomyosin Tm n3D23 (Figure 2.39) had similar affect of higher initiation rate and 
much lower elongation rate in comparison to actin alone with k value of 201 sec.  
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Table 2.5: The Hill simulation time course polymerisaiton curves of actin 
polymerisation. Vmax – complete saturation time, k – half time of saturation. N –gives 
the sigmoidicity of the curves (Hill coeffecient).  
 
The curves were fit to the Hill equation taking all the triplicate data available. The error 
bars are not calculated as the curves were generated using the formula giving the best fit 
using all the data together.  
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2.6 Discussion 
The recombinant tropomyosin synthesized from E. coli has unacetylated N-terminal 
methionine, and in few cases the N-terminal methionine is cleaved depending on the 
residue present next to N-terminal residue as explained earlier. In contrast tropomyosin 
extracted from muscle has intact N-terminal methionine but acetylated.  Höög et al., 
(1987) showed expression of human alcohol dehydrogenase in E. coli and confirmed that 
proteins expressed in E. coli do have eliminated N-terminal methionine but lack N-
terminal acetylation of serine after removal of the first methionine, but still express active 
unfused protein with correct folding. In E. coli only few ribosomal proteins are 
acetylated, and some proteins do not need acetylation to perform their function. The 
‘local’ structure of tm amino terminal is essential for head-to-tail polymerisation and for 
actin binding (Urbancikova and Hitchcock-DeGregori, 1994). When the N terminal 
methionine is acetylated, the nitrogen is having an amide bond similar to peptide bond, 
which is uncharged. On the other hand, the unacetylated  nitrogen group carries a positive 
charge in free amino state as shown in Figure 2.1b (Brown et al., 2001; Heald and 
Hitchcock-DeGregori, 1988; Monteiro et al., 1994). 
In mammalian Tpm-3 the initial methionine occupies the hydrophobic core a position 
(Figure 2.1a and b). As tropomyosin helical coiled coil follows heptad rule, the native Nt-
Met amino group is acetylated with a hydrophobic side chain. In recombinant 
tropomyosin produced in E. coli, the Nt-Met is not acetylated and carries a positive 
charge at the hydrophobic core position. The net positive charge of the two coils may 
cause electrostatic repulsion which destabilizes the helix (Monteiro et al., 1994) and the 
results shows weak binding to actin. Addition of 2 or 3 amino acids shifts the positive 
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charge to positions e and f respectively thereby reducing the electrostatic repulsion and 
stabilizing the coil keeping the native folding of the protein. The addition of peptides at 
the Nt of tropomyosin alters the stability and structure of tropomyosin molecule and 
affects the equilibrium constant from open to closed transition which determines the 
available actin binding sites to myosin during muscle regulation. The regulation 
properties of  recombinant tropomyosin varies on the length of the peptide added to the 
Nt end (Maytum et al., 2000; Monteiro et al., 1994).  
 In this study, Tpm3-Met and Tpm3-MM variants, Nt-Met is not removed because of the 
larger size of the amino acids present next to the Nt-Met which cause steric hindrance 
(Lowther and Matthews, 2000) and also due to the sequence specificity of the Nt ends 
(Bradshaw et al., 1998).  In the Tpm3 sequence the amino acid next to Methionine is Glu 
(E) and Met (M) which are large for the MetAps to catalyze (Xiao et al., 2010) hence it 
retains the Met and is not acetylated in contrast to (M)ASM variant where the second and 
third residue are smaller and Nt-Met is cleaved which is confirmed by masses obtained 
by mass spectrometry analysis. The present study confirms the previous research in the 
cleavage of Nt-Met in proteins produced in E. coli. 
Expression of Tpm4 protein in E. coli, the yield was very high in comparison to any other 
tropomyosin isoform produced in this study. The gene used was an ORF cDNA clone 
synthesized synthetically using the codons of E. coli. According to Goodman et al.,  
(2013), using Nt rare codons that are enriched at the Nt of the genes than the common 
ones increases the expression efficiency by >14 fold. Rare codons are frequently rich in 
A/T third position and codons ending in A/T were correlated with increased protein 
expression as compared with decrease in expression with G/C codons (Kudla et al., 
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2009). The proteins expressed in E.coli with change in the codons exhibit the same 
secondary structure with no change in total free energy of folding through the Nt region 
(Goodman et al., 2013). As seen from Figure 2.7 the synthesized sequence has G and C 
replaced with A and T from the native sequence. This may be the reason that there was 
higher protein expression with Tpm4.  
Purification of Tropomyosin 
The method used for purification of proteins with isoelectric precipitation produced 
higher yields (Maytum et al., 2000). All the three methods used for precipitating protein 
before purifying through anion exchange column, gave pure protein with less nucleic acid 
impurities. Ethanol precipitation gave higher yield of protein compared to pI and 
ammonium sulphate precipitation, however Ip precipitation had less impurities compared 
to the other two methods as confirmed by the UV spectroscopy results. The disadvantage 
of tropomyosin purification by pI precipitation at pH 4.6, is that DNA also get 
precipitated at the same pH as well as in ethanol, by careful adjustment of pH and anion 
exchange chromatography, nucleic acids can be removed from protein samples.  
Affinity of Tm for Actin 
From the studies of  Drabikowski and Nowak (1968) the ratio of  bound F-actin –
tropomyosin is 1:2 assuming Tm is in dimer state, where four strands of tropomyosin is 
bound to 2 strands of actin filament. Actin filament is completely saturated with tm alone 
at 1:2 ratio. At lower proportion of tropomyosin below the saturation ration, not all tm is 
bound to actin but rather exist in an equilibrium state of bound and free tropomyosin. 
This has been extended later by biophysical and structural studies that tropomyosin binds 
to actin in 1:7 ratio with one tropomyosin molecule, assuming to be in dimer state binds 
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around seven monomer actin molecules (Heald and Hitchcock-DeGregori, 1988; 
Hitchcock-DeGregori and Heald, 1987; Maytum et al., 2000; Maytum et al., 2001; 
Urbancikova and Hitchcock-DeGregori, 1994). 
 In this study the results show that by adding 2 additional amino acids (Ala, Ser) to 
Tpm3-Met sequence restores all the fundamental functional aspects of tropomyosin 
affinity to actin such as expected actin affinity and cooperativity as compared to Tpm1. 
Deletion of one amino acid (Met) from Tpm3-MM, from the sequence lowers its affinity 
and loses its cooperativity. Tpm3-MM keeping the original sequence (MM) of 285 aa at 
the N-terminal synthesised in E. coli also had lower affinity to actin may be due the 
unacetylated methionine remained at the end which does not seem to favour higher 
affinity to actin binding due to a positive charge carried at the hydrophobic core position 
(a) and the tropomyosin coil becomes unstable (Hitchcock-DeGregori and Heald, 1987; 
Monteiro et al., 1994) as compared to the truncated Tpm2 which does not have any 
fusion amino acids at the N-terminal sequence have lower affinity and loses its 
cooperativity. Further studies are required to confirm the original sequence of Tpm3 in 
humans to confirm the number of methionie at the N-terminal end of the sequence.  
Tpm4 binds to actin filaments and is present in both muscle and non-muscle. Its 
expression is lower in heart and muscles and is highly expressed in smooth muscles such 
as in lung tissue, liver, stomach and spleen for stabilising the cytoskeleton actin filaments 
(Gunning et al., 2005b; Helfman et al., 1999b).  Helfman (1999b) studied LMW Tpm4 by 
expressing with fusion Green fluorescent protein to show that LMW Tpm4 need other 
LMW isoforms of Tm like TM5, TM5a and TM5b to incorporate into actin filaments in 
neonatal rat cardiomyocytes. Zhao et al., (2008) suggests that HMW form of TPM4-
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variant1 with 284aa is a heart-specific variant and plays an important role in heart 
contractility.  They studied zebra fish embryonic heart by Tol2 transposon-mediated 
mutagenesis and showed that removal of functional Tpm4 stops the heartbeat of the 
embryonic heart and the death of the embryos. There is not enough data available for 
assigning the main function of Tpm4 in heart so far. From the co-sedimentation assays of 
Tpm4 with poor affinity to actin on its own, suggests that Tpm4 need other Tm isoforms 
coexpressed to perform actin regulation. Further characterisation studies are required to 
confirm the results for Tpm4 binding affinity to actin.  
In conclusion, expression of tropomyosin with two amino acid residues (Ala, Ser) 
extension at the N-terminal was reported to restore the native like function of Tm as 
revealed by a number of assays (Monteiro et ai, 1994). This study investigated this claim 
by applying actin-binding assays to compare Tpm3.12st isoform with already 
characterised Tpm1.1 and Tpm2.2 and found the substitution with two amino acids have 
similar actin binding affinity as native tropomyosin and similar to Tpm1.1 and Tpm2.2,  
resulting with binding efficiency in the range of 0.6 µM. free tropomyosin. Therefore, the 
Ala-Ser extension expressed at the N-terminus of Tm is a good mimic of the acetyl group 
for Tpm3.12st as well. From this study it is also suggested that the initial N-terminal end 
of the sequence for Tpm3.12st may be a single Met instead of Met-Met as Met Met on its 
own did not bind to actin as it is expected to behave normal without any modification. 
Further confirmation of this study is required to confirm the N-terminal end of the Tpm3-
12st sequence.  
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Effect of tropomyosin isoforms on actin polymerisation  
The fluorescent reagent N-(1-Pyrenly)Iodoacetamide used for labelling F-actin 
conjugates at the sulfhydryl group at Cys374 of F-actin (Kouyama and Mihashi, 1981; 
Tobacman and Korn, 1983). The increase in intensity of fluorescence of PyG-actin is 
enhanced to about 10 times by polymerisation to F-actin agreeing with the previous 
results (Cooper et al., 1983b). The advantages of using pyrene actin to study 
polymerisation kinetics is that at the initiation step of polymerisation, the fluorescence 
increase is at 100% rise and is not influenced by any dust particles or shearing or any 
other light scattering solid residues left in the assay solution which may result in change 
the polymerisation kinetics (Frieden and Goddette, 1983a; Wegner, 1982a). This will also 
has advantage of lower signal-noise ratio as opposed to light scattering experiments 
which was confirmed by Cooper et. al., (1983b) by studying the polymerisation with  
both stirred and unstirred solution. Stirring the sample breaks the polymers formed, the 
fluorescence assays does not affect the fluorescent signal form an unstirred solution as it 
does with light scattering experiments. Fluorescence studies is independent of the 
percentage of pyrene actin used as the critical concentration is not changed using 5%  
pyrene actin with the rest being unlabeled actin (Criddle et al., 1985a; Kouyama and 
Mihashi, 1981; Lal and Korn, 1986). Hence a trace amount of pyrene actin can be used 
with a bulk amount of unlabeled actin for polymerisation studies without compensating 
results. The concentration of monomeric actin does not change the critical concentration 
of actin after polymerisation however the concentration of polymeric actin varies once 
the reaction reaches a steady state (Tobacman and Korn, 1983; Wegner and Engel, 1975). 
However in this study the actin used is all pyrene labelled G-actin.  
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The polymerisation curves of actin in two different concentrations (2 μM and 6 μM) are 
shown in Figure 2.31.  The curves agree with previous studies (Cooper et al., 1983b; 
Frieden and Goddette, 1983a; Lal and Korn, 1986; Wegner, 1982a; Wegner, 1982b) in 
that by increase in the concentration of actin the polymerisation rate also increases, 
however the sigmoidicity of the curves is lost as the concentration is increased. Wegner 
(1982a) showed that at very low concentrations of actin, there is increase in sigmoidicity 
of the curves which may be due to spontaneous fragmentation and is found to be 
independent of Mg2+ and K+ concentrations.  This is primarily a concentration effect on 
initiation as the rate of polymerisation depends on the rate of nucleation during initiation 
phase.  
According to Tobacman and Korn (1983) the nucleation rate is directly proportional to 
the fourth power of monomeric actin indicating that the first nucleus formed to proceed to 
form a polymer is a tetramer. The data obtained in this study is not sufficient to study the 
nucleus size and the size of the polymer after the polymerisation reaction reached a 
steady state as it is previously stated that the halftime (given in Table 2.5) of the 
polymerisation reaction does not give the nucleus size (Frieden and Goddette, 1983a; 
Hitchcock-DeGregori et al., 1988). The critical concentration was also not calculated as 
the concentration of F-actin was not measured after spinning the assay solution which 
was used to run on the gel to check the efficiency of the binding. The present study gives 
a qualitative comparison of the effect of various tropomyosin isoforms on actin 
polymerisation and further studies are required to quantify the size of nucleus, nucleation 
–elongation rate constants and the reaction pathway by which tropomyosin is effecting 
the initiation phase of actin polymerisation.   
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According to Lal and Korn (1985) the fluorescent intensity during polymerisation was 
not reduced in presence of Tropomyosin due to hydrolysis of ATP on F-actin. The critical 
concentration of monomeric actin remained same 0.1 μM even though the association 
constant of actin polymerisation was reduced to 40% in presence of tropomyosin 
(Wegner, 1980).  
The main characteristic function of tropomyosin in both muscle and non-muscle cells is 
the prevention of spontaneous fragmentation of actin filaments by severing protein and 
tropomyosin has negligible or no effect on actin polymerisation. 
The effect of tropomyosin on actin polymerisation is found to vary depending on the 
concentration of actin and tropomyosin (Hitchcock-DeGregori et al., 1988; Wegner and 
Ruhnau, 1988). Tpm1 with two different concentrations of actin and tropomyosin show 
different polymerisation curves. With low concentration of Tpm1 (0.5 µM) the overall 
polymerisation was higher with initiation and elongation and the maximum fluorescent 
intensity was higher as well. As the concentration of Tpm1 increased to 5 µM, initiation 
was higher but the elongation and maximum fluorescent intensity after completion of 
polymerisation was lower than actin in absence of Tpm1. With lower concentration of 
actin (2 µM) and 5 µM showed the similar curve as using 6 µM actin (Figure 2.32). 
Hence it’s the concentration of tropomyosin that effects how actin kinetics are 
modulated, as long as the actin monomers are available the tropomyosin has same affect 
at a particular concentration. All the isoforms of tropomyosin have accelerated the 
initiation step and inhibited the elongation. The final filament intensity was higher in 
presence of tropomyosin indicating that there are more number of F-actin filaments and 
therefore it can be proposed that tropomyosin affects the critical concentration of actin.  
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Tpm2, Tpm3- MET and Tpm4 are shown to have an overall increase in polymerisation 
for an unknown reason. When compared to the affinity with actin these three isoforms 
have very low binding affinity to actin with lower cooperativity.  
The results in this study partially contradict previous research results which state that 
tropomyosin inhibits both initiation and elongation rate constants of actin mostly because 
they bound to the actin filaments and not to monomer actin (Hitchcock-DeGregori et al., 
1988; Lal and Korn, 1986; Wegner, 1979; Wegner, 1980; Wegner, 1982b; Wegner and 
Ruhnau, 1988). However Pragay and Gergely  (1968) reported that muscle tropomyosin 
accelerates the polymerisation of ATP-actin but is more pronounced with ADP-F-Actin 
studied by viscosity measurements at 0 0C and the acceleration is more pronounced at 
250C. Wegner and Ruhnau (1988) and Hitchcock De-Gregory (1988) both studied the 
effect of tropomyosin by nucleated polymerisation and spontaneous polymerisation 
reported that tropomyosin inhibits actin polymerisation. The inhibition did not overcome 
even after addition of F-actin nuclei, suggesting that tropomyosin along with inhibition of 
polymerisation may also inhibit elongation as well as fragmentation of filaments. 
Non-muscle tropomyosin were tested with muscle actin as it has been shown that both 
muscle and non-muscle actin does not show any variation in polymerisation kinetics 
(Buzan and Frieden, 1996; Nefsky and Bretscher, 1992). Tm5A and Tm5B have different 
effect on elongation, but both show acceleration of initiation.  
Tropomyosin has found to bind to actin at a rate of 2.5 x 106 to 4 x 106 M-1s-1 (Wegner 
and Ruhnau, 1988). Actin polymerisation is not only affected by presence of tropomyosin 
in presence of ATP, due to conformational change of filaments and ATP hydrolysis when 
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the polymerisation is near to steady state (Keiser and Wegner, 1985). Tropomyosin 
stabilizes actin filaments and prevent from spontaneous fragmentation (Wegner and 
Savko, 1982), changes in the concentrations of tropomyosin has also been reported due to 
high cooperativity of actin-tropomyosin binding, changes in conformation of actin is 
found when tropomyosin is head to tail association and in complete absence of 
tropomyosin (Wegner, 1976).  
When a salt binds to divalent metal ion (Mg2+ or Ca2+) monomer actin, the monomer 
undergoes a conformational change which is considered to be a significant step in 
polymerisation. This stage is called monomer activation step, which is the intermediate 
conformation of G-actin – F-actin (Fig. 3.2). Which can be shown as : 
 
Where, GF is called F-monomer that undergoes conformational change before forming a 
nucleus (Cooper et al., 1983a). Cooper et al., reported that this monomer activation step 
studying actin polymerisation in presence of Ca2+ and Mg2+ ion individually. In presence 
of Ca2+  ions the initiation of nucleation was slower and in presence of Mg2+ the initiation 
of polymerisation is faster, leading to state the principle that when Mg2+ binds to G-Ac a 
intermediate monomer conformation is formed (GF) which is a faster reaction and 
initiates the polymerisation faster. However the elongation rates have shown to be same 
with time in both the cases. The effect of tropomyosin on actin polymerisation show a 
different rates of polymerisation in presence of troponin and myosin (Cho et al., 1990; 
Hitchcock-DeGregori and Heald, 1987; Maytum et al., 2003; Smith et al., 2003).  
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In conclusion, in contrary to previous research results, tropomyosin isoforms show 
acceleration of the initiation step of actin polymerisation. As tropomyosin binds to only 
F-actin, how it has effect on initial polymerisation step is unknown. The stage of actin at 
which tropomyosin starts binding to actin, how big the actin filament should be for 
tropomyosin to affect polymerisation, does tropomyosin forms a surface for the monomer 
to form nucleus faster than in the absence of tropomyosin molecules? These are the 
question that arise from this study to clarify further. In physiological conditions there are 
many other major factors affecting nucleation and polymerisation of actin such as NPF 
proteins WASp and  Arp 2/3 complex, profilin, cofilin, and other actin binding proteins 
that affect the whole polymerisation process. Establishing kinetic dynamics in all these 
conditions is not easy. Techniques like single molecule imaging developed by Kad and 
his collaborators (Desai et al., 2014; Kad and Van Houten, 2014) studied cooperativity of 
thin filament activation by direct imaging of single molecule of myosin binding to actin 
and DNA repair. Using the single molecule imaging technique, an experiment can be set 
up by taking a single tropomyosin molecule in the pool of actin monomers to observe the 
mechanism of actin polymerisation in presence of tropomyosin. This may give deeper 
understanding of role of tropomyosin in actin polymerisation. Li et al (Li et al., 2010) 
used fluorescent electron microscopy and molecular dynamic simulation to study 
conformation changes of tropomyosin on actin showed that tropomyosin when bound to 
actin is semirigid and is essential for assembly of actin filaments. This method has 
potential in understand the dynamics of actin -tropomyosin binding. Schmidt et al., 
(Schmidt et al., 2014) showed weak monomer binding of tropomyosin to actin leads to 
nucleation sites which enhanced the interaction of actin to tropomyosin mostly dependent 
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on end-end interactions of tropomyosin molecule using TIRF microscopy with Alexa 532 
labelled tropomyosin. Techniques mentioned about may help to built polymerisation and 
building kinetics models for tropomyosin -actin polymerisation that would enable to fully 
understand the dynamics of tropomyosin on actin polymerisation.  
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Chapter III: Identification of Tropomyosin 3.12.st 
(TPM3.12st) using monoclonal antibodies 
 
3 Introduction 
Tropomyosins are highly conserved components of actin filaments both in vertebrates 
and non-vertebrates. Over 40 isoforms of Tm have been identified from four genes in 
mammals. The four genes encoded by tropomyosin (Tm) are αTm (TPM1), βTm (TPM2), 
γTm (TPM3) and δTm (TPM4). These genes undergo extensive alternative splicing of 
mRNA or have alternative promoters and different N-terminal modifications to give rise 
to >40 isoforms. The isoforms are differentiated broadly into two types depending on 
their molecular weight, high molecular weight (HMW) and low molecular weight 
(LMW) Tms (Lees‐Miller and Helfman, 1991; Leger et al., 1976).  
Tm isoforms regulate actin filaments and have different affinities with actin by either 
interacting or inhibiting or competing with various actin binding proteins (Bryce and 
Schevzov, 2003; Pittenger et al., 1995). Both in-vitro and in-vivo studies show that 
different Tm isoforms localize specifically at subcellular level in numerous cell types by 
directly affecting the actin filament concentration (Schevzov et al., 2008). Coulton (2010) 
and Stark (2010) showed in fission yeast that the localization of Tm isoforms is 
demonstration of evolutionary mechanism  in regulating actin filament composition.  
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3.1 Tropomyosin gene  
 
There are four genes that express tropomyosin, Tpm1 (α-Tm) located on chromosome 
15q22, Tpm2 (β-Tm) located on 9p13, Tpm3 (γ-Tm) located on 1q21.2 and Tpm4 (δ-Tm) 
located on 19p13.1 and these genes encodes >40 isoforms (Figure 3.1 to Figure 3.4) by 
alternative splicing, 3’ differential processing and presence of alternative promoters. 
Recently the nomenclature of the primary mammalian tropomyosins form humans, rat 
and mouse has been amended by Geeves et.al., (2014). These are shown in Figure 3.1 to 
Figure 3.4 shows the genes of Tpm1, Tpm2, Tpm3 and Tpm4 and their isoforms 
respectively with NCBI accession number of human isoforms (Rat and mouse accession 
numbers are not given in the tables). 
Replication of ancestral gene is thought to given rise to the tropomyosin gene family in 
vertebrates (Lees‐Miller and Helfman, 1991). As shown in the nomenclature, formal 
protein names are assigned according to the gene, isoform number and most importantly 
the tissue they are expressed, for example the Tpm1 encodes proteins Tpm1.1st- Tpm1 
gene isoform 1 striated muscle that is encoded in both skeletal and cardiac, Tpm1.3sm, 
which is isoform 3 encoded in smooth muscle and Tpm1.10br, Tpm1.11br and 
Tpm1.12br proteins encoded in brain and Tpm1.9cy encoded in cytoplasm (Geeves et al., 
2014; Lees‐Miller and Helfman, 1991; Perry, 2001). Each gene produces both high 
molecular and low molecular weight proteins by alternative splicing of the exons and 
transcriptional initiation. Form the different Tms, exon 1a in with either 2a or 2b encoded 
N- terminal end encodes HMW isoforms with 284 aa that are mostly predominant in 
striated muscles and exon 1b (excluding exon 2) encodes LMW isoforms with 248aa that 
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are mostly expressed in smooth muscle tissue.  All these variants have either 6a or 6b and 
variation of exon 9 (9a, 9b, 9c or 9d) at the C-terminal end. Exons 3, 4, 5, 7 and 8 are 
common to all the Tm isoforms regardless of the tissue they express.  
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Figure 3.1: Tropomyosin isoform sorting of TPM1/ αTm Gene: a. TPM1 gene (human 
gene ID: 7168) and the isoforms formed by alternative splicing of exons gives rise to a 
variety of isoforms. Muscle isoforms have 1a and either 2a or 2b and also either 6a or 6b. 
They also exhibit variations at the carboxyl terminal at exon 9 terminating with a polyA 
tail. Low molecular weight isoform have 1b as the N-terminal exon. The black boxes 
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represent the exons common to all isoforms, open boxes represent untranslated regions 
and lines represent introns and A represents poly A tail. b. Table showing the isoforms 
expressed by Tpm1 gene, protein name and the human protein accession number. St-
straited (cardiac/skeletal tissue), sm-smooth, Br –brain, cy, cytoplasm (Geeves et al., 
2014; Lees‐Miller and Helfman, 1991).  
 
 
Figure 3.2: Tropomyosin isoform sorting of TPM2/ βTm Gene: a. TPM2 gene (human 
gene ID: 7169) and the isoforms formed by alternative splicing of exons gives rise to a 
variety of isoforms. Muscle isoforms from β gene have 1a and 2b and either 6a or 6b. 
They exhibit variations at the carboxyl terminal at exon 9 with 9a or 9d terminating with 
a polyA tail. The black boxes represent the exons common to all isoforms, open boxes 
represent untranslated regions and lines represent introns and A represents poly A tail. b. 
Table showing the names given to the isoforms, protein name and the human protein 
accession number. St-straited (cardiac/skeletal tissue), sm-smooth, cy, cytoplasm (Geeves 
et al., 2014; Lees‐Miller and Helfman, 1991). 
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Figure 3.3: Tropomyosin isoform sorting of TPM3/ γTm Gene: a. TPM3 gene (human 
gene ID: 7170) and the isoforms formed by alternative splicing of exons gives rise to a 
variety of isoforms. Muscle isoforms from γ gene have 1a and 2b and either 6a or 6b. 
They exhibit variations at the carboxyl terminal at exon 9 with 9a or 9c or 9d terminating 
with a polyA tail. Tpm3.8 and Tpm3.9 have 9c exon shaded light as it can be substituted 
with 9a in some cases. Low molecular weight isoforms have 1b as the N-terminal exon.  
The black boxes represent the exons common to all isforms, open boxes represent 
untranslated regions and lines represent introns and A represents poly A tail. b. Table 
showing the names given to the isoforms, protein name and the human protein accession 
number. St-straited (cardiac/skeletal tissue), cy, cytoplasm (Geeves et al., 2014; 
Lees‐Miller and Helfman, 1991). 
  
136 
 
 
Figure 3.4: Tropomyosin isoform sorting of TPM4/δTm Gene: a. TPM4 gene (human 
gene ID: 7171) and the isoforms formed by alternative splicing of exons gives rise to a 
variety of isoforms. Muscle isoforms from δ gene have 1a and 2b and 6b exons. The 
Tpm4 gene has only 9d at the carboxyl terminal terminating with a polyA tail. Low 
molecular weight isoform have 1b as the N-terminal exon. The black boxes represent the 
exons common to all isforms, open boxes represent untranslated regions and lines 
represent introns and A represents poly A tail. b. Table showing the names given to the 
isoforms, protein name and the human protein accession number. cy, cytoplasm (Geeves 
et al., 2014; Lees‐Miller and Helfman, 1991). 
 
3.2 Distribution of Isoform Expression  
Each isoform express distinct patterns depending on specific tissues and also exhibit 
variation during development of an organism from embryonic to adult stage  The proteins 
expressed by these genes are differentially distributed depending on the differential 
functional distribution. There are more number of Tm isoforms are expressed in non-
muscle cells like in fibroblasts of rat, mouse, human and chicken fibroblasts (5-7 
isoforms) and smooth muscles, such as brain cells have 3 specific isoforms which are 
unique to neurons itself. On the other hand primary muscle related isoforms in striated 
muscle (both cardiac and skeletal) have 2 to 4 isoforms found so far (Helfman et al., 
1999a; Lees-Miller, 1990).  
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Isoforms from Tpm1 gene predominates in most of the organs, in striated muscle (both 
cardiac and skeletal muscle) Tpm1.1st predominates followed by lower amounts of 
Tpm1.2st (κTm) Tpm2.2st. Tpm1.1st is predominant in fast cardiac muscles and 
Tpm2.2st in both fast skeletal and slow skeletal muscles in different proportions.   
In the heart, cardiac muscle filaments is differentiated form fast skeletal and slow skeletal 
muscle due to specific adaptation demands of the organ for continuous function. 
Tpm1.1st is found to be predominant in small mammalian hearts like mouse, rat, rabbit 
and dog  however Tpm2.2 is also found in larger mammals like sheep, cow, pig hearts in 
1:4 ratio (Leger et al., 1976). Rajan et al., (2010) found κTm in human heart muscle and 
Peng et al., (2013) suggested that there is variation in distribution of expression of these 
isoforms in different regions of the heart by top down mass spectrometric analysis from 
tropomyosin purified form human heart tissue. The novel κTm is found to be highest in 
left atria followed by right atria and right ventricle but not detected in left ventricle and 
phosphorylation of α-Tm was higher in atria rather than in ventricles. The presence of 
γTm in heart is not confirmed by both studies conducted by Marston et al., (2013)and  
Peng  et al., (2013) using different techniques. 
It is a well-known fact that in skeletal and cardiac muscle Tm plays a major role in 
muscle contraction in association with troponin (Tn) complex. When calcium ions are 
released in the muscle cell, troponin C binds to the calcium ions causing a conformational 
change initiated by troponin-tropomyosin complex, which in turn is initiated by the 
ATPase activity causing contraction. However, troponin is not present in smooth muscle 
and non-muscle cells and hence the contraction is solely controlled by the calcium-
sensitive regulatory mechanism. The role of Tm in these smooth and non-muscle cells is 
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found to regulate the actin filaments, intracellular transport, motility and cytoskeleton 
structure (Pittenger et al., 1994). Muthuchamy et al., (1993) by tropomyosin-mRNA 
studies in mouse heart showed that the ratio of β-Tm to α-Tm exists in 1:4.5 ratio at 
embryonic state and the amount of βTm declines to a ratio of 1:60.5 in adult heart 
showing that it is important in cardiogenesis in mouse heart and shift in the isoform 
composition. On the contrary, it is known that the amount of mRNA directly proportional 
to the protein expressed,  Rethinasamy and Muthuchamy (1998) found that the 
composition variation of protein isoforms occurs at translation state in mice.  
The variation in the exon composition found in different isoforms leads to different 
functions of tropomyosin proteins affecting actin binding affinity, head-to-tail 
polymerisation and the interaction of Tm with other binding proteins (Lees‐Miller and 
Helfman, 1991; Pittenger et al., 1994b). Recently Hook et al., (2004) showed that the low 
molecular weight products of TPM3 (γTm) gene are necessary for the cell survival of 
embryonic stem cells and  embryonic development as these are not found in the adult 
stage of mouse. Again in 2011, Hook et al., studied the embryonic viability of knock out 
mice by knocking off either 1a or 1b and 6a or 6b exons and 9a or 9b/c/d and found that 
non-viable mice were produced by deletion of 1b exon and partial viability with deletion 
of 9d exon but no effect on viability with deletion of 9c exon. All these cells had full 
expression of α and β Tms (Hook et al., 2011).  But in humans normal and failing heart 
muscles have typically 95% α-Tm with a smaller amount of β and γ Tms are found and 
4% of κ isoform (product of TPM1 gene) are found (Marston et al., 2013; Maytum et al., 
2011; Purcell et al., 1999; Rajan et al., 2010).  
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The main objective of this chapter was to produce monoclonal antibodies specific to 
HMW Tpm3 to identifying Tpm3-iso12st protein in muscle tissue which could be used 
with tissue extracts, cell extracts or by histocytochemistry in healthy and diseased tissues 
instead of using CG3 antibody (Lin et al., 1985) which identifies both HMW and LMW 
proteins that are expressed by TPM3 gene.  
Twelve antibodies against HMW Tpm3.12st sequence were prepared. Recombinant Tm 
proteins characterised in Chapter II were used for antibody reactions. Dot blot technique 
was used to identify the reactivity of the antibodies with Tpm1.1st, Tpm2.2st and 
Tpm3.12st isoforms in native and denatured state. As the results were not consistent, 
western blotting was employed for characterisation with antibodies with denatured 
protein of all the four Tpm1.1st, Tpm2.2st, Tpm3.12st and Tpm4.1cy isoforms. From the 
results obtained with western blotting, an ELISA method was developed to compare the 
sensitivity of Tpm3.12st with only Tpm1.1st using different dilutions of antibodies with 
various concentrations of proteins.  
3.3 Materials  
All the list of materials used for the experiments are given in Table 6.1 in Appendix 
(page 252). Others that are not stated in the list are given in the text. 
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3.4 Experimental Methods 
3.4.1 Monoclonal antibodies production 
 
Specific monoclonal bodies for Tpm3 were bought from Abmart Inc. China. The 
company produced the monoclonal antibodies based on their key technology algorithm 
called SEAL –Protein Surface Epitopes Targeted by Monoclonal Antibody Library 
where antibodies for the target protein are made only by protein sequence (Figure 3.5). 
The immunogen design algorithm will predict potential epitopes for a target protein and 
each epitope peptide contains 10 amino acids strictly. Those potential epitopes are then 
integrated into Abmart expression vector to produce recombinant antigens for further 
immunization (Abmart Inc). Based on the Tpm3.12st protein sequence 12 potential 
epitopes were selected, with each epitope contains 10 amino acid residues. All the 
selected peptides were integrated consequently into expression vectors to generate 
antigens for further immunization in mice.  
 
Figure 3.5: SEAL technology for antibody production (Abmart Inc.) 
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Protein immunogen was over expressed in E. coli and purified by Ni-affinity 
chromatography. After purification the antigen was used in animal immunization. Three 
8-12 week old female mice were immunized with an immunogen and the mouse with best 
immune response was chosen to produce hybridomas cells from spleen. The spleen cells 
were fused with SP2/0 myeloma cells to generate the hybridomas in HAT medium. 
Stable clones that secrete antibodies with the ability to bind to antigen were selected and 
injected in the peritoneal cavity of mice. After 10-14 days tumors containing an antibody 
rich fluid called ascites fluid is produced. The ascites fluid is collected and tested for the 
reactivity of the antigen. Methodology work flow is shown in the Figure 3.6. The 
screening confirmed 12 antibodies, that recognize 5 peptides from the sequence and are 
listed in Table 3.1 and the exon position of the epitopes aligned with Tpm3.12st sequence 
of the antibodies are given in the Figure 3.7.  
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Figure 3.6 : work flow for the production of monoclonal antibodies. 
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Figure 3.7: Sequence alignment of Tpm3 with Tpm1, Tpm2. a. Shows the TPM3 gene and Fig. b shows the sequence 
resemblance alignment of high molecular weight (284 aa) human Tpm1, Tpm2, Tpm3 and Tpm4 protein sequence with exons. 
The sequence alignment also shows the sequence resemblance of the epitopes of monoclonal antibodies produced for this 
study with the peptide number given. The highlighted epitopes are the antibodies used and the non-highlighted once are the 
once that are the initial epitopes produced by the company to check the specificity. P- peptide number, dots represent the 
amino acid residue identity. 
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Table 3.1: List of antibodies and the corresponding peptide sequence, epitope 
similarity of all the four isoforms and the predicted binding assumption. Non-
identical residues are highlighted in red. The antibody rows with similar colour have 
same peptide recognition.  
Antibody 
number 
Residue 
position 
Peptide 
Sequence 
Theoretical 
binding 
assumption 
Epitope similarity for  
all four isoforms 
1 
 
(2,6,9) 
259-268 
DELYAQKLKY 
P5 
Tpm3,Tpm1 
DELYAQKLKY-Tpm1 
DEVYAQKMKY-Tpm2 
DELYAQKLKY-Tpm3 
EKLAQAKEEN-Tpm4 
2 259-268 
DELYAQKLKY 
P5 
Tpm3,Tpm1 
DELYAQKLKY 
DEVYAQKMKY 
DELYAQKLKY 
EKLAQAKEEN 
3 171-180 
VIIEGDLERT 
P4 
Tpm3 
VIIESDLERA 
VILEGELERS 
VIIEGDLERT 
VILEGELERA 
4 116-125 
EAEKAADESE 
P3 
Tpm1,Tpm2, 
Tpm3,Tpm4 
EAEKAADESE 
EAEKAADESE 
EAEKAADESE 
EAEKAADESE 
5 24-33 
EQAEAEQKQA 
P1 
Tpm3 
EQAEADKKAA 
EQAEADKKQA 
EQAEAEQKQA 
EQAEADKKAA 
6 259-268 
DELYAQKLKY 
P5 
Tpm3,Tpm1 
DELYAQKLKY 
DEVYAQKMKY 
DELYAQKLKY 
EKLAQAKEEN 
7 
(8,10,1
1,12) 
34-43 
EERSKQLEDE 
P2 
Tpm3 
EDRSKQLEDE 
EDRCKQLEEE 
EERSKQLEDE 
EDKCKQVEEE 
8 34-43 
EERSKQLEDE 
P2 
Tpm3 
EDRSKQLEDE 
EDRCKQLEEE 
EERSKQLEDE 
EDKCKQVEEE 
9 259-268 
DELYAQKLKY 
P5 
Tpm3,Tpm1 
DELYAQKLKY 
DEVYAQKMKY 
DELYAQKLKY 
EKLAQAKEEN 
10 34-43 
EERSKQLEDE 
P2 
Tpm3 
EDRSKQLEDE 
EDRCKQLEEE 
EERSKQLEDE 
EDKCKQVEEE 
11 34-43 
EERSKQLEDE 
P2 
Tpm3 
EDRSKQLEDE 
EDRCKQLEEE 
EERSKQLEDE 
EDKCKQVEEE 
12 34-43 
EERSKQLEDE 
P2 
Tpm3 
EDRSKQLEDE 
EDRCKQLEEE 
EERSKQLEDE 
EDKCKQVEEE 
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3.4.2 Dot Blot 
 
Dot blot technique is similar to western blotting except that the proteins are not separated 
by gel electrophoresis. Hence native protein can be used for identification and analysis of 
proteins by using antibody probe. The advantage this method gives is by saving the 
amount of protein used and the time and reagents consumed are less when compare to 
western blotting.  
In this method proteins are spotted on a nitrocellulose membrane and are then hybridized 
with specific antibody probe. Nitrocellulose membrane (GE healthcare Hybond ECL 
nitrocellulose membrane) was cut into strips and each strip is used for the 12 antibodies 
using for identification of Tpm3. Using a pencil the strips are labelled and dots were 
spotted with 1cm apart to indicate the region where protein is being spotted as shown in 
results Figure 3.10. First all the recombinant proteins produced in Chapter II (Tpm1, 
Tpm2, Tpm3 –all there version, Tpm1 A63V, Tpm1-K70T) were used to establish the Ab 
sensitivity (Figure 3.10A) In the second experiment (Figure 3.10B) different 
concentrations of Tpm1 and Tpm2 were at constant dilution of Abs, 1 in 8K dilution was 
used to check sensitivity of protein concentration to Ab and third time constant protein 
concentration with constant Ab dilution was used but with protein in its native and 
denatured state with Tpm1, Tpm2 and Tpm3 as shown in Figure 3.10C. The denatured 
protein is prepared by incubating the protein with 0.1% SDS at 950C for 5min, cooled 
and then used for blotting. 2 μl of 10 μM protein was spotted slowly on the membrane. 
The membrane was allowed to dry for 1 hour and was blocked with 5% no fat milk 
(Marvel semi-dried milk powder) in 1X phosphate buffer saline with 0.05% Tween 20 
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(1X PBS-T) for 1 hour at room temperature. Membrane strips were incubated for 1 hour 
with assigned primary monoclonal antibody in individual 50 ml falcon tubes. The list of 
monoclonal antibodies is given in Table 3.1. 
 After washing three times for 10 min in 1X-PBS-T, the strips were incubated with 
horseradish peroxide (HRP) -rabbit anti-mouse IgG antibody (1:50K v/v) for 1 hour. The 
membrane strips were washed thoroughly again for 3X10 min with 1X-PBS-T and 
treated with 1%  Dextran sulfate in 10 mM citrate-EDTA buffer pH 5.0 for 10 min before 
treating with 3,3’,5,5’-tetramethlybenzidine (TMB) to develop the membranes. Blue 
colour bands appear where ever there is antibody binding. 
3.4.3 Western Blotting 
3.4.3.1 SDS-PAGE 
Proteins were analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) using 13.5% acrylamide (Laemmli, 1970).  Total protein is denatured and 
reduced in 4X SDS sample buffer containing 500 mM Tris, 40% Glycerol, 10% SDS, 
10% β-mercaptoethanol, 0.05% bromophenol blue. Approximately 3 μg of protein was 
loaded onto the gel and was run at 200 volts for 45 min to 1 hour. Fungal tropomyosin 
from Neurospora crassa, which is of 14494 kDa (161 residues) protein is used as a 
negative control for the antibody binding and is processed similar to the other human 
tropomyosin isoforms. All the gels were run in duplicates for assessment of individual 
monoclonal antibodies efficiency to Tpm3.12st.  
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3.4.3.2 Blotting  
Gels were soaked for 5 min in transfer buffer containing 48 mM Tris-HCl, 40 mM 
Glycine, 2% SDS, 20 % methanol to equilibrate the gel. Nitrocellulose membrane was 
also soaked in transfer buffer for 5 min and protein bands were transferred onto the 
membrane using Bio-Rad Trans-Blot semi-dry electrophoretic transfer cell following the 
manufacturer’s protocol for 35 min at 10-15V as shown in Figure 3.8.  Bio-Rad precision 
plus prestained standard marker was used for the SDS-PAGE to visualize the transferred 
bands. The membrane was blocked with 5% milk in phosphate buffer saline with 0.05% 
Tween-20 (PBS-T) for 1 hour to prevent non-specific binding. Membranes were rinsed 
with PBS-T and incubated in 1/2000 dilution monoclonal primary antibody for 1 hour at 
37 0C. The epitopes of the protein for the antibodies are given in the Figure 3.7. The list 
of monoclonal primary antibodies and their theoretical binding expression are given in 
Table 3.1. All antibodies and CH1 (Lin et al., 1985)were made in 1 in 2000 dilution 
except Ab11 and CG3 (Lin et al., 1985) antibody which were used at 1 in 500 dilution. 
The monoclonal CG3 antibody is mapped to aa 29-44 by exon 1b of Tm5 gene (LMW 
isoform of Tpm3). The CG1 and CG3 antibodies were donated by Prof. Marston from 
National Heart and Lung Institute, Imperial College, London. The membranes were 
washed 3 times 10 min in 1X PBS-T and were incubated in 1 in 50K dilution of 
horseradish peroxidase (HRP) anti mouse conjugate form Sigma Aldrich as secondary 
antibody for 1 hour at 37 0C and washed 3 time 10 min in PBS-T. Both primary and 
secondary antibodies were diluted in 1X PBS buffer. Membranes were washed with 1% 
dextran sulfate in citrate-EDTA buffer pH 5.0 for 10 min and rinsed with PBS before 
developing the membranes with 3,3ꞌ,5,5ꞌ- Tetramethylbenzidine (TMB) liquid substrate 
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solution for membranes from Sigma Aldrich. Pictures of the membranes were taken using 
a 8 megapixel camera and pictures were processed using Image J software (Schneider et 
al., 2012). 
 
Figure 3.8: Arrangement of membrane and SDS-PAGE for transfer of proteins in 
Bio-Rad Trans-Blot semi-dry electrophoretic transfer cell. 
 
3.4.4 ELISA 
 
The enzyme linked immunosorbent assay (ELISA) is an effective method for detecting 
and quantifying a specific protein using an antigen/antibody either in a complex mixture 
or confirmation of pure protein (Engvall and Perlmann, 1971). An indirect ELISA is used 
to quantify the Tpm3.12st in comparison to Tpm1.1st.  
The assay was optimized by using checkerboard titration method to establish the Abs 
reaction with tropomyosin. Different dilutions of Abs were prepared by serial dilutions 
starting from 1/ 4 and following to 1/8, 1/16, 1/32, 1/64, 1/128, 1/256, 1/512 and different 
concentration of Tpm1 and Tpm3 were prepared. (10 μM, 1.0 μM, 0.1 μM, 0.01 μM and 
  
149 
 
0.001 μM). Standards (b1-Ab was coated on the wells and b2-blank wells treated as Tm) 
were also coated by adding varying dilution of Abs to each well and treated as Tm when 
processing the assay. Costar 96 well, flat bottom medium binding plates were used. The 
checker board plating of the Abs and proteins is shown in Table 3.2 where each 
concentration of Tm was probed with all dilutions of Ab.  
Table 3.2: Preliminary optimization of ELISA plate set-up for method development 
of Ab reaction. b1 are the well coated with Ab of variable dilutions and b2 empty wells 
coated with only buffer, both b1 and b2 were treated same as Tm to generate standard 
curve to check background intensity of Abs.  
  
 
An assay was developed by coating 50 μl of tropomyosin in each well following the 
Table 3.2 arrangement diluted with sodium phosphate buffer, pH 7.5 and plates were 
incubated for 2 hours at 37 0C. Plates were rinsed 2 times with 250 μl 1X PBS, pH 7.0 
and dried on paper towels to remove excess protein. 300 μl of blocking buffer (5% milk 
in 1X PBS-T) was added to each well and incubated at room temperature (RT) for 30 min 
and the plates were washed with wash buffer, 1X PBS-T, pH 7.0, three times for 10 
minutes on a shaker. 100μl of primary antibody Tpm3.12st specific monoclonal 
antibodies was added to each well and incubated for 30 min at 37 0C. The plates were 
washed three times for 10 min at RT to remove excess unbound primary antibodies and 
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100 μl of horseradish peroxidase (HRP) anti mouse conjugate as secondary antibody was 
added in 1/50K dilution to each well and incubated for 30 min at 37 0C. Secondary 
antibody acts as a probe for quantifying the signal by reacting with the substrate 
producing a colorimetric reaction. The plates were washed three times for 10 min at RT 
and dried on paper towels. TMB (3, 3′,5 ,5′-Tetramethylbenzidine) liquid substrate, 
supersensitive, for ELISA from Sigma Aldrich (T4444-100ML) was used which 
produces a pale blue colour at RT. The reaction is stopped by adding 0.2 M H2SO4 which 
gives a pale yellow colour that was measured at 450 nm by UV microplate reader. 
Standard curves were generated by plotting the OD on Y-axis and the dilutions of Ab on 
X-axis. The protein reactivity curves were plotted against OD on y-axis and the 
concentration of Tm on X-axis. Figure 3.9 shows the work flow of the ELISA 
methodology followed.  
The assay was repeated three times on different days and hence the mean values cannot 
be taken as this will result in in-accurate data. The results from about method were not 
reproducible for protein reactions, however it was helpful to establish the dilution at 
which there was least background (non-specific binding) of Ab. This was calculated by 
taking the ratio of b1 and b2 and the value with lower ratio Ab was taken for further 
quantification experiment.  
Repeating the experiment with different concentration of tropomyosin with constant Ab 
dilution, the set of concentration used below were found to give a linear reaction 
intensities. For quantification of protein, 1/16000 dilution of Ab was used as this dilution 
had very low non-specific binding, and different concentrations of tropomyosin was used. 
An assay was developed by coating 50 μl of tropomyosin in triplicates at a concentration 
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between 0.1 nM to 50 nM in   0.1 M sodium carbonate buffer, pH 9.6 and incubated at    
4 0C overnight. A typical assays plate design used for this experiment is shown in     
Table 3.3. Nunc-Immuno Maxisorp flat bottom 96well microwell plates were used for 
this method. The protocol was similar with changes in coating the plates overnight at 4 0C 
rather than 2 hours at 37 0C and the incubation times were increased from 30 min to 1 
hour at each stage and the rest of the method was followed similar as mentioned above. 
Table 3.3: Elisa plate assay design: The setup of the plate used for quantifying 
Tpm1 and Tpm3 using two antibodies for each plate.  
Note: b-blank with only secondary antibody, b1 empty wells treated with primary and 
secondary antibody and c is wells coated with primary antibody and treated as protein.     
( ꞌ - duplicate, ꞌꞌ - triplicate).  
 
3.4.5 Reaction of HRP with TMB  
 
ELISA assays are mostly performed by using horseradish peroxidase (HRP) as a marker 
enzyme. HRP is a metalloenzyme found in the root of horseradish plant. The most 
commonly used is the HRP-C which is most abundant and has been successful in 
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production of recombinant enzyme (Veitch, 2004). HRP have heme group at its center 
and uses hydrogen peroxide to oxidize both organic and inorganic compounds. The 
detection limit of HRP on its own in colorimetric assays is very low. This was overcome 
by using 3,3ꞌ,5,5ꞌ-Tetramethylbenzidine (TMB) which forms a blue colour soluble 
substrate linked with HRP gives higher detection limits which can be read at 650 nm 
(Porstmann and Kiessig, 1992). 
In immunoassays the protein is linked with HRP as a secondary antigen that can be 
oxidized with TMB to detect the protein levels. TMB acts as electron donor for the 
reduction of hydrogen peroxide in presence of HRP. 3,3ꞌ,5,5ꞌ-Tetramethylbenzidine is 
oxidized to blue colour 3,3ꞌ,5,5ꞌ-Tetramethylbenzidine diimine which can be stabilized by 
adding acid (H2SO4) by lowering its pH to forming a yellow colour substrate which can 
be read at 450 nm (Josephygg et al., 1982) and also stops the reaction. Stopping the 
reaction is important as the intensity of the colour keeps increasing along with increase in 
time resulting in excess intensity which may not give accurate results.  
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Figure 3.9: Work flow of indirect ELISA methodology.  
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3.4.6 Interpretation of Elisa data used for quantifying Tpm1 and Tpm3. 
 
The data obtained from the experiment as explained in the section 3.4.4 (according to 
Table 3.3), was fitted according to 4 parameter logistic nonlinear regression model which 
gives a sigmoidal curve in relation to concentration. This is a generalized model used for 
ligand binding assays such as ELISA (Findlay and Dillard, 2007). The 4-parameter 
logistic (4-PL) model is generally used as a reference model for calibration curves that 
gives a sigmoidal relationship. This provides an accurate representation of the measured 
sensitivity response and the concentration of the analyte. Origin 6 software was used for 
interpretation of the calibration curves of the data obtained from the assays. The 4-PL 
model formula used by the software to interpret the data is as follows:  
 
Where , y is the response, A1 is the initial value at zero analyte concentration, A2 is the 
final value,  x0 is the slope (the inflection point on the calibration curve) and p is the 
slope factor. The response is monotonic, increase with concentration as the A1 < A2 and 
decrease in concentration as A1 > A2 and the calibration curve is symmetric at x0 with 
response at a specific concentration and the slope factor p defines the steepness of the 
curve. As the curve is sigmoidal the slope (x0) changes through out depending on the 
concentration.  
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3.5 Results  
3.5.1 Dotblot       
    
Dot blot results (Figure 3.10) show three repeated experiments of Dot-blot reactions of all 
the 12 antibodies produced against five epitopes of Tpm3 sequence. In blot Figure 3.10A 
and Figure 3.10C protein used was at 10 μM and in Figure 3.10B, various concentrations 
of proteins (10, 1.0, 0.1, 0.01, 0.001) was used as mentioned in methodology. It can be 
observed from Figure 3.10A that Tpm3-MASM has higher sensitivity to the Abs than 
Tpm3-Met and Tpm3-MM. From all three blots Ab4, Ab5 and Ab7 have lower reactivity 
on their own when used as a positive control. Blots from Figure 3.10A and C, Ab1, Ab2, 
Ab3, Ab4 and Ab9 show reactivity with Tpm2 in both native and denatured state. In 
Figure 3.10A, B Tpm1 and Tpm2 have sensitivity to Ab11 and Ab12 with both Tpm1 
and Tpm3 in native state in contrast to Figure 3.10C where they have reactivity to Tpm1 
only in denatured state. In blots Figure 3.10B similar to other blots (A and C) show 
sensitivity to all antibodies, however at low concentration of 0.1 and 0.01 Ab 11 and 
Ab12 show reactivity to only Tpm3.  With the above results the difference in reaction of 
the antibodies, western blotting was performed where the protein is in the denatured state 
and ELISA with native protein.  
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Figure 3.10: Dot blot strips showing the antibody reaction. Three experiments of Dot-
Blot of all the 12 antibodies produced against the 5 epitopes. A. Each blot in A have all 
the recombinant proteins produced in native state for this study (No Tpm4). Cp-control 
proteins mainly containing tropomyosin and troponin, AV is a cardiomyopathy mutation 
A63V and K70T.  B. Tpm3 and Tpm1 in different concentration of native protein, top 
layer-Tpm3 and bottom layer -Tpm1. C. Each blot contains both native and denatures 
versions of the proteins as labelled. left to right: Tpm3, Tpm1, Tpm2. The vertical 
numbers show the antibody numbers. 
 
3.5.2 Western Blotting 
 
Western blotting was performed by loading 3 μg of protein onto 13.5% acrylamide gels 
and the proteins were transferred through semi-dry membrane transfer as described in the 
methodology.  Affinity of the monoclonal antibodies obtained from western blotting 
show a different profile compared to dot blot results. Figure 3.11 shows the Coomassie 
Blue stained gel of all the isoforms used for the western blotting. Tropomyosin of fungi 
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Neurospora crassa, which is of 14494 kDa protein with 161 aa was used as a negative 
control for the antibody binding. From the gel it is clearly seen the isoforms run 
differently on the gel even though they do not vary much in their calculated molecular 
weight. Tpm4 run same as Tpm2 even though Tpm4 is has more sequence similarity to 
Tpm1.  
 
Figure 3.11: Coomassie Blue stained SDS-PAGE gel used for western blotting. M-
Marker, 1-Tpm1, 2-Tpm2, 3-Tpm3, 4-Tpm4 and Nc- Neurospora crassa tropomyosin. 
Details of protein loaded on the gel are given in methodology section.  
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Figure 3.12: Western blots probed with 12 monoclonal antibodies individually. 
Details of the method are given in the methodology section. Ab-Antibody with number, 
M- Marker, 1-Tpm1, 2-Tpm2, 3-Tpm3, 4-Tpm4, and Nc – Neurospora crassa 
tropomyosin. The membrane was reacted with primary monoclonal antibody linked with 
HRP and developed with TMB substrate that gives blue colour to the protein bound to the 
membrane. The pictures of the developed membranes were taken by 8 megapixel camera 
and processed with Image J software.  
 
 
 
 159 
 
All the antibodies have affinity to Tpm1, Tpm3 and Tpm4 with different sensitivity other 
than Ab7 (EERSKQLEDE) which did not show reactivity to any of the isoform (Figure 3.12). 
Ab4 and Ab9 are the once that identified Tpm2 unlike the rest of the Abs and have same 
level of sensitivity to all the isoforms. In contrast to dot blot where Ab1, 2, 3 showed 
reactivity with Tpm2, western blot did not show the same result even after repeated 
attempts. Another factor that was also observed is that the Coomassie stained gel (Figure 
3.11) does not show any stained lower molecular proteolytic protein bands at the given 
amount of protein loaded on the gel, but the membranes probed with antibodies shows 
different proteolytic protein fragment profiles with individual monoclonal antibodies.  
The reaction of all the isoforms probed with CG1 (Figure 3.13) gave the expected 
outcome (Marston et al., 2013; Schevzov et al., 2011) , but the CG3 (Figure 3.13) seems 
to have slight affinity to Tpm4 as well, as opposed to the previous studies which was 
supposed to bind only to Tpm3 (Marston et al., 2013; Schevzov et al., 2011). 
 
Figure 3.13: Western blots of tropomyosin isoforms probed with CG1 and CG3.  
The membranes after protein transfer were treated same as the Tpm3 monoclonal 
antibodies as detailed in methodology.  
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3.5.3 ELISA  
 
ELISA immunoassay was used to determine to quantify the sensitivity of monoclonal 
antibodies of Tpm3 in comparison to TPM1.  
3.5.3.1 Standard Curves 
Figure 3.14, Figure 3.15Figure 3.16, show the preliminary optimization reaction standard 
curves generated by the intensities obtained from wells coated with Abs and empty wells 
treated similar to tropomyosin at varying dilutions to check the non-specific binding and 
establish an Ab dilution with lowest background reaction.  The assay was repeated three 
times and the results of standard curves of all the three reactions are given in the Figures 
mentioned above. Form the curves, ratio between b and b2 were calculated to check the 
dilution with minimum back ground and 1/16K dilution of Abs was chosen for using in 
further protein quantification assays, the lowest back ground can also been seen clearly 
from the curves in the figures. Only Tpm1 is chosen as it is the most dominant isoform 
with high sequence similarity with all the other isoforms. 
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Figure 3.14: Standard curves of Ab1, Ab2, Ab3 and Ab4. Triplicate standard curves of Ab1, Ab2 and Ab3 and Ab4 and the 
average with error bars are shown above. Curves were generated by taking the OD on Y-axis and Ab dilutions on the X-axis to check 
the background of the antibody binding. Blue line is Ab coated in the well and treated similar to Tm (b1) and Pink line is empty wells 
treated similar to Tm (b2). a, b and c corresponds to triplicate reactions of the Abs. 
 162 
 
 
Figure 3.15: Standard curves of Ab5, Ab6, Ab7 and Ab8. Triplicate standard curves of Ab4, Ab5 and Ab6 are shown above. 
Curves were generated by taking the OD on Y-axis and Ab dilutions on the X-axis to check the background of the antibody binding. 
Blue line is Ab coated in the well and treated similar to Tm (b1) and Pink line is empty wells treated similar to Tm (b2). a, b and c 
corresponds to triplicate reactions of the Abs. 
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Figure 3.16: Standard curves of Ab9, Ab10, Ab11 and Ab12 reaction. Triplicate standard curves of Ab10, Ab11 and Ab12 are 
shown above. Curves were generated by taking the OD on Y-axis and Ab dilutions on the X-axis to check the background of the 
antibody binding. Blue line is Ab coated in the well and treated similar to Tm (b1) and Pink line is empty wells treated similar to Tm 
(b2). a, b and c corresponds to triplicate reactions of the Abs. 
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3.5.3.2 ELISA Preliminary optimization of checker board Assay 
The results from Figure 3.17, Figure 3.18 andFigure 3.19 show the optimization of 
ELISA method for monoclonal Abs affinity to Tpm3.12st. Ab1, Ab2 and Ab3 show 
increase in binding according to the increase in concentration.  
 
Figure 3.17: Preliminary ELISA assay with varying dilutions of Ab1, Ab2, Ab3 and 
Ab4 with different concentrations of Tpm3 and Tpm1. Varying dilutions of Abs were 
reacted to different concentrations of protein as explained in methodology. OD was 
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measured at 450 nm and plots were generated by taking OD on Y-axis and the 
concentrations of Tm on X-axis. Series of the curves are shown on the side.  
 
Figure 3.18: Preliminary ELISA assay with varying dilutions of Ab5, Ab6, Ab7 and 
Ab8 with different concentrations of Tpm3 and Tpm1. Varying dilutions of Abs were 
reacted to different concentrations of protein as explained in methodology. OD was 
measured at 450 nm and plots were generated by taking OD on Y-axis and the 
concentrations of Tm on X-axis. Series of the curves are shown on the side. 
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Figure 3.19: Preliminary ELISA assay with varying dilutions of Ab9, Ab10, Ab10 
and Ab11 with different concentrations of Tpm3 and Tpm1. Varying dilutions of Abs 
were reacted to different concentrations of protein as explained in methodology. OD was 
measured at 450 nm and plots were generated by taking OD on Y-axis and the 
concentrations of Tm on X-axis. Series of the curves are shown on the side. 
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3.5.3.3 Quantification of Tpm1 and Tpm3 using monoclonal antibodies  
The data obtained from the ELISA results were analysed using 4 parameter logistic 
model for interpretation of the sensitivity of the antiboides to Tpm3 as explained in 
section 3.4.6.  
 
Figure 3.20: Elisa affinity curve of Ab1 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
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Figure 3.21: Elisa affinity curve of Ab2 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
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Figure 3.22: Elisa affinity curve of Ab3 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
 
 170 
 
 
Figure 3.23: Elisa affinity curve of Ab4 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
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Figure 3.24: Elisa affinity curve of Ab5 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
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Figure 3.25: Elisa affinity curve of Ab6 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
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Figure 3.26: Elisa affinity curve of Ab7 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
 
Table 3.4: values obtained from fitting ELISA data to 4 parameter logistic model.  
 
Note: A1 – initial value, A2 – final value, x0 – slope, p – slope factor. Ab – antibody.  
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Ab8-Std Dev
Conc (nM) TPM1 TPM3
0 0.09 0.09
0.1 0.01 0.03
0.5 0.03 0.04
1 0.04 0.03
2 0.02 0.02
5 0.02 0.05
10 0.02 0.03
50 0.01 0.05  
Figure 3.27: Elisa affinity curve of Ab8 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
 
 
Ab9-Std Dev
Conc (nM) TPM1 TPM3
0 0.01 0.01
0.1 0.07 0.04
0.5 0.02 0.02
1 0.02 0.05
2 0.02 0.02
5 0.03 0.06
10 0.04 0.01
50 0.09 0.06  
Figure 3.28: Elisa affinity curve of Ab9 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
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varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
 
 
Ab10-Std Dev
Conc (nM) TPM1 TPM3
0 0.006 0.006
0.1 0.003 0.016
0.5 0.002 0.018
1 0.006 0.021
2 0.004 0.022
5 0.004 0.019
10 0.004 0.018
50 0.013 0.011  
Figure 3.29: Elisa affinity curve of Ab10 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
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Ab11-Std Dev
Conc (nM) TPM1 TPM3
0 0.001 0.001
0.1 0.010 0.005
0.5 0.019 0.008
1 0.012 0.004
2 0.009 0.004
5 0.010 0.005
10 0.007 0.004
50 0.013 0.002  
Figure 3.30: Elisa affinity curve of Ab11 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
 
Ab12-Std Dev
Conc (nM) TPM1 TPM3
0 0.008 0.008
0.1 0.003 0.002
0.5 0.001 0.001
1 0.001 0.003
2 0.003 0.006
5 0.005 0.000
10 0.010 0.002
50 0.013 0.005  
Figure 3.31: Elisa affinity curve of Ab11 with Tpm1 and Tpm3. The assay was 
developed to measure the specificity of monoclonal antibody affinity to Tpm3.12st by 
varying concentration of protein (0.1nM to 50nM) with constant concentration of 
antibody at 1/16000 dilution. The curves were generated using 4 parameter logistic 
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nonlinear regression model as explained in the section 3.4.6. The intensity (OD) 
measured at 450 nm taken on Y-axis against the concentration of the protein on X-axis. 
The data is the mean of triplicate reactions. Blue - Tpm1 and Red - Tpm3. The table 
shows the standard deviation of the triplicate reactions.  
 
Figure 3.20Figure 3.31 shows the plots of ELISA for individual antibodies and the table 
on the side of the plots gives the standard deviation of the results obtained for triplicate 
reactions. Ab8 to Ab12 (Figure 3.28 toFigure 3.31) did not have any reaction at lower 
concentration and were saturated at higher concentrations and does not show any 
sigmoidicity to use them in the 4PL model. Hence these antibodies were not shown with 
the 4PL model as they would not give any meaningful curves. Table 3.5 shows the 
overall results data obtained from western blotting and ELISA results and the reactivity 
of all the antibodies grouped according to the peptides they react with the relative ratio of 
sensitivity of Ab1 to Ab6 with Tpm1 and Tpm3. From the table it is observed that Ab3 
(VIIEGDLERT – P4) and Ab5 (DELYAQKLKY-P5) shows higher sensitivity to Tpm3 than 
Tpm1 at the same concentration of protein. Ab1 has higher affinity to Tpm1 and Ab2, 4 
and 6 does not show much difference in sensitivity between the two proteins. Table 3.4 
gives the values obtained from the 4PL model where the sensitivity of the Abs could be 
seen from x0 values.  
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Table 3.5: Table showing the peptides numbers where the antibody is binding, the 
experimental results and the relative ratio of the sensitivity of Ab to the specific 
peptide. Ratio was calculated from the slopes of Tpm1 and Tpm3. Ratios of Abs 7-12 
was not calculated as there was no linearity exhibited from the reaction of these Abs with 
the Tm isoforms.  P1, P2, P3, P4 and P5 are the peptide number reacting with the 
antibodies which are grouped together with similar colour.   
Peptide 
Sequence/No. 
Antibody 
number 
Residue 
position 
Experimental 
results 
western blot 
Sensitivity 
Ratio   
ELISA 
Isoform with 
high sensitivity   
ELISA 
EQAEAEQKQA 
P1 
5 24-33 
Tpm1 
--- 
Tpm3 
Tpm4 
2.91 Tpm3 
EERSKQLEDE 
P2 
7 
(8,10,1
1,12) 
34-43 
--- 
--- 
--- 
--- 
- - 
EERSKQLEDE 
P2 
8 34-43 
Tpm1 
--- 
Tpm3 
Tpm4 
- - 
EERSKQLEDE 
P2 
10 34-43 
Tpm1 
--- 
Tpm3 
Tpm4 
- - 
EERSKQLEDE 
P2 
11 34-43 
Tpm1 
--- 
Tpm3 
Tpm4 
- - 
EERSKQLEDE 
P2 
12 34-43 
Tpm1 
--- 
Tpm3 
Tpm4 
- - 
EAEKAADESE 
P3 
4 116-125 
Tpm1 
Tpm2 
Tpm3 
Tpm4 
0.40 Tpm3 
VIIEGDLERT 
P4 
3 171-180 
Tpm1 
--- 
Tpm3 
Tpm4 
5.81 Tpm3 
DELYAQKLKY 
P5 
1 
 
(2,6,9) 
259-268 
Tpm1 
--- 
Tpm3 
Tpm4 
0.83 Tpm1 
DELYAQKLKY 
P5 
2 259-268 
Tpm1 
--- 
Tpm3 
Tpm4 
1.21 Tpm3 
DELYAQKLKY 
P5 
6 259-268 
Tpm1 
--- 
Tpm3 
Tpm4 
0.36 Tpm3 
DELYAQKLKY 
P5 
9 259-268 
Tpm1 
Tpm2 
Tpm3 
Tpm4 
- - 
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3.6 Discussion 
Tropomyosin isoform pattern in humans are extensively studied in recent years (Gunning 
et al., 2005; Hook et al., 2004; Marston et al., 2013; Maytum et al., 2011; Peng et al., 
2013). For these studies many isoform specific antibodies have been generated to identify 
the diverse isoforms expressed by tropomyosin family (Schevzov et al., 2011). From the 
research so far, it is well extablished that human tropomyosin isoforms are highly 
conserved and have high sequence similarity having few residue variations at the N-
terminal and C-terminal ends of the sequence (Gunning et al., 2008b).  
The use of different promoters differentiates the N-termini of the isoforms. Exon 1a along 
with 2a or 2b gives to high molecular weight Tms and the alternative 1b exon at the N-
termini gives low molecular weight Tms. At the same time the sequence selectivity of the 
exons at the C-terminal between 9a, 9b, 9c and 9d gives sequence divergence at the C-
termini. The sequence similarity of the exons of different genes is found to be higher than 
the sequence similarity of alternative exons of the same gene  (Lees‐Miller and Helfman, 
1991).  
There are many antibodies available that are characterised for specific Tm isoform. Few 
are monoclonal and few are polyclonal antibodies that identify specific Tm isoform 
(Schevzov et al., 2011). Only one antibody is available for Tpm3 protein isoforms, which 
identifies all the protein isoforms that are generated by Tpm3 gene. Lin et al., (1985) 
produced monoclonal antibodies for chicken Tm isoforms. According to Lin et al., CG1 
reacts with all the skeletal muscle isoforms Tpm1 and Tpm3 and CG3 reacts to all the 
isoforms of Tm. However recent studies show that CG1 reacts with all the Tm isoforms 
and the results from this study also show that it reacts to all Tpm1, Tpm2, Tpm3 and 
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Tpm4 (Tpm4 needs more confirmatory tests to assign as Tpm4 in this study) similar to 
the previous studies (Hook et al., 2011; Marston et al., 2013b; Schevzov et al., 2011). 
From western blotting analysis the CG3 antibody showed reaction with HMW Tpm3 and 
Tpm4. If the CG3 antibody epitope is designed for 1b exon of Tpm3 gene (Schevzov et 
al., 2005) which is responsible for encoding LMW Tms, and it is not supposed to react 
with HMW Tpm3. May be there is cross reactivity of the antibody or there must be some 
discrepancy regarding the epitope sequence of CG3. However according to Lin et al., 
(1985)  who originally produced CG3 antibody  mentioned that CG3 has cross reactivity 
with Tpm1 but has strong reactivity with Tpm3. 
  In this study the Tm isoform produced are all HMW isoforms with the exon sequence 
1a,2b, 3, 4, 5, 6b, 7, 8, 9a (Figure 3.7). It can be clearly seen that Tpm4 has higher C-
terminal sequence variance compared to other three isoforms. Tpm1, Tpm2 make up the 
skeletal muscle and Tpm3 is found in slow twitch skeletal muscle (also referred to as 
αsTm) and Tpm4 is found in smooth muscles. As mentioned before in this chapter 
(section 3.2), the isoform variance of C-terminal may be due to the functional differences 
of smooth muscle from skeletal muscle (Gunning et al., 2008b; Lees‐Miller and Helfman, 
1991).  
The 12 monoclonal antibodies designed were depended solely on HMW Tpm3. The 
preliminary checker board assay was used to establish the Ab sensitivity and protein 
concentration to be used for further quantification analysis. The data obtained from 
standard curves (Figure 3.14, Figure 3.15 Figure 3.16) Ab dilution of 1/8 and 1/ 16 
showed lower back ground noise. This was compared with presence of both isoforms of 
protein Tpm1 and Tpm3 where the background noise was lower at 1/8 and 1/16 dilution 
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of Ab and also it reaches saturation limit of intensity. Hence for further assays 1/8 
dilution of Ab was chosen for quantification analysis.  
The experimental results of western blotting coincide with the quantification of ELISA in 
respect to the sensitivity of various peptides. Dot blot results were not comparable with 
the western blotting and ELISA results. The sensitivity of the antibodies was different for 
each peptide even though the epitope of sequence is similar to the same peptides. The 
Ab1, Ab2, Ab6 and Ab9 have affinity for same peptide (P5-DELYAQKLKY) located at 
the C-terminal of the sequence on Exon 9, however the reaction of each antibody to the 
same peptide is different. Ab1 showed higher sensitivity to Tpm1 than Tpm3 (with a 
slope value of x0 13.975 for Tpm1 and 7.064 for Tpm3 from Table 3.4) even tought the 
sensitivity is higher the Tpm3 reaches saturation faster as seen by the values and the 
curves. On the other hand Ab2, Ab6 had higher sensitivity to Tpm3 than Tpm1 and Ab9 
reacted to all Tm four isoforms Tpm1, Tpm2, Tpm3 and Tpm4 along with Ab4 which 
recognizes peptide 3 (P3-EAEKAADESE) located on exon 3. The Ab7 (P2- 
EERSKQLEDE) peptide 2, located in between exons 1 and 2 did not react to any of the 
isoforms from both western blotting data and ELISA data (Table 3.4 and Figure 3.26).  
From western blotting data Ab8, Ab10, Ab11 and Ab12 had very low reactivity to Tpm1, 
Tpm3 and from ELISA results the sensitivity of these antibodies was visible only at 
higher concentrations of protein with no reaction at lower concentrations. Hence the 4PL 
model was not applied to antibodies Ab8 – Ab12 as they do not agree with the 
sigmoidicity of the curves and no meaningful curves and values would be obtained to 
validate them. The only antibody that had substantial differentiation of sensitivity from 
Tpm1 was Ab3 (P4) which was five times higher than Tpm1. Even though Ab5 was 
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expected to bind only to Tpm3 due to the presence of more variable residues in the 
epitope (peptide 1 –P1) experimental results did not give the same predicted outcome. 
Unfortunately none of the antibodies could be used to identify specific HMW Tpm3 but 
Ab4 and Ab9 could be used for identifying all the Tm isoforms.  
In general 5 out of 10-15 of each epitope influence strong binding and substitution at 
these binding sites contribute to reducing the binding constant to two-three folds. The 
binding of the antibody to the epitope also depends on the availability of the binding sites 
due to the structural arrangement of the protein (Dougan et al., 1998; Frank, 2002). 
Sometimes the antigen raised against a particular epitope may have higher binding 
capacity to the relevant epitope due to the antibody valence (number of interacting 
binding sites) to the target epitope (Regenmortel, 1998). Due to the few mentioned 
reasons, the antibodies raised against Tpm3 sequence and the high sequence similarity 
with the other Tm isoforms, different antibodies show variable sensitivities to Tpm3 and 
Tpm1.  
From the data obtained from western blotting, low molecular weight bands between 20 
kDa and 15 kDa were visible on the assay developed gels. Denaturation of the protein 
may be due to the heat when the protein was denatured with heat at 95 0C before running 
on SDS-PAGE. According to  Pato et al., (1981) N-terminal of 1-13 base pairs and 
central region of 123-183 base pairs are susceptible to proteolytic denaturation. 
Antibodies that are used in this study are specific to certain peptide in the sequence. It is 
expected that the protein bands with different antibodies show different bands, but all the 
antibodies reacted with same denatured protein bands which indicated that the residues in 
those denatured bands must be having higher similarity with the antibody peptides.  
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In conclusion, due to the very high sequence similarity of tropomyosin isoforms, it is a 
challenging task to design an antibody that reacts with only one isoform of tropomyosin. 
CG3 which was confirmed by many studies to be specific to only Tpm3 does not seem to 
be accurate as it has shown some cross reactivity with Tpm4 as well. It was also 
confirmed by Lin et al (1985) that CG3 has high cross reactivity with other isoforms of 
tropomyosin. Form this study it is observed that designing an antibody by combining the 
sequence of peptides P1 and P2 (aa 24 -43) locating on Exon 1a and 2b may have an 
advantage of producing an antibody specific to Tpm3.12st.  
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Chapter IV: Method Development for 
Quantification of Thin Filament Protein Isoforms 
from Tissue Lysates 
4 Introduction 
 
Analytical techniques in biomedical research form a holistic approach in understanding 
human diseases to the protein level have the potential to identify novel therapeutic targets 
and biomarkers which act as prognostic indicators. Heart disease is one of the most 
common disorders of muscle.  It is one of the most common causes of death in the United 
Kingdom, most of which are caused due to disorders in muscle.  According to the British 
Heart foundation, nearly 41% of total deaths in the UK are due to heart failure (Lloyd-
Jones et al., 2010) and nearly 1 in 9 deaths reported were because of heart failure in 2010 
(Go et al., 2014). Other disease like nemaline myopathy, Congenital myopathy with fibre 
type disproportion (CFTD) (Nance et al., 2012), Alzheimer’s disease (Reitz et al., 2011)  
and cancer tumours relating to cytoskeleton (Stehn et al., 2013) are related to muscle 
disorders caused due to genetic mutations and alternative splicing. Comprehensive 
analysis of the proteoforms (a unified term designated to define  all the entities present in 
the proteome such as protein degradation products, RNA splice variants, isoforms and 
PTMs of a gene product) is necessary to identify, understand, diagnose and treatment of 
these disease.  
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A proteome is the cell and time specific protein compliment of a genome (Wilkins et al., 
1996). Genome is largely a fixed entity and identical for all the cells in a single organism 
and is consistent among species, the proteome is constantly variable and extremely 
complex as it is continuously affected by external  and internal factors of the cell such as 
temperature, nutrition, drugs and chemicals , signaling networks to name a few (Pandey 
and Mann, 2000). Decoding the proteome of a system is essential to understand the 
cellular and molecular interactions in relation to their functions in health and disease.  
However due to the dynamic nature of proteome with large plethora of complex post 
translational modifications, isoform expressions and sequence variants analysis of 
proteome of a system  is very challenging (Neverova and Van Eyk, 2005).  
Human gene consists of nearly 30,000 genes and the number of proteins expressed is 100 
times greater due to the mRNA processing and post translational modification of proteins 
(O’Donovan et al., 2001). Due to the high complexity of proteome and the number of 
proteins expressed a single technique is not sufficient to analyse all the proteins present. 
A combination of techniques for separation and identification are required. Liquid 
chromatography and mass spectrometry are the most predominant techniques used for 
analysis of proteins and PTMs (Patterson and Aebersold, 2003). 
Importance of proteomics analysis for studying thin filament proteome 
 
Myofilament proteome analysis is found to be difficult in many studies with current 
methods using 2D gel electrophoresis with tandem mass spectroscopy or peptide mass 
fingering printing (PMF) to analyse complex protein mixtures in the proteome. 
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Separation of all the proteins is hampered by very wide range of pI of proteins and their 
varying molecular weights. The staining methods available are not suitable for all 
proteins and their associated protein abundance reflect the efficiency of the technique 
(Arrell et al., 2001b; Labugger et al., 2002). These techniques involving 2D gel is 
laborious and time consuming as not only do 2D gels typically require an overnight run, 
any data obtained usually require further processing such as isolating the protein spot and 
incomplete recovery of peptides after trypsin digestion result in loss of information 
obtained for the proteins of interest regarding the position of PTMs and sequence 
variations arising due to point mutations (Zhang and Ge, 2011b).  However, several 
studies have shown myofilament proteome changes using these classic techniques 
(Erban, 2011; Scruggs et al., 2010). 
Mass spectrometry by ‘top down’ proteome analysis is one of the emerging techniques 
which provides a ‘birds eye’ view of all the proteoforms. The top down method involves 
analysis of intact proteins. This method has an advantage of preventing  any loss of 
information caused from sample preparation and handling process (Zhang and Ge, 2011) 
Some progress in this area has already been made with Ge et al., (2009b) used top-down 
high resolution mass spectrometry analysis to characterize cardiac myosin binding 
protein-c phosphorylation sites and tropomyosin isoforms (Peng et al., 2013) 
individually. The phosphorylation sites of rat cardiac troponin have been reported by 
Solis et al., (2008) by top-down MS using electron capture dissociation ionisation. 
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A variety of mutations occurring in thin filament have been reported that causes different 
types of cardiomyopathy. There is a lot of literature available in case of Troponins and 
especially TnI (Ge et al., 2009b; Seidman and Seidman, 2011; Tardiff, 2011b). Alpha Tm 
is found to cause FHC due to altered contractile function with Asp175Asn mutation and 
is reported to lead to severe dilated cardiomyopathy (DCM) (Prabhakar et al., 2001; 
Regitz-Zagrosek et al., 2000; Thierfelder et al., 1994). Protein kinase C (PKC) 
phosphorylation of both TnI and Tm (Sarko and Pollack, 2002; Vahebi et al., 2007) are 
considered important PTMs in the thin filament. Degradation products of TnI (Wu et al., 
1998) are used as a biomarker for HCM, as they are released in the bloodstream 
following a myocardial damage. Table 4.1 gives the list of few PTMs occurring in 
sarcomere proteins with the mass in Daltons that is shown in mass spectrometry analysis.
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Table 4.1: Few of the major post-translational modifications occurring in sarcomeric proteins and their functions.  
PTM Δ mass * (Da) Process Functions  
Acetylation 
 
+42 Introduction of acetyl functional group by 
acetyltransferases at  N-treminal position of the 
protein sequence catalyzed by methionine 
aminopeptidase (MetAP)  
   
Protein stability, protein regulation, prevent 
protein degradation at N-terminus (Gunning 
et al., 2008a). 
Phosphorylation 
 
+80 (Ser, Thr, 
Tyr) 
Protein kinases play an important role in 
phosphorylation of proteins. Oxidative 
phosphorylation uses ATP to phosphorylate 
certain amino acids in the protein sequence. 
Activation or inactivation of proteins and 
their regulation, molecular interactions and 
signalling. 
eg., PKC –Serine residues in TnI (Sarko and 
Pollack, 2002), 
 Tm (Vahebi et al., 2007) 
PKA, PKC, Cam II – MyBP-C (Lim et al., 
1985; Stelzer et al., 2007), MLCK - Myosin 
RLC (Yuan and Solaro, 2008) 
Degradation >1000 - Ubiquitin/proteosome system (UPS) 
- Ca2+ dependant or calpain-mediated protein 
degradation.  
Degradation of TnI is vastly studied for 
cardiac disfunction, as it even considered to  
be biomarker for Hypertrophic cardiac 
myopathy (Wu et al., 1998) 
Oxidation  
 
 
Nitrosylation  
-27 (Arg) 
+15 (lys) 
+16(Met) 
 
Reactive-oxygen species (ROS) and Reactive – 
Nitrogen species (RNS) play major role in 
cellular processes.  
Protein regulation and signalling 
There is profound evidence showing excess 
production of ROS and RNS in acute and 
chronic heart failure conditions in animals 
and humans (Prasan et al., 2007; Seddon et 
al., 2007). 
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+45 (NO2) 
 
*The mass data is obtained from  http://www.abrf.org/index.cfm/dm.home.  
PKC-Protein kinase C, PKA -Protein kinase A, MyBP-C – Myosin binding protein C, MLCK – myosin light chain kinase, 
RLC- regulatory light chain. 
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The ‘top down’ proteomics approach  presents the next level in understanding muscle 
diseases related to heart, skeletal muscle diseases, cancers and other neurodegenerative 
diseases and cardiac adaptations, where the physiological changes and genetic mutations 
are responsible for cardiac adaptations can be explained in terms of the changes occurring 
in sarcomere at the protein level. The post-translational modifications (PTMs) of 
sarcomere proteins affect the structure and function of proteins resulting in shifts in 
isoform populations, forming degradation products, addition or deletion of protein 
availability, altered protein expression, availability of Ca2+ ions and ATPase activity 
(Tardiff, 2011b; Zhang and Ge, 2011b). These changes are being identified using 
advanced techniques of mass spectrometry for protein isoform identification, PTMs  and 
protein interactions (Arab et al., 2006b; Arrell et al., 2001b; Peng et al., 2010; White and 
Eyk, 2007). 
Challenges in ‘top down’ MS approach  
For top down mass spectrometry one of the main challenge is the protein solubility. For 
the ‘bottom up’ analysis proteins are digested by an enzyme where protein solubility does 
not pose any issue. However in top down approach, where intact protein is used for 
analysis having a soluble protein is the major factor as MS needs the proteins to be 
ionised (Gregorich and Ge, 2014) The reagents used for solubilising proteins like SDS 
and Triton X are not compatible for MS analysis.  
Another major is the size of the protein affect the signal to noise ratio in MS analysis. 
Top down method allows protein analysis of the size no larger than 70 kDa 
(approximately of the m/z ratio < 4000 not more than 35 charge states). Proteins larger 
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than that are associated with difficulty in detection and fragmentation in MS (Compton et 
al., 2011).  
Protein separation/fractionation is one the crucial step for mass spectrometry analysis. 
The proteome of thin filament is highly dynamic and due it complexity protein separation 
effective separation techniques are required for top-down MS. The most popular method 
for fractionation of intact proteins is reverse phase liquid chromatography (RPLC) which 
separates proteins based on their hydrophobicity. This method one of the most 
compatible techniques available due to the use of organic solvents acetonitrile and formic 
acid or trifluoroacetic acid (TFA) (Neverova and Eyk, 2002). Many advanced LC 
methods such as 2D LC or 4D LC are developed recently coupled with RPLC for 
proteome analysis. 2D LC  is separation of protein by their pI and then coupled online or 
offline with RPLC and 4D is separation of protein by their pI in the first step followed by 
gel-eluted liquid entrapment electrophoresis, which separates proteins depending on their 
size and coupled with RPLC and MS for direct analysis (Neverova and Van Eyk, 2005). 
C5 or C8 columns are used for top-down MS are suitable for separation of proteins 
(Wagner et al., 2002). The most commonly used MS analysis is RPLC connected to  ESI-
MS/MS for intact protein analysis which maintains the gentle ionisation technique 
keeping the peptide bonds intact for MS analysis (Cole, 2000) There are many other 
techniques in LC coupled with MS which is beyond to discuss in this study (Gregorich 
and Ge, 2014; Gregorich et al., 2014). 
Quantification and data analysis is also one of the major challenge to over come in top 
down MS. Changes in the protein expression using protein abundance of m/z value is not 
sufficient for quantifying proteins. Measuring the abundance by MS and consequently the 
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abundance of peptides generated by MS/MS is used for quantifying the protein 
modification and their expression levels (Bantscheff et al., 2012; Ong and Mann, 2005; 
Peng et al., 2010; Peng et al., 2013; Pesavento et al., 2006).  
Major Sarcomeric Proteins 
The sarcomere consists of alternating thick and thin filaments that form the major 
contractile apparatus in the muscle. The proteins in the thick filament constitute myosin 
heavy and light chains which interact with the thin filament protein actin regulated by 
tropomyosin and troponins. Table 4.2 gives an overview of major sarcomeric proteins 
that are responsible in regulating the normal functioning of the heart showing the 
difference in molecular weight of actin, tropomyosin and troponin complex protein in 
humans, rabbit, chicken and mouse.  
The hypothesis on which this project is based is that the heart adapts in response to 
disease and physiological changes. A significant part of that adaptation is changes in the 
muscle protein isoforms expressed and the post translational modification of them. 
Quantification of the isoforms expressed and their PTMs will therefore give insight into 
heart adaptation and potentially act as a prognostic indicator. 
In order to understand the changes taking place in sarcomere it is important to understand 
the role of sarcomeric proteins that regulate the cardiac function. There are studies 
defining individual protein phosphorylation of sarcomere, but currently there is no 
quantitative data available for protein levels and their post translational modification 
covering a range of thin filament proteins (actin, tropomyosin and troponin) in diseased 
and normal states of thin filament proteins.   
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This study is an attempt to establish a method to extract the muscle regulatory proteins 
from chicken and mouse skeletal muscle and chicken heart left ventricle muscle and 
mouse heart. The study provides optimisation of buffers used for thin filament proteins, 
storage limit of tissue lysates and preliminary optimisation method of reverse phase (RP) 
HPLC technique for isolation of these proteins which is suitable for top down mass 
spectrometry technique that will provide a “birds eye view” of thin filament proteome 
providing information of PTMs of all the proteins together with one single extraction, 
reducing the time for analysis and sample size.  
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Table 4.2: Major Sarcomeric proteins and their molecular weight. 
Protein Human  Chicken  Rabbit  Mouse  Function 
Myosin Heavy 
Chain (MHC) 
(Da) 
220 000    Both MHC and MLC binds to actin 
binding sites thorough the myosin heads 
to initiate motor muscle contraction and 
relaxation 
Myosin Light 
Chain (MHC) 
(Da) 
20 000    
α Actin 42051    Back bone of the thin filament and plays 
a major role in contraction-relaxation 
along with Tm and Tn complex to form 
actin binding complex that regulate 
muscle functioning. 
αTropomyosin 
(Tpm1.1) (Da) 
32708.5  
(Lees‐Miller 
and Helfman, 
1991) 
32960  
(Gooding et al., 
1987) 
32680.5 
 (Stone and 
Smillie, 1978) 
32680.5 
(Gariboldi et 
al., 1995) 
Binds to actin and regulate the 
interaction of actin-myosin filaments 
during contraction-relaxation process. 
βTropomyosin 
(Tpm2.2) (Da) 
32850.5  
(Libri et al., 
1990) 
28671  
(Helfman et al., 
1983) 
32836.7 
(Stone and 
Smillie, 1978) 
32957.7  
(Strausberg et 
al., 2002) 
 
Troponin T (TnT) 
(Da) 
28152  
(Wu et al., 
1994) 
31141(Sk) 
(Pearlstone and 
Smillie, 1982) 
35985.7 (C) 
(Druyan et al., 
2007) 
27809.7 
(alpha) 
29683.3 (beta) 
(Pan and 
Potter, 1992) 
32299.9 (Sk) 
(Koch et al., 
1997) 
35498 (C) 
(Kobayashi et 
al., 2013) 
Links the Tn complex and binds to 
tropomyosin. 
Troponin I (TnI) 24007.1 21234.4 (Sk) 21,214 (Sk) 21357.5 (Sk)  Binds to actin and inhibits actomyosin 
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(Da)  (Hijazi et al., 
2014) 
(Blumenschein et 
al., 2006) 
23628.0 ( C)  
(Hastings et al., 
1991) 
 (Vassylyev et 
al., 1998) 
24122.6 (C)  
(Grand and 
Wilkinson, 
1977) 
(Koppe et al., 
1989) 
24258.7 (C)  
(Ausoni et al., 
1994) 
ATPase depending on the Ca2+ 
sensitivity. 
Troponin I (TnC) 
(Da) 
18387  
(Zhang et al., 
2013) 
18430.5  
(Dvoretsky et al., 
2002) 
18402.5  
(Predicted 
NCBI) 
18420.5  
(Grote et al., 
2013) 
Ca2+ binding site 
 
 198 
 
4.1 Material and Methods 
4.1.1 Extraction of myofilament proteins  
 
Thin filament proteins were extracted from chicken pectoral muscle and left ventricle of 
the heart and wild type mouse thigh muscle and whole heart. Chicken heart and muscle 
were obtained from freshly killed chicken that was between 16 weeks old and stored at -
200C. Mouse heart and thigh muscle were obtained from 12 weeks old wild type mouse. 
The tissues and heart were kept on ice immediately after dissection and stored at -80 0C 
after couple of hours until use.  Approximately 100mg of tissue was taken and 
homogenised with a motor and pestle and from that two sets of whole protein extracts 
were made with approximately 5mg and 2mg of tissue. The tissue was homogenized in 
200µl of different buffers containing 1 mM of benzamidine hydrochloride (inhibitor for 
trypsin, thrombin, arginine specific serine proteases) and 1 mM of PMSF (trypsin, 
chymotrypsin, cysteine proteases and mammalian acetylcholinesterase) as protease 
inhibitors. Tissues were taken from frozen samples of left ventricle of chicken heart and 
pectoral muscle. In case of mouse samples, whole heart was homogenised and the 
amount required was taken from the tissue homogenate. The extraction was repeated 
three times for reproducibility. Table 4.3 below shows the different buffers used for 
extraction. 
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Table 4.3: Different buffer conditions used for extraction of thin filament proteins from 
muscle tissue. KCl – Potassium chloride, NaCl – Sodium chloride, SDS – sodium dodecyl sulphate. 
Homogenization condition Buffers  
1 6M Urea 
2 1M KCl 
3 6M Urea + 1M KCl 
4 6M Urea + 1M KCl+ 0.5% TritonX-100 
5 1M NaCl 
6 6M Urea + 1M NaCl+ 0.5% TritonX-100 
7 6M Urea + 1M NaCl+ 0.5% TritonX-100 
8 6M Urea + 1M NaCl+ 0.5% SDS 
  
Approximately 5 mg and 2 mg of tissue simple was homogenized in 200 µl of buffer 
using an Eppendorf homogenizer for five minutes on ice and vortex for 5 min. Samples 
were centrifuged at 13000 rpm for 5 min at 4 0C. 20 µl of pre-dialysed sample extract 
was denatured in 20 µl 4X SDS buffer at 95 0C for 5 min and stored at 4 0C to run on the 
gel along with dialysed samples. The rest of the extract was subjected to micro dialysis 
overnight in low salt buffer containing 2 mM pH 8.8 Tris-HCl, 2 mM CaCl, and 0.2 mM 
Dithiothreitol (DTT) to precipitate myosin. The dialysed samples were spun at 13000 
rpm for 5 min to remove any precipitate and 20 µl of sample is denatured with 4X SDS 
buffer. Proteins were separated on 13.5% SDS-acrylamide gel and visualised by staining 
with coomassie stain (0.1% Commassie blue G250, 25% Methanol and 5% Acetic acid) 
over night for saturation, quantified by scanning them with Biorad GS800 calibrated 
densitometer. Approximately 100 ng of sample was loaded on the gels. The gels were 
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scanned along with AFGA density strip tablet and Stouffer 21 transmission step wedge 
which acts as a standard for constructing a calibration curves. Protein quantification was 
performed using ImageJ software (Schneider et al., 2012). Total protein concentration of 
the tissue lysates was estimated using BCA assay.   
Determining the storage time for the tissue lysates 
From the results obtained from tissue extracts from 5 mg and 2 mg tissue lysates, 3 buffer 
conditions were chosen according to the amount of protein yield form each buffer to 
estimate the length of time the proteins could be stored for analysis. This experiment was 
performed with chicken skeletal muscle and left ventricle heart muscle tissues. For 
skeletal muscle tissue buffers KCl, NaCl and Urea-NaCl- SDS were chosen and for heart 
tissue Urea, Urea-KCl and Urea-NaCl were chosen as the amount of protein was higher 
in those buffers for that particular tissue. The tissue lysates were analysed using the same 
method as the whole tissue extracts stated about using SDS-PAGE and Image J software. 
Dialysed lysates were analysed on the same day of extraction, 1 day of freezing, 1 week 
of freezing and 4 weeks of freezing both at -20 0C and -80 0C.  
Extraction of control proteins 
Control proteins (CP) are the proteins that are left after actin extraction from the acetone 
powder. CP has high concentrations of tropomyosin and troponin complez proteins (TnT, 
TnI and TnC). The solid residue obtained after actin extraction (Chapter II, section 
2.4.3.1) was suspended in buffer containing 10 mM Tris-HCl, 20 mM DTT and 1 mM 
sodium azide and stirrer at room temperature for five hours. The muscle suspension was 
filtered through a cheese cloth and the filtrate was stored at 4 0C overnight. To the 
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measured volume of the filtrate ammonium sulphate is added to 40% saturation slowly 
while stirring on ice. The filtrate is incubated on ice while stirring for 30 min and the 
precipitate was separated by spinning at 9K rpm for 30 min. The pellet is discarded and 
to the filtrate ammonium sulphate is added increasing the saturation to 60%. The filtrate 
was incubated on ice for 30 min and precipitate obtained was left in the ammonium 
sulphate and stored at 4 0C. For optimising the RP-HPLC CP were used as a standard for 
tropomyosin and troponin elution times for comparison with tissue lysates. The proteins 
were precipitated out form 60% ammonium sulphate solution by spinning the 200 μl of 
the filtrate at 9K rpm for 30 min. The palette is resuspended in 5 mM Tris with 0.5 mM 
DTT. The proteins were dialysed against 1 mM ammonium bromide buffer for HPLC 
analysis.  
Reverse-phase HPLC technique  
After optimising the amount of the tissue required for the proteins to analysed to be 2 mg, 
separate extractions were made to optimise method for separation and identification of 
thin filament proteins primarily actin, tropomyosin isoforms and troponin I, troponin T 
and troponin C. The lysates were dialysed overnight at 4 0C in 1 mM ammonium bromide 
((NH4)Br) buffer. The lysates were stored in an ice box at 4 
0C to avoid denaturation 
from freeze-thaw cycles. Proteins were analysed within 2 days of extraction. Control 
proteins (CP) (mainly tropomyosin and troponin isoforms) extracted during the procedure 
of extraction of pure actin form muscle acetone powder both from rabbit and chicken 
muscle acetone powder were used as control to identify the protein peaks from the tissue 
extracts. Water CapLC was used with reverse phase SUPELCO analytical Discovery BIO 
wide pore C5 column (10cm x 1.0 mm, particle size 3 μM, pore size 300Å) with 40 
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μl/min flow rate and 25 μl of sample was injected containing approx., 200 ng of total 
protein. Protein elution profiles were monitored by extinction at 280 nm. Proteins were 
eluted by increase in hydrophobicity using far UV acetonitrile with 0.1% formic acid as 
buffer B and Milli Q ultrapure water with 0.1% formic as buffer A.  
To optimise the method first a gradient from 1% B to 60% was developed to for elution 
profiles. After finding the prominent proteins were primarily eluting form 20% - 40% B, 
gradient was changed from 20% to 50% B for collection of fraction and analysing the 
fractions on the SDS-PAGE gel. The gradient method used is given in the Table 4.4 with 
a flow rate of 40 μl/min. 
Table 4.4: Gradient method for separation of thin filament proteins. 
Time (min) B% 
0.0 1.0 
5.0 1.0 
5.01 20 
45.0 50 
45.01 100 
50.0 100.0 
50.01 1.0 
60.0 1.0 
 
CP samples from chicken and rabbit were run 3 times to check the reproducibility of the 
column. As the protein extraction did not vary much with different buffers, single buffer 
extraction was selected for each skeletal and heart tissues. Proteins extracted from KCl 
for skeletal muscle and Urea-KCl for heart tissue were chosen for analysis of both mouse 
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and chicken lysates to maintain comparison. The reverse phase fraction for each 
prominent peak were collected, approximately 50-100 μl. Collected fractions were 
concentrated using SpeedVac (Savant Speec vac concentrator) until completely dry, 10 μl 
of 2x Lamellae buffer was added and heated at 95 0C for 5 min and analysed using 7 cm, 
13.5% SDS-PAGE gels, stained by coomassie blue (G250 coomassie brilliant blue), de-
stained with 25% methanol and 7% acetic acid and the gels equilibrated in water before 
scanning with Biorad GS800 calibrated densitometer. The gels were analysed using 
imageJ software. 
4.2 Results 
4.2.1 Myofilament Protein Extraction 
4.2.1.1 Skeletal Muscle Tissue 
 
To optimise the method for extraction of myofilaments proteins from skeletal and cardiac 
muscles eight different homogenization conditions were used with two different sample 
amounts. Figure 4.1 shows the gels with all the eight buffer conditions, dialysed and 
undialysed protein bands extracted from both 5 mg and 2 mg tissue. Known amount of 
BSA was loaded on the gel as an internal standard. The relative staining intensities of the 
protein bands were calculated by relative to the BSA band intensity of the same gel, 
dividing the value with a standard BSA band intensity. 
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Figure 4.1: Chicken pectoral muscle proteins visualised in SDS-PAGE. Chicken 
pectoral muscle – 5 mg and 2mg in 200µl buffer. M-Marker, 1-Urea, 2-potassium 
chloride (KCl), 3-Urea+KCl (UK), 4-UK+TritonX-100, 5-NaCl, 6-Urea+NaCl (UN), 7-
UN+TritonX-100 (UNT), 8-UN+sodium dodecylsulphate (UNS). d-dialysed, skTnT- 
skeletal troponin T, (I and C). Low molecular weight skTnC is yet to be confirmed and is 
labelled comparing with previously confirmed protein bands. 
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Figure 4.2:Chicken pectoral muscle tissue extraction quantification using Image J. 2 mg and 5 mg tissue lysates in 200µl buffer : 
U-Urea, KCl-potassium chloride, UK-Urea+KCl, NaCl-Sodium chloride, SDS-sodium dodecylsulphate, UD-Undialysed, D-Dialysed, 
X – buffers selected for further analysis.The prominent peaks are protein bands that are identified highlighted in Fig.5.3.
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Figure 4.3: Extraction profile for chicken pectoral muscle with 2 mg tissue. Pectoral 
muscle protein bands from Image J quantification peaks of three short listed buffers KCl, 
NaCl and Urea-NaCl-SDS from the prominent peaks obtained from Coomassie stained 
SDS-PAGE gels.   
 
The prominent proteins labelled (actin, tropomyosin and troponins) and the other visible 
protein bands on the gel were used for quantification of band intensities to obtain the total 
protein using Image J software. Figure 4.2 shows the sum of the protein band intensities 
obtained from Coomassie stained SDS-PAGE gels of skeletal muscle form 5 mg and 2 
mg tissue extractions. Among the eight conditions three buffer conditions were short 
listed depending on the total protein and the amount of prominent proteins visible on the 
gel after dialysis. The proteins on SDS page were labelled according to Maytum et al., 
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(2003). The protein bands can be observed as peaks from the spectrum obtained from 
Image J analysis of SDS-PAGE as shown in Figure 4.3 which is taken from 2 mg tissue 
extraction. Form the data obtained from 5 mg and 2 mg together, KCl, NaCl and 
Urea+NaCl+SDS (UNS) buffers were shortlisted with a relative staining intensity of 
844.8, 482.9 and 2580.7 of total protein respectively for further analysis of skeletal 
muscle proteins. The above buffer were chosen as protein gels from these buffers show 
complete removal of myosin (220 kDa) after dialysis with low salt buffer (Figure 4.1) as 
myosin seems to precipitate out after dialysis. Removal of myosin is important as this is a 
very high molecular weight protein and being a relatively sticky and insoluble protein 
which will have high back ground effect during HPLC separation as well as mass 
spectrometry analysis.  
4.2.1.2 Heart muscle tissue extraction 
 
Figure 4.4 shows the Coomassie stained SDS-PAGE gels for the tissue lysates from the 
extraction of proteins from the left ventricle of heart tissue samples.  However from both 
(2 mg and 5 mg) of the extraction profiles, buffers containing urea and detergents gave a 
higher amount of protein but from the Figure 4.4 it can be seen that the lower molecular 
proteins in the gel are not resolved completely. The same is observed in the reproduced 
gels as well. It is a well-known fact that detergents affect the mass spectrometric analysis 
by high back ground noise ratio in mass spectrum and hence to be removed before 
analysis by dialysing in low salt buffer. Hence for heart samples buffers without 
detergents were chosen to reduce the back ground noise in MS analysis. Buffers 
containing Urea, Urea-KCl and Urea-NaCl with band intensities of 3045.5, 2079.6 and 
 208 
 
1836 respectively, were chosen as it is observed from Figure 4.6 that these buffers give 
good resolution of proteins from heart muscle and also there is higher amount of purified 
protein after dialysis compared to other buffers. Another reason for favouring these 
buffers is the removal of myosin after dialysis. This may be because some proteins after 
dialysis must have been precipitated out and proteins show higher resolution after 
dialysis.  
 
Figure 4.4: Proteins of left ventricle of the chicken heart visualized on SDS-PAGE 
gel. Heart left ventricle-5mg and 2mg in 200µl buffer. M-Marker, 1-Urea, 2-potassium 
chloride (KCl), 3-Urea+KCl (UK), 4-UK+TritonX-100, 5-NaCl, 6-Urea+NaCl (UN), 7-
UN+TritonX-100 (UNT), 8-UN+sodium dodecylsulphate (UNS). d-dialysed, cTnT- 
skeletal troponin T, (I and C). Low molecular weight cTnC is yet to be confirmed and is 
labelled comparing with previously confirmed protein bands. 
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Figure 4.5: Chicken heart-left ventricle (LV) tissue extraction quantification using Image J. 2 mg and 5 mg tissue lysates 
in 200µl buffer : U-Urea, KCl-potassium chloride, UK-Urea+KCl, NaCl-Sodium chloride, SDS-sodium dodecylsulphate, UD-
Undialysed, D-Dialysed, X – buffers selected for further analysis.  
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Figure 4.6: Heart muscle Left ventricle protein profile from Image J quantification peaks 
of three short listed buffers Urea, Urea- KCl, Urea-NaCl .  
 
Figure 4.6 shows the spectrum obtained from the quantification of SDS gels by using 
image J analysis with the short listed buffers.  
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Figure 4.7: Difference in the protein profile of the heart and skeletal muscle.  
 
Figure 4.7 shows the difference in the skeletal and heart muscle proteins separation on 
SDS page, the proteins are distributed and separated differently on SDS page may be due 
to the difference in the isoforms of skeletal and heart muscle proteins. With help of MS 
analysis it may be possible to see the difference in the skeletal and cardiac protein 
difference and their PTMs. The low molecular weight proteins (cTnC and skTnC) masses 
are yet to be confirmed. The labelling is based on assumption of theoretical mass and data 
obtained from previous research.  
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Both skeletal muscle and heart tissue extracts were performed in triplicates, however 
quantification for all the buffers was done only for one replicate. Triplicate quantification 
was performed for storage time experiments using short listed buffers for both types of 
tissues. Both tissues have been observed to prefer different salt and urea condition for 
solubilising the respective proteins.  
4.2.1.3 Mouse Skeletal and heart extracts 
Wild type mouse skeletal muscle from thigh area and heart were used for extraction of 
thin filament proteins using the same buffers as used for chicken heart LV. Triplicate 
extractions were made and used for HPLC analysis. The triplicates are shown in Figure 
4.23, quantification was not performed for these extracts with densitometry, as the 
buffers were already selected using chicken samples, total protein form the extracts was 
quantified by BCA assay. It can be seen form Figure 4.8 and the gels from Figure 4.23 
that the distribution of proteins on SDS-PAGE are different between chicken and mouse 
cardiac proteins may be due to difference in the isoform distribution in both species. 
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Figure 4.8: Difference in the protein distribution of chicken and mouse heart 
proteins on SDS-PAGE. Image spectrum generated by using Image J software.  
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4.2.2 Storage of tissue extracts 
4.2.2.1 Skeletal muscle samples 
Shortlisted buffers were used to extract proteins for checking the storage limitations of 
the tissue lysates after extractions. This is important when using human tissue samples as 
the sample would be limited for extraction and analysis. Three technical replicate 
extractions were prepared and analysed using densitometry of SDS-PAGE gel images. 
The gel images for skeletal muscle and heart muscle are shown in Figure 4.9 and Figure 
4.12 respectively. The replicates were performed for reproducibility and hence error was 
not calculated as there would be a large difference with the gels being treated separately 
and the staining time and destaining time effects the density of the bands even though 
care was taken to keep the timing as close as possible, BSA as a standard. Analysis was 
done as described previously.  
The quantification data of average relative staining densities of total proteins from all 
three replicates and the data obtained from single replicate are in given in Figure 4.12. As 
previously observed from Figure 4.1, buffer with detergent SDS, gave higher amount of 
total protein yield than the buffers with only salts. 
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Figure 4.9: Chicken skeletal muscle tissue extracts triplicates. Experiment was performed as explained in methodology. 2- 
KCl, 5- Nacl, 8 – Urea-Nacl –SDS. Samples were thawed on ice for sample preparation for analyzing with SDS-PAGE. 
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Figure 4.10: Average of relative staining ratios of skeletal proteins lysates stored at -
20C and -80C. 
 
UNS have higher extractions but myosin is left in the lysates after dialysis. KCl seems to 
have better storage capacity than NaCl, however at 20 0C NaCl have slightly higher 
protein than KCl in contract with 80 0C where KCl is left with higher protein. It also 
observed that in one day there is substantial loss of protein, however freezing for one day 
and one week does not have much difference, but 4 weeks freezing is not preferable 
(Figure 4.9 and Figure 4.10). However, as long as protein bands are visible on an SDS-
PAGE, it would be enough protein for analysis using mass spectrometry. It has to be 
added that, unless mass spectrometry analysis is performed it is not known how much the 
proteins are proteolysed. It can be observed that for some reason samples frozen for one 
day and one week does not show much difference in protein loss, however protein stored 
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at -80 0C have more protein left in the lysates than the lysates stored at -20 0C. In both 
cases, there is substantial loss of protein by storing the samples for four week. 
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Figure 4.11: Relative staining intensities of individual prominent protein bands of skeletal muscle and the difference in 
freezing times. Averages are taken from triplicate data.  
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The data obtained from quantification of stored samples was also used to check the 
variation of individual prominent proteins actin, tropomyosin and troponins (TnT, TnI 
and TnC) and their affect due to storage shown in Figure 4.11. For some reason 
proteolysis is different at -20 0C and -80 0C with NaCl and KCl with all the individual 
proteins, actin, Tm, and Tn’s. Actin and Troponin I seems to favor KCl and Tm and TnT, 
TnC seems to store well in NaCl. Both KCl and NaCl could be used for mass 
spectrometry analysis, however NaCl forms protein adducts and effect mass spectrometry 
analysis by reducing the overall molecular ion abundance and signal distribution for any 
given charged state (Flick et al., 2012). It is also observed that after four week TnC is 
completely lost or may be its not left enough to be visible on a gel. The concentration of 
salts could be reduced by buffer substitution with ammonium bicarbonate or ammonium 
bromide which are volatile and are evaporated during mass spectrometry analysis. The 
relative loss in intensities has been observed relatively similar with other replicates, the 
figures shows the average of the data taken from all the replicates.  
4.2.2.2 Heart LV samples 
 The heart samples treated similar to skeletal muscle samples other than that the buffers 
used were different. Urea, Urea-KCl and U-NaCl were used for extraction of heart 
muscle proteins. Figure 4.12 shows the triplicate SDS gels of all the freezing conditions. 
The relative staining intensities were calculated same as skeletal muscle proteins. 
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Figure 4.12: Chicken heart LV tissue extracts triplicates. Experiment was performed as explained in methodology. 1Urea, 
3-Urea-KCl, 6– Urea-NaCl. Samples were thawed on ice for sample preparation for analyzing with SDS-PAGE. 
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Figure 4.13: Average of the  relative staining ratios of heart protein lysates stored at 
-20C and -80C. 
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Figure 4.14: Relative staining intensities of individual prominent protein bands of heart LV muscle and the difference 
in freezing times taken from triplicate data.  
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The cardiac muscle proteins also had substantial loss similar to skeletal muscle proteins. 
Form Figure 4.13 it is seen that there is an increase in intensity for -20 0C UK and -80 0C 
Urea for one week freezing samples, which is due the back ground staining of the gel as 
seen from Figure 4.12. Otherwise the loss seems to be similar without effect of how long 
the sample is stored.  
Form the data presented in Figure 4.14, actin, tropomyosin and troponins of cardiac 
muscle are found to last longer from degradation in Urea-KCl buffer both at -20 0C and -
80 0C, however they seem to be less stable than the skeletal muscle proteins.  
Form both muscle tissues, it is observed that one week storage is better than one day 
storage, if it needs to be stored for one day, it is better to store the sample at 4 0C rather 
than freezing.  
4.2.3 BCA quantification 
 
 
Figure 4.15: BCA quantification standard curve - skeletal and cardiac muscle 
proteins. 
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Figure 4.16: Protein concentration of dialysed samples of skeletal muscle and 
cardiac muscle protein extracts by BCA assay.  
Figure 4.15 shows the standard curve of the BCA quantification used for quantifying total 
protein from tissue lysates shown in Figure 4.16.  
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4.2.4  Reverse Phase HPLC analysis 
 
Control proteins of rabbit muscle extracted during the preparation of actin from acetone 
muscle powder. The protein lysate consist mainly of Tropomyosin and Troponin 
complex. As seen in the Figure 4.17a, the lane labelled T is the dialysed protein lysate 
containing troponin complex (Tnc, TnT, and TnI )and tropomyosin with traces of actin, 
as actin has already been extracted for actin polymerisation studies. The tropomyosin 
band separation clearly shows αTm (32680 Da)  and βTm (32836.5 Da) (Table 4.2). The 
proteins lysate was dialysed in 1 mM ammonium bromide and this seems to keep proteins 
stable for analysis. The elution profile (Figure 4.17b) shows the separation of all the 
proteins present in the lysate.  
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Figure 4.17: RP liquid chromatography (LC) elution profile of Rabbit skeletal 
muscle proteins. a. SDS gel showing the proteins of control proteins (CP) of rabbit 
skeletal muscle extracted form acetone muscle powder (mainly containing tropomyosin 
and troponin with traces of actin) and the eluents collected form the LC profile. b. elution 
profile of HPLC run. c. table showing the peak number, retention time and the % B 
relating to the elution profile. The peak number resembles the number of the peak in the 
elution profile and on the gel for comparison. T- the dialysed CP proteins loaded for 
comparison.  
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Figure 4.18: RP liquid chromatography elution profile of chicken control proteins. 
a. SDS gel showing the proteins of control proteins (CP) of chicken skeletal muscle 
extracted form acetone muscle powder (mainly containing tropomyosin and troponin with 
traces of actin) and the eluents collected form the LC profile. b. elution profile of HPLC 
run. c. table showing the peak number, retention time and the % B relating to the elution 
profile. The peak number resembles the number of the peak in the elution profile and on 
the gel for comparison. T- the dialysed CP proteins loaded for comparison.  
 
Studying Figure 4.18, the CP of chicken skeletal muscle, from the tissue lysate it is 
clearly seen that actin is not completely removed from the lysate after actin preparation. 
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The protein lysate have high concentration of proteins and it seems the elution profile 
seen on the gels have all the protein separated frequently and not only in one single 
elution time. However at 30-32% B (100 % acetonitrile), TnT seems to elute and also low 
molecular weight protein band around 15 kDa is also eluted along with TnT. However 
chicken TnI did not seem to elute at the same time as of rabbit TnI. Chicken TnC is in 
comparison with rabbit TnC elution percentage.  
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Figure 4.19: Chicken skeletal muscle protein extraction in triplicates for LC 
separation of proteins. Skeletal muscle proteins were freshly prepared for optimizing 
the LC method.  
 
Figure 4.19 shows the freshly prepared chicken skeletal muscle lysates undialysed and 
dialysed (dialysed in low salt buffer as explained in methodology section 4.1.1)  samples. 
After dialysis proteins seem to get more concentrated and resolved completely. The 
proteins extracted from KCl was used for using to separate protein by LC, as KCl shows 
higher concentration of proteins and UNS have still lot of soluble myosin left in the 
lysate, which is a notorious sticky protein and is not suitable for running through LC 
column.  From the elution profile (Figure 4.20) TnC eluted very much later in 
comparison with Tm and other Tn complex, may be because in presence of actin in tissue 
 230 
 
lysates and the tropomyosin, TnT complex is still bound tightly in contrast to CP proteins 
where actin is removed from the lysate.  
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Figure 4.20: RP LC elution profile of chicken skeletal muscle. a. SDS gel showing the 
proteins of chicken skeletal muscle extracted form tissue in KCl and the eluents collected 
form the LC profile. b. elution profile of HPLC run. c. table showing the peak number, 
retention time and the % B relating to the elution profile. The peak number resembles the 
number of the peak in the elution profile and on the gel for comparison. T- the dialysed 
CP proteins loaded for comparison. Maximum effort was taken to emphasise the eluent 
protein bands on the gel during scanning, however they are not visible in the pictures as 
the band staining intensities were very low. 
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Figure 4.21: Chicken heart LV tissue lysates and triplicates. Freshly prepared for use 
in optimizing the LC method.  
 
From the Figure 4.21, it is seen that buffer containing Urea-KCl with Triton X-100 gave 
good protein extraction and better resolution of proteins on the gel after dialysis, and 
from the solution profile, separation of protein from both UKT and UK were performed, 
but UKT did not give any recognizable bands on the gel from the eluents. Figure 4.22 
shows the solution profile of protein form UK and the gel from UKT and it seems only 
Troponin complex is being eluted at the same %B as of skeletal proteins from both the 
solution profiles. UKT seem to keep the troponin complex intact in the buffer system and 
may TnT from the UKT has been eluted along with other Tn complex proteins. Actin and 
tropomyosin are not seen on the gel, may be because the lysates were stored on ice at -
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40C for 3 days before analysis avoiding freezing the samples. The results from the storage 
experiments showed (Figure 4.14) cardiac proteins does not show stability during 
storage, hence may be the other proteins must have been degraded.  
 
Figure 4.22: Chicken heart RP –HPLC elution profile. a. SDS gel showing the 
proteins of chicken heart muscle and the eluents collected form the LC profile. b. elution 
profile of HPLC run. c. table showing the peak number, retention time and the % B 
relating to the elution profile. The peak number resembles the number of the peak in the 
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elution profile and on the gel for comparison. T- the dialysed CP proteins loaded for 
comparison. Maximum effort was taken to emphasise the eluent protein bands on the gel 
during scanning, however they are not visible in the pictures as the band staining 
intensities were very low.   
 
Figure 4.23: Mouse skeletal muscle extracts and triplicates. Ud-undialysed, d-
dialysed, M- marker, K-KCl, Na – NaCl, UNS- Urea-NaCl-SDS.  
 
Mouse skeletal extraction (Figure 4.23) shows urea with salt and detergent keeps myosin 
solubilize in the lysate without precipitating out  in the even after dialysis. KCl and NaCl 
have similar extraction profiles, but KCl seems to have better resolution of TnT complex. 
The elution profile of mouse skeletal proteins (Figure 4.24) from buffer KCl show the 
separation of actin and tropomyosin at 36% and 37 % of B respectively in similar to 
chicken skeletal protein elution profile. Troponin complex proteins were not visible, 
however a band of approximately 13 kDa is observed on the gel which may be a fragment 
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of TnT (Ohtsuki, 1979) on SDS page. At around 42% all the proteins are eluted. Elution 
of protein with UNS were also however no identifiable bands on the SDS-gel were 
observed and hence the data is not given.  
 
Figure 4.24: Reverse phase LC separation of mouse skeletal proteins. a. SDS gel 
showing the proteins of mouse skeletal muscle and the eluents collected form the LC 
profile. b. elution profile of HPLC run. c. table showing the peak number, retention time 
and the % B relating to the elution profile. The peak number resembles the number of the 
peak in the elution profile and on the gel for comparison. T- the dialysed CP proteins 
loaded for comparison.  
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Figure 4.25: Mouse heart tissue extracts and triplicates. U-Urea, UK-Urea-KCl, 
UKT-Urea-KCl-Triton X100, UN-Urea-NaCl. Ud-undialysed, d- dialysed, M-marker.  
 
Four buffers were used to check the extraction of mouse heart tissues (Figure 4.25) All 
the four buffer used, urea, UK, UKT and UN have shown to precipitate out myosin, and 
on the gel all buffers seem to show similar resolution of proteins, however a substantial 
loss of protein is observed after dialysis. Two buffer UK and UKT were selected for 
separation of protein by LC column, only UK profile is shown, as UKT gels did not show 
any identifiable bands hence the data is not shown.  The elution profile shows (Figure 
4.26) separation of Tropomyosin and Troponin T, at 36% and 38% B respectively. The 
bands are not clearly visible due to the gel background.  
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Figure 4.26: Elution profile of RP-LC for mouse heart proteins. a. SDS gel showing 
the proteins of mouse heart muscle and the eluents collected form the LC profile. b. 
elution profile of HPLC run. c. table showing the peak number, retention time and the % 
B relating to the elution profile. The peak number resembles the number of the peak in 
the elution profile and on the gel for comparison. T- the dialysed CP proteins loaded for 
comparison. Maximum effort was taken to emphasise the eluent protein bands on the gel 
during scanning, however they are not visible in the pictures as the band staining 
intensities were very low. 
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4.3 Discussion 
Extraction of thin filament proteins 
The thin filament proteins including actin, tropomyosin and troponin are the key 
mediators for contraction of cardiac muscle and skeletal muscle for performing the basic 
physiological functions of movement. Analysis of these proteins with a holistic approach 
will help to understand of human diseases relating to muscle disorders such as heart 
diseases.  
 In this study, an efficient extraction method is being developed for extraction of thin 
filament proteins using different buffer conditions with minimum amount of 2 mg tissue 
and also estimated the storage limitations of proteins in each buffer. This extraction 
procedure dramatically reduces the complexity of extraction method for thin filament 
proteins to study whole myofilament proteome relevant to heart left ventricle and skeletal 
muscle proteins.  The analysis of thin filament of heart and skeletal muscle proteins by 
proteomic techniques has always been challenging due to the availability of biopsy 
samples especially heart samples and is limited by its small sample size. The amount of 
tissue chosen (2 mg) in this method is to reflect the amount of tissue available when 
human tissue is used which is very minimum from the methods available so far for thin 
filament tissue extraction methods. This method is modified from Labugger et al., (2002) 
who used 100 mg of tissue in four times volume of buffer. Here the amount of sample 
used and the volume of buffer is significantly reduced to 2 mg in 200 µl of buffer. The 
amount of tissue used in this method is the minimum amount of tissue used for a 
extraction of thin filament proteins for proteome analysis so far. Recently Peng et al., 
(2014b) developed method for analysis of cardiac myofilament proteome of swine heart 
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using 5 mg of protein in HEPES buffer for loading of 500 µg of sample per analysis and 
others . Anderson et al., (1991) used ~1 g of tissue from human heart for extraction of 
TnT isoforms and Erban (2011) also used 100 mg of tissue from mite bodies for 
purification for analysis of tropomyosin , actin and troponin using 2D gels. This method 
is an attempt to skip 2D gel analysis and also protein digestion step for analysis of protein 
by top-down mass spectrometry of the whole thin filament proteome. The amount of 
protein loaded on the SDS gel was ~200 ng and which was successful in visualizing the 
protein bands of actin, tropomyosin, TnT, TnI and TnC and myosin light chains identified 
using previous research results (Maytum et al., 2003). The main challenges to overcome 
for tissue extractions for mass spectrometry analysis is that the proteins extracted in the 
lysates should be pure for identification of proteins and their post-translational 
modifications. Secondly, it is important how long a tissue lysates could be stored for 
analysis. 
Form the extraction profiles of chicken pectoral muscle (Figure 4.1), chicken heart 
(Figure 4.4), mouse skeletal (Figure 4.23) and mouse heart (Figure 4.25) shows the SDS 
page gels of the samples mentioned extraction. The major thin filament proteins were 
successfully identified from all the tissue samples with the small amount of protein lysate 
loaded (200 ng). 
Storage of tissue and tissue lysates 
The storage differences in time and differences in buffer conditions, it is clearly seen that 
there is substantial loss of protein even after one day of storage after dialysis (Figure 4.10 
and Figure 4.11) for chicken skeletal samples and Figure 4.13 and Figure 4.14 for heart 
samples.  Freezing the extracted samples for one week or 4 weeks at -20 0C or -80 0C 
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does not vary much in losing the proteins. However this cannot be decided only by SDS 
page analysis, it would be beneficial to analyse the samples by mass spectrometry. As our 
mass spectrometer was broken and there was not enough time and funding to outsource 
the analysis, MS analysis was not performed.  
It is important to consider the storage of tissues as well along with tissue lysates. The 
chicken skeletal muscle used in this study was frozen for 3 years. Comparing the Figure 
4.1, Figure 4.9 and Figure 4.18, the number of protein bands visible are reduced from as 
the samples was stored at -20 0C and the difference in time of extraction and storage is in 
the order of 6 months to 1 year.  After first extraction, the muscle was completely thawed 
in the fridge overnight due to power failure in the laboratory. The extraction from Figure 
4.9 and Figure 4.18 were prepared after this incident with a time difference of few 
months, it can be clearly seen that the proteins are being degraded even in the tissue after 
thawing and freezing back. In the same manner heart samples extracted from frozen 
chicken hearts for couple of years from Figure 4.4 and Figure 4.11 and the tissue extracts 
from Figure 4.20 were prepared with in couple of months of freshly frozen chicken heart. 
From this it can be stated that out most care needs to be taken during proteomic analysis 
of tissues as freeze-thaw cycles may degrade the proteins which may result in loss of 
information while studying diseases.  
Though there are many studies for tissue extraction and analysis (referenced in the above 
discussion) so far, there are no studies that reported regarding the storage of tissue and 
protein lysates. This gives an insight into the innate importance of storage of tissues for 
analysis of disease states.  
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Reverse phase liquid Chromatography 
The RP- liquid chromatography elution profiles show that it is possible to elute thin 
filament proteins all at the same time to study the thin filament proteome with single 
extraction using a simple C5 column with a minimum sample amount loaded onto the 
column as less as ~100 ng. The preliminary method developed showed the separation of 
major thin filament actin, tropomyosin, troponin complex protein in rabbit, chicken and 
mouse samples. If this method is suitable for the tissue samples of these animals, it is 
possible to analyse human tissue samples with this minimum amount of sample size. 
Other methods available so far for proteome analysis shows either single protein isoforms 
by top-down mass spectrometry (Peng et al., 2013) using state-of-art advance MS 
systems like FTIR-MS or by peptide mass finger printing by tryptic digested peptides 
suing ESI-Tandem MS (Arrell et al., 2001b; Erban, 2011; Labugger et al., 2002). As the 
proteins fractions collected and run on the gel are visible on the gel with such a small 
amount of sample using Coomassie staining, more sensitive staining method like silver 
stain will enable to visualize the protein bands more clearly. There are many other 
proteins that are visible on the gel which may be the fragments of troponin, that can be 
seen around 20 kDa and 13 kDa (Ohtsuki, 1979) myosin light chain seen around 20 kDa  
and other isoforms and smaller additional proteins. If mass spectrometry analysis is 
applied there is high possibility of identifying these proteins. In the non-availability of 
MS system, monoclonal antibodies specific to all the known proteins could be used to 
identify the protein bands.  
Acetonitrile used in this method is one of the most compatible solvents for MS analysis 
(Neverova and Van Eyk, 2005), is another advantage for this method for analysis of thin 
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filament proteome for top down MS as use of methanol for prolonged use in RPLC may 
result in methylation of few proteins during analysis (Gregorich and Ge, 2014).  
In conclusion, this study shows an efficient method for extraction of tissue samples with 
minimum amount of sample size and the RP-HPLC method developed gives efficient 
myofilament protein separation suitable for mass spectrometry analysis. When the 
proteins are visible on an SDS-PAGE, it can be noted that the sample lysate used has 
enough proteins required for identification by MS analysis. This method surpass the use 
of time consuming 2D gel analysis and may prove useful for identification and 
quantification of proteins and their changes in various forms of cardiac and skeletal 
muscle diseases with a single extraction reducing the time for analysis and sample size.  
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Chapter V 
5 Conclusion 
Expression of tropomyosin 3.12st in E.coli 
Tropomyosin 3.iso12st protein encoded by TPM3 gene found in slow twitch muscle 
fibers. It is found to be responsible for many muscle disorders caused by genetic 
mutations such as described in sections 1.6, 1.7 and 1.8. In the present study Tpm3.12st 
was successfully expressed in E.coli and its actin binding affinity was characterised in 
comparison with three other protein isoforms encoded with the alternative genes of 
tropomyosin (Tpm1.1st, Tpm2.2st and Tpm4.1cy). Tpm1.1st is the most extensively 
studied tropomyosin isoform from the time tropomyosin was discovered (Gunning et al., 
2008a; Hitchcock-DeGregori et al., 1985; Lehman et al., 2000a; Schevzov et al., 2005; 
Spudich and Watt, 1971; Wegner, 1979). Tpm2.2 has also been characterised. Tpm3.12st 
and nonmuscle Tpm4.1cy are not characterised so far for its actin binding affinity. 
Marston et al., (2013) expressed Tpm3.12st in baculovirus expression system to study the 
isoform variations in comparison with tissue extracts of tropomyosin however it was not 
characterised for its actin binding properties. Tropomyosin is one the thin filament 
proteins which plays a major role in regulating actin filaments in muscle and nonmuscle 
cells. Hence understand how this isoform is affecting in comparison with other major 
striated muscle isoforms (Tpm1 and Tpm2) and non-muscle isoform (Tpm4) is very 
important to decipher its role in health and disease states.  
Tpm3 was successfully expressed in E. coli with three variants of N-terminal extension. 
Tpm3-Met, Tpm3-MM and Tpm3-(M)ASM were purified and checked for its actin 
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binding affinity along with Tpm1 (with N-terminal AS), Tpm2 (Without N-terminal AS) 
and Tpm4 (with N-terminal AS). The N-terminal extension with AS mimics the post-
translational modification process of N-terminal acetylation (Monteiro et al., 1994) and is 
required to maintain its ‘local’ structure for head-to-tail polymerisation and for actin 
binding (Urbancikova and Hitchcock-DeGregori, 1994) as discussed in section 2.4.2.3 
Proteins expressed were found to be pure and the molecular weight is confirmed by mass 
spectrometry showed the protein to be Tpm3 with a molecular weight of 32823.6, 
32950.8 and 32821.1 for Tpm3-Met, MM and MASM variants respectively. From the 
mass it is confirmed that MASM variant lost its N-terminal Met and the other two 
variants had intact Met (Table 2.3). Tpm4 isoform produced had a mass difference of ~57 
Da, the possibility of losing the C-terminal lysine was higher but could be confirmed at 
with the available data. Further investigation is need to confirm the sequence.  
Actin binding affinity  
These variants were studied for their actin binding affinity along with Tpm1 and Tpm2 as 
the later were characterised for their binding affinity (Heald and Hitchcock-DeGregori, 
1988; Maytum et al., 2001). Cosedimentation assays were performed for their actin 
binding affinity using ultra centrifugation. The tropomyosin affinity to actin is important 
for its regulatory function in physiological conditions. Tpm3-MASM was found to have 
similar binding affinity as Tpm1 with 0.2 µM tropomyosin (half saturation). However 
Met and MM bound to actin weekly with half saturation of ~6 µM and 8 µM respectively 
(Figure 2.24Figure 2.25Figure 2.26). Even though Met was expected not to bind actin 
efficiently, however MM was expected to bind to actin in similar way to Tpm1 as this 
resembles the original sequence of human Tpm3 isoform and also the presence of two 
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small MM should be retaining the actin binding property. However this was not the case, 
as MM affinity to actin was very low. From this it can be stated that the original N-
terminal sequence of Tpm3 (Figure 2.1) should be having a single methionine residue 
rather than two methionine. Further investigation in this area is need to confirm the 
sequence and it would be advantage to study the stability of the tropomyosin polymers 
using circular dichroism to differentiate the stability with in the three variants of 
tropomyosin.  
Effect of tropomyosin isoforms on actin polymerisation 
Characterising the role of tropomyosin isoform function in non-muscle actin 
polymerisation produced very interesting results and has high potential for future work in 
understanding the dynamics of actin polymerisation in presence of different isoforms of 
tropomyosin (section 2.2) Different muscle and non-muscle isoforms affect rate of actin 
polymerisation differently by effecting either initiation or elongation or affecting both of 
the mechanisms (Keiser and Wegner, 1985; Wegner, 1982b). Since 1990’s there have 
been very few studies that carried out effect of tropomyosin isoforms on actin 
polymerisation. Although there are many studies on the structural analysis of  interaction 
of actin-tropomyosin (Ecken et al., 2014; Lehman et al., 2000b), the information 
available on isoform specificity on actin polymerisation is limited. This work provides 
the preliminary information on the isoform specificity on actin polymerisation dynamics.  
The present study shows contradictory results obtained from previous studies which 
states that tropomyosin inhibits actin polymerisation (Hitchcock-DeGregori et al., 1988; 
Kouyama and Mihashi, 1981; Lal and Korn, 1986). The present study shows the data that 
tropomyosin accelerates the initiation stage of actin polymerisation, however inhibits the 
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elongation process, but the amount of filament formation seems to be higher in presence 
of tropomyosin for some isoforms (section 2.5.8, Table 2.5). It is also observed that it’s 
the concentration of tropomyosin that is affecting the actin polymerisation kinetics and 
varying the actin concentration does not have any effect on individual polymerisation 
stages of actin such as initiation or elongation. As the concentration of actin increases the 
polymerisation is faster without affecting the critical concentration. However, from the 
data available critical concentration of actin is affected in presence of tropomyosin as 
there seem to be higher amount of filament formation in presence of tropomyosin 
observed from the increase in fluorescence intensity after the polymerisation reaches a 
steady state (which is an indicator of critical concentration of monomer actin). Further 
investigation is needed to understand the role of tropomyosin and isoform specificity on 
actin polymerisation. From the data available a kinetic model needs to develop to 
accurately justify the data.  
Identification of Tpm3.12st using monoclonal antibodies 
An attempt was made to design an monoclonal antibody to react specifically to 
Tpm3.12st (Chapter III). None of the 12 antibodies produced did not have specificity to 
only Tpm3.12st, however one of the antibody (Ab3) reacting to P4 have higher 
sensitivity to Tpm3.12st than Tpm1.1st (Table 3.5)  Due to very high sequence similarity 
of tropomyosin isoforms, it is a difficult task to design an antibody specific to only one 
isoform. Gajbhiye et al., (2012) identified Tpm3 isoforms from laparoscope samples of 
women reproductive organs having cystic fibrosis. However the peptides when matched 
with the high molecular weight Tpm3 sequence were having sequence similarity with 
Tpm1 and Tpm4. From the observation of this study and previous studies (Schevzov et 
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al., 2011a), an antibody designed with Tpm3.12st sequence form amino acids 24 to 43 
may have high chances of producing an antibody specific to Tpm3.12st. The ELISA 
screening method developed is very useful to check the sensitivity of antibodies and to 
quantify the Tm-antibody reactivity. Accurate quantification of tropomyosin isoforms is 
key to understanding their function and the effects of modulation of isoform composition 
in health and disease.  
Resolution of thin filament proteome using RPLC 
A successful preliminary optimization of an effective method for extraction of thin 
filament proteins mainly actin, tropomyosin and troponin and other small soluble proteins 
was established using a minimum amount of 2 mg of tissue sample with different buffer 
conditions. This method surpass the use of 2D gels and has the potential of identifying 
proteins and their isoforms and post-translational modifications found in the skeletal and 
cardiac muscle proteins using top down mass spectrometry. The RPLC method developed 
was successful in identification of actin, tropomyosin and troponin subunits. The amount 
of sample loaded on the column was ~100 ng and it is the first time anyone used such a 
small amount to identify thin filament proteins although there have been few research 
groups that developed method for analysis of cardio proteome (Peng et al., 2014b) and 
Matthijs Jan Faber (PhD research work 2012 from Erasmus university of Rotterdam). As 
with this amount of sample a protein band is visible on a SDS-gel page there is possibility 
of using much lower amount of sample using the buffer conditions.  
The method once optimized has a great potential to use as a diagnostic indicator to 
identify the protein modifications in diseased heart in a very short amount of time with 
minimum amount of sample. This will enable to understand the cause of muscle 
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adaptation due to age, exercise or diseases in humans. This method is also useful for 
quantification of identified protein isoforms and the ratio of the of the isoform 
composition by top-down mass spectrometry as it established to be in compatible with 
MS analysis. The method also has an advantage in its ability to prediction of functional 
and structural changes occurring in thin filament.  
The work in this thesis, establishes various methods to quantify tropomyosin isoforms 
identify the function and composition of tropomyosin isoforms and to quantify the 
changes in the dynamics of actin polymerisation in presence of various tropomyosin 
isoforms and  provides some research questions for future work in understanding the role 
of tropomyosin in muscle and nonmuscle cells in health and disease. 
5.1 Future Work 
The work presented in this thesis although have produced some successful results, the 
work could be extended in characterizing the tropomyosin isoforms because of 
significance of these isoforms in maintaining the muscle’s health. It is important to 
understand the role of specific tropomyosin isoforms, in this case Tpm3.12st, in order to 
recognize the modifications occurring during the diseased states and how it is affecting in 
comparison with other major striated muscle isoforms (Tpm1 and Tpm2) and non-muscle 
isoform (Tpm4). 
Characterisation of Tpm3.12st 
Studying the stability of different variants of Tpm3.12st isoforms using circular 
dichroism to further characterize the protein would be useful to compare this protein with 
other striated tropomyosin isoforms as well as for confirmation of the N-terminal 
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sequence. Studies involving the comparison of difference in the binding affinity of 
recombinant protein with tissue extracted from pure tropomyosin.   
Further extending the characteristion of tropomyosin isofroms in their role in actin 
polymerization as it is well established fact that tropomyosin isoforms in non-muscle 
cells are in different concentrations depending on the function of the region of the cell. 
The importance of studying the effect of tropomyosin on actin polymerisation is it gives the 
ability to quantitatively measure the incorporation of monomer to polymer and how presence 
of tropomyosin molecule affects this polymer association.  
A specific answer to whether tropomyosin plays a role in actin polymerisation is not 
available so far and there is no data available for explaining the reasons even thought it is 
well established that tropomyosin plays a significant role in regulating actin filaments as 
explain in section 2.2.4.  The present study provides qualitative data showing that 
tropomyosin effect the inititation rate of actin polymerisation and the effect is different with 
various tropomyosin isoforms. Inorder to achieve a better understanding of diverse  functions 
of tropomyosin isofroms in actin polymerisation it is important to study and establish a 
experimental protocol to obtain more data to decipher the significant role played by 
tropomyosins in actin polymer formation. 
From the data obtained in this study more data relating to nucleation – elongation rate 
constants need to be collected. Measuring the filament length of F-actin after 
polymerisation by tagging it by phallodin and obtaining data using fluorescence 
microscopy would give information of the filament length of actin in presence and 
absence of tropomyosin and also whether tropomyosin initiaties fragmentation of actin 
filaments in specific conditions. Secondly, the initial G-actin and final G-actin and F-
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actin concentration needs to be measured to check the critical concentration of 
monomeric actin in presence and absence of tropomyosin, which may give approximate 
values in comparison to biological systems.  
Some of the methods mentioned below can be applied for studying actin polymerisation:  
 Polymerisation can be studied under fluorescent microscopy by labelling 
tropomyosin with fluorescent dye such as N-(1- anilinonaphth-4-y1) maleimide 
(Morris and Lehrer, 1984) or (dimethylamino)naphthalene (Weigt et al., 1991) 
label covalently linked to tropomyosin can be used along with pyrene labelled G-
actin to see how tropomyosin is effecting the nucleation / initiation stage of actin 
polymerisation. The effect of tropomyosin on actin can be studied with i. various 
concentration of tropomyosin, ii. Various concentration of actin iii. different 
concentration of Mg2+ and K+ ions  
 By collecting the above data mentioned, developing a kinetic model to accurately 
present the data and to explain polymerisation kinetics of actin in presence of 
tropomyosin. 
 Single molecule fluorescent imaging (Desai et al., 2014; Kad and Van Houten, 
2014) by using single tropomyosin molecule in a pool of G-actin may help to 
investigate the initiation  step  by polymerizing G-actin in presence of 
tropomyosin alone.  
Identification of tropomyosin isofroms  
In this study twelve antibodies with five peptides were generated in order to differentiate 
Tpm3.12st isofrom from other muscle and non-muscle isofroms. From the results 
obtained as explained in section 3.5.3.3, designing an antibody for Tpm3.12st isoform 
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from amino acids residues of 24-43 (Figure 3.7) may produces a monoclonal antibody 
which may be only specific to Tpm3.12st. 
On the other hand a method was developed for extraction of thin filament proteins and 
separation of the proteins using reverse phase liquid chromatography. The method 
developed has potential in using for identification and quantification of tropomyosin 
isofroms, actin and troponin isofroms from one single extraction with minimum amount 
of tissue sample (2 mg). Proteins were successfully separated and identified on an SDS 
PAGE gel comparing from previous research. However, using specific antibodies for 
identification of α-actin, TnC, TnI and TnT, myosin light chains, and tropomyosin will 
confirm the proteins eluted from the separation of proteins form the tissue lysate. 
Optimizing the method for analysis of the proteins by mass spectrometry would be highly 
advantages to identify isoforms and post translational modification of thin filament 
proteins. This method could be beneficial to extend it to analysis of human biopsy 
samples to investigate the differential expression of proteins and PTMs where the amount 
of tissue available is critical for analysis.  
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6 Appendix 
6.1 List of chemicals and reagents 
Table 6.1: List of Chemicals 
Chemicals / Reagents / Reagent kits Suppliers 
Acrylamide-Bisacrylamide  30% Protogel  
Adenosine triphosphate (ATP) Sigma Aldrich 
Agar Fisher Scientific 
Agar for electrophoresis Bioline 
Ammonium bicarbonate Acros Organics 
Ammonium bromide Fisher scientific 
Ampicillin Sigma Aldrich 
Ammonium persulfate (APS) Fisher scientific 
Amersham Hybond ECL Nitrocellulose membrane
  
GE Healthcare 
Bacteriological peptone Oxoid 
Benzamidine hydrochloride Sigma Aldrich 
Bromophoenol Blue Fisher Biotech 
Clones Thermo scientific 
Calcium chloride BDH 
Citric acid Fisher Scientific 
Coomassie brilliant blue G250 Fisher Scientific 
DNA plasmid extraction Kit Eppendorf 
Deoxynucleotide Triphosphates (dNTPs) Thermo Scientific 
Dextran BDH 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
Dimethylformamide (DMF) Sigma Aldrich 
Dithiothreitol (DTT) Sigma Aldrich 
Ethanol (absolute) Fisher Scientific 
Ethidium bromide Sigma Aldrich 
Ethylenediaminetetraacetic acid (EDTA) BDH 
Ethylene glycol-bis(2-aminoethylether)tetraacetic acid BDH 
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(EGTA) 
Formic acid Fisher Scientific 
Gel purification kit Eppendorf 
Glacial acetic acid Fisher Scientific 
Glucose AnalaR 
Glycerol Fisher Scientific  
Glycine Fisher Scientific 
Hydrochloric acid Fisher Scientific 
Iso Propanol  Fisher Scientific 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Melford 
3-(N-Morpholino)propanesulfonic acid (MOPS) BDH 
N-(1-Pyrenyl)iodoacetamide Sigma Aldrich 
β-Mercaptoethanol Sigma Aldrich 
Magnesium chloride Fisher Scientific 
Magnesium sulfate Fisher Scientific 
Methanol Fisher Scientific 
Milk powder Marvel original dried skimmed milk 
powder 
Nunc-immuno maxisorp , flat bottom 96well plates  Sigma-Aldrich  
Primers Thermo Scientific 
PCR buffer  Thermo Scientific 
Protein marker  Biorad Precision plus 
Phenylmethylsulfonyl fluoride (PMSF) Sigma Aldrich 
Polyethylene glycol Fisher Scientific 
Potassium chloride Fisher Scientific 
Potassium monophosphate BDH 
Pyrene iodoacetamide Sigma Aldrich 
Restriction enzymes New England Biolabs (NEB) 
Sodium azide BDH 
Sodium chloride Fisher Scientific 
Sodium dodecyl sulfate (SDS) Fisher Scientific 
Sodium hydroxide BDH 
Sodium phosphate Fisher Scientific 
Sodium monophosphate BDH 
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Sodium ortho pohophate BDH 
Sucrose BDH 
Sulphuric acid Sigma Aldrich 
3,3ꞌ,5,5ꞌ- Tetramethylbenzidine (TMB) Sigma Aldrich 
N,N,Nꞌ,Nꞌ-Tertamethylethylenediamine (TEMED) Sigma Aldrich 
Taq Polymerase Thermo Scientific 
Tris Base Fisher Scientific 
Triton X Sigma Aldrich 
Tween 20 Sigma Aldrich 
Urea Fisher Scientific 
Yeast Extract Oxoid 
6.2 BUFFERS 
Resolving Gel (13.5%) 
 
Chemical 30% Protogel Acrylamide (2gels)  
Acrylamide-Bisacrylamide  3.6ml 
Resolving buffer (4x – 1.5M, pH8.8)) 2.0 ml 
dH2O 2.33 ml 
Ammonium Persulfate (APS) 50ul 
TEMED 15ul 
Stacking Gel 
Chemical 30% Protogel Acrylamide (2gels) 
Acrylamide –Bisacrylamide 1.07 ml 
Stacking buffer (0.5M, pH 6.8) 1.0 ml 
dH2O 1.9 ml 
APS 30ul 
TEMED 10ul 
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Resolving buffer  
Chemical 250ml 
1.5M Tris base (MW 121.14) 45.42 g 
0.4% SDS  10g 
dH2O 250ml 
 Dissolve Tris in 150ml water and adjust the pH to 8.8 using HCl and add SDS and make 
up the volume to 250ml.  
Stacking Buffer    
Chemical 250ml 
0.5mM Tris(1.5M  Stock , pH 8.8) 83.3 ml  
0.4% SDS  10g 
To 83.3 ml of 1.5 M Tris Stock, add 100ml dH2O, adjust the pH to 6.8 and add SDS and 
make up to 250ml with water. 
Extraction buffers for muscle tissue  
Chemical  (mol weight) 50ML 
6M Urea (60.06) 18.018g 
1M KCl (74.56) 3.728g 
1M NaCl (58.44) 2.92g 
0.5% Triton X 0.25ml 
0.5% SDS 0.25g  
Low salt buffer for dialysis  
Chemical 1L 
2mM Tris  1ml from 1.0M Tris-HCl stock, pH 8. 
2mM CaCl2 1ml from 1M CaCl2 stock 
0.2mM DTT  0.015g (15µg)  
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4X SDS loading buffer  
Chemical 10ml 
0.5M Tris-HCl pH 6.8 2.5ml (can use stacking buffer) 
Gylcerol 4.0ml 
10% SDS 0.25g (250mg)(Use solid) 
0.1% Bromophenol blue 50mg 
β mercaptoethanol 1ml 
Coomassie Stain – Brilliant blue G (or commassie blue G250)  
Chemical 500ml 
0.1%Coomassie blue G250 500mg 
25% Methanol 125ml 
5% Acetic acid  25ml 
10X SDS Running buffer 
Chemical 500ml 1000ml 
Tris base (solid) 15.15g 30.3g 
Glycine 72.0g 144.0g 
SDS 5.0g 10.0g 
Protease Inhibitors 
0.1M PMSF stock – 0.01744g in 1ml ethanol 
0.1M Benzamidine  - 0.01566g in 1ml ethanol 
10ul of stock give 1mM in 1ml buffer  
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LB medium  
Chemical 1L 500ml 250ml 100ml 
Bactopeptone 10g 5g 2.5g 1.0g 
Yeast extract 5g 2.5g 1.25g 0.5g 
NaCl 5g 2.5g 1.25g 0.5g 
Agar (1.5%) 15g 7.5g 3.75g 1.5g 
pH 7.5 with NaOH 
Ampicillin stock 100mg/ml: Working concentration  (100µg/ml) : 1µl to 1ml give 
100µg/ml  
1L medium – 100mg solid 
IPTG stock 100mg/ml: Working concentration (100ug/ml) : 1µl to 1ml give 100µg/ml  
1L medium – 100mg of solid 
Competent cell preparation media 
Medium A  
10mM MgSO4  0.5ml from 1M stock 
0.2% Glucose 1ml from 10% stock 
*1ml is saved for storage process at the end 
Stocks for medium A 
MgSO4 – 1M 12.324g in 50ml 
Glucose 10% 5g in 50ml 
*Filter sterilize then before storing 
Storage solution B  
Glycerine 36% 
PEG 12% 
MgSO4 12mM 
*Added to LB medium and filter sterilized  
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Lysis buffer  
Chemical 100ml 
20mM Tris pH 7.5 0.242g 
150mM NaCL 0.8766g 
5mM EDTA  0.2081g 
From stocks 
Stock Conc. 100ml 250ml 
1M Tris-HCl pH 7.5 20mM 2ml 5ml 
NaCl (Use solid) 150mM 0.8766g 2.193g 
500mM EDTA 5mM 1ml 2.5ml 
Phosphate buffer  
1M NaH2PO4 + 1M Na2HPO4 – 100ml 
1M NaH2PO4 1M Na2HPO4 
12g 14.2g 
*Mix both the solutions to pH 7.0. For 500ml-5mM working solution – 2.5ml of 1M  
TIP* - take di-basic first and add the acidic mono-basic to it.  
PBS buffer 
Chemical 1L 500ml 
NaCl 80g 40g 
KCl 2.0g 1.0g 
Sodium monophosphate (dihydrate) 
Na2HPO4.2H2O 
14.4 7.2 
Potassium monophosphate (KH2PO4) 2.5g 1.2g 
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10X TAE buffer  
Chemical  500ml 
40mM Tris base 24.2g 
20mM Glacial acetic acid 5.7ml 
1mM EDTA (dibasic) 0.186g 
Western blotting transfer buffer 
Chemical 250ml 500ml 
48mM Tris base 1.45g 2.91g 
39mM Glycine 1.465g 0.733g 
SDS 0.187g 0.095g 
20% Methanol 100ml 50ml 
Note: Make it fresh when ever needed.  
Citric-EDTA-Dextrane sulfate buffer 
Chemical 100ml 
Citric acid 0.21g 
1% Dextran sulfate 1g 
EDTA 0.37g 
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6.3 ProtParam – Tpm3 Sequence information 
Protein sequence information extracted from ExPASy-ProtParam tool. 
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6.4 Duplicates of Elisa Preliminary checker board optimization.  
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